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Malignant catarrhal fever (MCF) or Snotsiekte, a lymphoproliferative disease of both
domestic and wild ruminants is characterised by high fever, profuse nasal discharge,
lymphadenopathy, leukopenia and severe inflammation of the conjunctival, oral and
nasal mucosae. Alcelaphine herpesvirus 1 (A1HV-1) is one of the gammaherpesvirus
responsible for the condition in cattle, sheep, deer and other ruminants. A1HV-1
genome has been well characterised and the complete sequence of the genome is
available.
The open reading frame (ORF) 57 of A1HV-1 is homologous to genes identified in
all classes of herpesviruses. The homologues in HSV-1, EBV, HVS and KSHV act
as transactivator proteins. The ORF 57 gene product in those viruses has trans-
regulatory function and can either activate or repress viral gene expression by a
posttranscriptional mechanism. It encodes for a nuclear protein and has the ability to
bind viral RNA, to shuttle between the nucleus and cytoplasm, and is required for
efficient nuclear export of viral transcripts.
The aim of this study was to functionally characterise the A1HV-1 ORF 57 gene
product. RT-PCR experiments have shown that A1F1V-1 ORF 57 is expressed as an
immediate early gene. A1HV-1 ORF 57 gene product is a transactivator protein with
regulatory functions. In transient transfection assays A1HV-1 ORF 57 gene product
has been shown to have effect only on A1HV-1 ORF 50 promoter. The ORF57 gene
product up-regulated another immediate early protein encoded by ORF 50 to 50 fold
XIV
when it is fused to unspliced reporter gene and to 6 fold when it is fused to spliced
reporter gene. RT-PCR analysis using RNAs extracted from BHK cells transfected
with spliced and unspliced 50 promoter reporter constructs with or without addition
of ORJF 57 expression construct have established that ORF 57 gene product acts at
post-transcriptional level. Transient transfection assays with full length ORF 57 and
truncations of ORF 57 have demonstrated that the activation domain of ORF 57 lies
at the C-terminus.
When ORF 57 was fused to the enhanced green fluorescent protein (EGFP), the
fusion protein exhibited a punctate nuclear distribution. The Immunofluorescence
studies carried out have shown that ORF 57 protein co-localises with the nucleolar
phosphoprotein C23. It was also observed that EGFP-ORF 57 shuttle from the
nucleus to the cytoplasm in the presence of Actinomycin D. The functional domain
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Herpesviruses represent a very large, clearly defined group of viruses that are of
considerable medical and veterinary importance. They have been found in all species
of animals, birds, and humans that have been investigated. Among all herpesviruses,
about 100 have been at least partially characterised and the genomes of 19 including
Alcelaphine herpesvirus-1 have been sequenced completely. Generally,
herpesviruses are very fragile and they do not survive well outside the body. They
are well known for their establishment of latency, which allows them to be
perpetuated, even in very small isolated host groups. Latent herpesvirus genomes are
maintained in host cells in a circular episomal (extra chromosomal) form. This
allows persistent infection with periodic or continuous shedding of virus. All the
known herpesviruses share four significant properties: (1) They all synthesize
specific enzymes and other factors involved in the nucleic acid synthesis and
metabolism (e.g.: DNA polymerase, helicase, thymidine kinase), (2) DNA
replication and encapsidation occur in the nucleus, (3) production of infectious
progeny virus results in irreversible destruction of the infected cell and (4) they
possess the ability to remain latent in their natural hosts (Fields et al., 1996).
Eight human herpesviruses have been identified, several of which are endemic in the
population. For instance, 95% of people carry the herpes simplex virus (HSV-1) and
about 90% are seropositive for the Epstein Barr virus (EBV). In the majority of
cases, reactivation or recrudescence does not occur in immunocompetent hosts. The
genetic and environmental cues that elicit reactivation in some individuals but not
2
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others have not been clearly defined. However, herpesvirus reactivation is strongly
associated with immunosuppression and, in this context, may cause serious and
potentially fatal disease.
1.1.1. Virion properties
Herpesvirus virions are enveloped and are about 120-300 nm in diameter. A typical
herpes virion consists of (a) a core containing a linear double stranded DNA, (b) an
icosahedral nucleocapsid approximately 100 nm in diameter, composed of 162
hollow capsomeres, 150 hexamers and 12 pentamers, (c) an amorphous, asymmetric
material that surrounds the capsid and is designated as the tegument and (d) a typical
lipoprotein membrane with numerous glycoproteins embedded within it and is
termed the envelope (Fig. 1.1).
1.1.2. Herpesvirus genomes
The size, composition and organisation of the genome of herpesviruses vary
considerably. The majority of the DNAs extracted from virions are linear, double
stranded molecules. The size varies from 125-235 kb. The percentage of guanine
plus cytosine (G+C %) varies between 32 and 74%. The organisation of the genome
varies in a complex fashion and according to this the herpesviruses can be divided
into six groups (Fig. 1. 2).
Group A - Unique sequence flanked by a direct repeat which may be larger than 10





Tegument Capsid Core Double-stranded DNA
Fig. 1.1 Diagrammatic representation of a Herpesvirus particle
LTR RTR
Fig. 1.2. Schematic diagram of sequence arrangements
in six different classes of herpesviruses
— Unique region TR-Terminal repeat
LTR-Left terminal repeats UL-Unique long region
RTR-Right terminal repeats Us-Unique short region
IR-lnternal repeat R1-R4-Repeat regions
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Group B -Unique sequence is flanked by a variable number of repeated sequences at
each terminus, e.g: Herpesvirus Saimiri.
Group C - The number of direct terminal repeats is smaller, but there may be other,
unrelated, sequences greater than 100 bp that are directly repeated and which
subdivide the unique sequences into well separated stretches, e.g: Epstein Barr virus.
Group D - The different elements at each terminus are present internally in inverted
orientation, e.g: Human herpesvirus 3, Varicella zoster virus.
Group E - The sequences from both termini are repeated in an inverted orientation
and juxtaposed internally dividing the genomes into two components, e.g: Human
herpesvirus-1 (herpes simplex 1).
Group F - The sequences at two termini are not identical and are not repeated
directly or in an inverted orientation, e.g: Tupaiid herpesvirus 1.
1.1.3. Classification of herpesviruses
Though herpesviruses do possess some shared properties, they vary greatly in their
biological properties. Based upon these biological properties, the family
Herpesviridae is divided into three subfamilies and has accorded well with further
molecular characterisations. They are, Alphaherpesvirinae, Betaherpesvirinae, and
Gammaherpesvirinae (Fenner et al., 1993). Examples of herpesviruses in different
subfamilies are given in table 1.1.
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Table 1.1- Examples of Herpesviruses in different subfamilies
Name Host Disease
ALPHAHERPESVIRINAE
Herpes simplex 1 (HSV-1) Human Cold sores, keratitis, ocular disease
Herpes simplex 2 (HSV-2) Human Genital herpes
Bovine herpesvirus 2 (BHV-2) Cow Pseudo-lumpyskin disease
Marek's Disease Virus (MDV) Chicken T cell lymphoma
Varicella zoster (VZV) Human Chicken pox, shingles (zoster)
Pseudorabies virus Pig Aujeszky's disease
Equine herpesvirus 1 (EHV-1) Horse Spontaneous abortion
BETAHERPESV1RINAE
Human Cytomegalovirus Human Foetal deformities
(HCMV) Lymphoproliferation in
immunocompromised individuals
Human heipesvirus 6 (HHV-6) Human Roseola infantum, exanthema subitum
Human herpesvirus 7 (HHV-7) Human
G AM M A11E R P E SV1RINA E






Herpesvirus saimiri (HVS) Squirrel Fatal lymphoproliferative disease in
Monkey cotton tail rabbits, New World monkeys
e.g. marmosets
Kaposi's sarcoma herpesvirus Human Kaposi's sarcoma




Rhesus monkey rhadinovirus Old world Experimental lymphadenopathy and
(RRV) Monkey vascular hyperplasia
Equine herpesvirus 2 (EHV-2) Horse
Herpesvirus sylvilagus Cotton tail Lymphomas
Rabbit Lymphoproliferations
Woodchuck herpesvirus Woodchuck
Murine gammaherpesvirus 68 Murid Lymphomas, Pneumonia (experimental)
(MHV-68) rodents
Bovine herpesvirus 4 (BHV-4) Cow
Alcelaphine herpesvirus 1 Wildebeest Malignant catarrhal fever (MCE) in
(AIHV-1) cattle




The prototypic viruses of this subfamily are human herpesvirus 1 (herpes simplex
virus 1) and human herpesvirus 3 (varicella-zoster virus). Most alphaherpesviruses
grow rapidly, lyse infected cells, establish latent infections in sensory ganglia and
have a broad host range.
1.1.3.2. Betaherpesvirinae
This subfamily consists of the cytomegalovirus of many species, the prototype being
human cytomegalovirus (Human herpesvirus 5, HHV-5). Human herpesvirus 6 & 7
(HHV-6, HHV-7) are also included in this subfamily under the genus Roseolovirus.
The members of this family have a restricted host range. Their replicative cycle is
slow and slow spread of infection from cell to cell in culture occurs. The viruses may
remain latent in secretory glands, lymphoreticular tissues, kidneys and other tissues.
1.1.3.3. Gammaherpesvirinae
This subfamily comprises the herpesviruses that are lymphotropic and the prototype
is Epstein-Barr virus. They have a narrow host range and become latent in
lymphocytes; some are responsible for oncogenic transformation of lymphocytes
(e.g., EBV and Burkitt's lymphoma and nasopharyngeal carcinoma in humans) but
some may also cause cytocidal infections in epithelial and fibroblastic cells. Viruses




Gammaherpesviruses include socio-economically important members of the
herpesviridae family. They share similarity in their genome organisations and in
early and late lytic genes that are required for viral replication (Roizman ,1995). A
distinct characteristic of gammaherpesviruses is their ability to replicate in
lymphoblastoid cells, with different members of the subfamily being specific for
either T or B cells. They are responsible for establishing latency in lymphoid tissue
in vivo and lymphoproliferative diseases and cancers (Roizman, 1995). They can also
enter a lytic stage, with production of infectious virions. This subfamily is
subdivided into yi-herpesviruses (Lymphocryptovirus) and 72-herpesviruses
(.Rhadinovirus) (Honess and Watson, 1977; Roizman, 1982; Honess, 1984; Roizman
et al., 1992).
The word 'cryptos' originated from the Greek word kryptos meaning, "hidden".
Hence, lymphocryptovirus means virus hidden inside the lymphocyte. The
lymphocryptoviruses include the most extensively studied and the well-characterised
Epstein-Barr virus (EBV) and several viruses of primates. EBV is the prototype and
it establishes a latent infection in B-lymphocytes. It is of particular interest to cell
biologists, virologists, and pathologists due to its association with a variety of human
cancers. It is associated with several human malignancies such as Burkitt's
lymphoma, nasopharyngeal carcinoma and Hodgkin's disease. Over 90% of the




The term Rhadinovirus originated from the Greek word 'Rhadino' meaning fragile.
As the term indicates, the DNA of the viruses in this genus are very fragile and the
prototype is Herpesvirus Saimiri (HVS), a virus of squirrel monkeys which induces
T-cell lymphomas in other New World monkeys (Fleckenstein and Desrosiers, 1982;
Jung et al., 1999). Other members of this genus include Alcelaphine herpesvirus-1
(A1HV-1) (Roizman et al., 1981; Bridgen et al., 1989; Bridgen, 1991; Ensser et al.,
1997), Ovine herpesvirus-2 (OvHV-2) (Bridgen and Reid, 1991; Roizman et al.,
1992), Human herpesvirus-8 [HHV-8 or Kaposi's sarcoma associated herpesvirus
(KSHV)] (Russo et al., 1996; Ganem, 1997; Schulz, 1998), Murine
gammaherpesvirus-68 (MHV-68) (Efstathiou et al., 1990; Virgin et al., 1997; Simas
and Efstathiou, 1998), Herpesvirus ateles (AtHV-3) (Albrecht, 2000), Rhesus
monkey rhadinovirus (RRV) (Searles et al., 1999; Alexander et al., 2000), Equine
herpesvirus-2 (EHV-2) (Telford et al., 1995) and Bovine herpesvirus-4 (BHV-4)
(Bublot et al., 1992; Lomonte et al., 1996). HHV-8 is the first known human member
of the genus Rhadinovirus and is associated with Kaposi's sarcoma (KS), Acquired
Immune deficiency Syndrome (AIDS) related B-cell lymphomas and multicentric
Castleman's disease (MCD).
1.1.5. Herpesvirus replication
Herpesvirus infection of a cell can result either in a lytic replication with production
of virus progeny and consequent death of the host cell or a latent infection, during
which the virus genome is maintained as a circular episome and expresses a
restricted subset of genes. Replication of the latent genome occurs during host cell
division which utilises host cell machinery but does not generate virus progeny. The
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term "lytic replication" implies cytolytic destruction of the cell, although not all
herpesviruses cause cytolysis. A more accurate description of herpesvirus replication
that results in generation of progeny is "productive replication". Since the
herpesvirus terminology has been defined by the prototypical cytolytic herpesvirus,
HSV-1, the terms are used interchangeably. Herpesvirus replication has been studied
most extensively with herpes simplex virus. Betaherpesviruses and
gammaherpesviruses also follow a similar pattern, but the replication cycle is slower.
Virus entry involves attachment of the herpesvirus glycoprotein peplomers to host
cell receptors. Following attachment, the virus penetrates the cell by fusion of the
virus envelope with the cell plasma membrane. Subsequently, the nucleocapsid is
released into the cytoplasm. Recent studies have demonstrated that virus attachment
and penetration is a highly complex process involving the cooperative activities of
multiple viral glycoproteins. HSV-1 possess 10 envelope glycoproteins and are
involved in the complex attachment and penetration process. Of this, heparan sulfate
proteoglycan has been identified as the most important and initial receptor for HSV-1
infection (Kasamatsu and Nakanishi, 1998; Laquerre et al., 1998). In EBV,
glycoprotein gp350/220 is mainly involved in the attachment to a B-lymphocyte
surface protein CR2 (Gong and Kieff, 1990). The nucleocapsids then traverse closer
to the nucleus in association with microtubule and dynein-like structure (Kasamatsu
and Nakanishi, 1998). Integrity of the microtubule network is important in
facilitating this movement. When the nucleocapsid reaches near the nuclear pore
complex, tegument proteins are shed and then the viral DNA is delivered into the
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nucleus. Tegument proteins dissociated from the nucleocapsid are directed to the
various cellular compartments in which they function.
Transcription of viral DNA by host RNA polymerase II occurs in the nucleus in a co-
ordinately regulated cascade. There are three kinetic groups of genes: the immediate
early (IE or a) genes, the early (E or p) genes and the late (L or y) genes. In addition
to these, herpesviruses encode a small subset of genes and non-translated RNAs
during latent infection. The HSV-1 transactivator, VP 16, together with the cellular
octamer DNA-binding protein, Oct-1, activate the expression of immediate early
genes. These serve as transactivators of early and late gene subsets. The early genes
encode the viral proteins necessary for nucleic acid metabolism, DNA replication
and virus assembly e.g. DNA polymerase, helicase-primase, dUTPase and thymidine
kinase. The late genes encode virion structural proteins: tegument proteins, envelope
glycoproteins, and proteins necessary for nucleocapsid assembly and genome
packaging (Lehman and Boehmer, 1999).
In the nucleus, genome circularisation is a prerequisite for viral replication. The
origin of replication can be either oris or orii_. The virus genome is replicated by a
rolling circle mechanism, producing head-to-tail concatemers that are cleaved at
consensus sequences into single genome units and packaged into newly synthesised
capsids (Deiss et al., 1986; Lehman and Boehmer, 1999).
Capsid assembly of HSV-1 is a multistep process initiated in the cytoplasm and then
completed in the nucleus. The envelopment and egress of the virus from the cell is
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not well characterised. There is evidence to suggest that HSV-1 capsids bud through
the nuclear membrane, acquiring immature viral glycoproteins (Vlazny et al., 1982).
Immature virus particles would then pass through the Golgi network, facilitating
glycoprotein processing, and proceed to the plasma membrane in a Golgi-derived
vesicle before being released from the cell by a process of reverse exocytosis
(Johnson and Spear, 1982; Desai et al., 1988). Alternatively, the nucleocapsid may
acquire its final envelope at the plasma membrane. There is also evidence to suggest
that the virus is enveloped in the golgi and undergoes uncoating and re-envelopment
steps during egress (Whiteley et al., 1999). EBV envelopment is believed to occur
at the plasma membrane or following envelopment by post-golgi vesicles (Gong and
Kieff, 1990).
1.2. Human herpesviruses
At present, eight members of the family Herpesviridae are known to infect humans
(Table 1. 2). These viruses are distributed worldwide and no animal reservoirs of
infection are known for any of the human herpesviruses. They are morphologically
similar and indistinguishable even by electron microscopy. The members of the
human herpesviruses which have strong oncogenic associations include EBV with
nasopharyngeal carcinoma (NPC) and Burkitt's lymphoma (BL), and KSHV with KS






Genus Common name and
abbreviation
Site of latency
Human Alpha- Simplex virus Herpes simplex virus
herpesvirus 1 type 1 (HSV-1)
Human Alpha- Simplex virus Herpes simplex virus Sensory nerve
herpesvirus 2 type 2 (HSV-2) ganglia
Human Alpha- Varicello virus Varicella zoster virus Sensory nerve
herpesvirus 3 (VZV) ganglia
Human Gamma Lymphocryptovirus Epstein-Barr virus Leucocytes,
herpesvirus 4 - (EBV) epithelial cells
Human Beta- Cytomegalovirus Human B lymphocytes
herpesvirus 5 cytomegalovirus Macrophages
(CMV)
Human Beta- Roseolovirus HHV-6 T lymphocytes
herpesvirus 6 (CD4+),
epithelial cells
Human Beta- - HHV-7 T lymphocytes
herpesvirus 7 (CD4+)
Human Gamma Rhadinovirus Kaposi's sarcoma- B lymphocytes,
herpesvirus 8 - associated epithelial cells
herpesvirus (KSHV)
1.2.1. EBV
EBV was isolated from lymphoblastoid cell lines derived from Burkitt's lymphoma
(Epstein et al., 1964). Since then, seroepidemiological studies have shown that this
virus is a ubiquitous agent and over 90% of adults worldwide are seropositive. EBV
is an important virus which is associated with several disease states. In some it is the
sole aetiological agent while in others, it acts as an essential cofactor in a complex
series of events that ultimately lead to the disease. It is the sole aetiological agent of
infectious mononucleosis (IM) (Niederman et al., 1976; Meerbach et al., 2001). It is
also associated with nasopharyngeal carcinoma (NPC) (Hsu et al., 2001), nasal T cell
lymphoma (Jones et al., 1988), a subset of Hodgkin's lymphoma (Anagnostopoulos
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et al., 1989), oral hairy leukoplakia (OHL) (Greenspan et al., 1985) and a minority of
carcinomas of the stomach (Imai et al., 1994). Like other herpesviruses, EBV also
establishes lifelong persistence in the host.
The EBV genome is 172kb in length consisting of alternating unique and internal
tandem repeat regions flanked by terminal repeat sequences (TR) and encodes for
over 90 predicted open reading frames (Baer et al., 1984). It also codes for two small
RNA species (EBERS) which form abundant transcripts but are untranslated. There
are two subtypes, EBV-1 and EBV-2, which share extensive homology but exhibit
variation in the nuclear antigen genes and the small polyadenylated RNAs (Sample et
al., 1990).
The host range of EBV is limited to its natural host (humans) and some non-human
primates including the Gibbon, Owl monkey, Squirrel monkey and some species of
Tamarin. In humans, B-lymphocytes are regularly infected. But, squamous epithelial
cells can also be infected. The outcome of infection of B cells and squamous
epithelial cells differs markedly. In epithelial cells a lytic infection occurs with
production of new viral progeny and cell death, whereas in B cells it leads to
immortalisation (Sixbey et al., 1984). From immortalised B cells, lymphoblastoid
cell lines can be generated and these cell lines are used extensively to study the latent
infection of EBV (Pope et al., 1968; Yoo and Speck, 2000). In these cells, the
genome is maintained as an episome. However, a small number of cells within this
population undergo productive replication (1-5%). The switch from latency to lytic
replication is characterised by maturation and differentiation of B cells and can be
13
CHAPTER 1 INTRODUCTION
induced by agents such as sodium butyrate (Luka et al., 1979), phorbol esters (zur
Hausen et al., 1978) and antibodies to surface immunoglobulin (Tovey et al., 1978).
1.2.1.1. Infectious Mononucleosis (IM)
IM is an acute febrile illness characterised by severe sore throat, malaise, fever,
hepatosplenomegaly, abdominal discomfort and generalised lymphadenopathy
resulting from primary infection with EBV. Classically it infects adolescents and
young adults, but children as young as 5 years may also be affected. The incidence is
30 times higher in whites than in blacks (Henle and Henle, 1970). Primary infection
occurs by the oral route but other routes such as blood and sexual contact also exist.
The subsequent infection of trafficking B-lymphocytes and those of the lymphoid
plexus of the pharynx (Waldeyer's ring) result in immortalisation of B cells
The acute IM is usually associated with involvement of the central and peripheral
nervous system (Grose et al., 1975), myocarditis and percarditis, kidney disease and
cervicitis (Sixbey et al., 1986). The age of the patient has a profound influence on the
clinical manifestation of the disease. In children, primary infection is usually
asymptomatic. Symptomatic IM is more likely to occur when the individual is
infected in early adulthood. The virus replicates in the oropharyngeal epithelium and
is intermittently found in the throat washings of seropositive individuals, resulting in
oral transmission (Rickinson et al., 1975; Yao et al., 1989). During the acute phase
of disease, T lymphocytes capable of suppression of immunoglobulin synthesis are
demonstrable in the peripheral blood (Tosato et al., 1979).
14
CHAPTER 1 INTRODUCTION
1.2.1.2. X-linked lymphoproliferative disease (XLP) (Duncan's Disease)
XLP is characterised by three phenotypic manifestations: (1) the most common is the
occurrence of IM relatively early in life among boys. This exhibits the typical
clinical features of more benign disease with fever, malaise, generalised
lymphadenopathy, and hepatosplenomegaly (Purtilo et al., 1991). Pathologically,
there is explosive polyclonal B and T cell proliferation (Tazawa et al., 1993). (2) The
second phenotypic expression of XLP is the development of an extranodal non-
Hodgkin's B cell lymphoma. It may occur independently without an initial bout of
IM, or develop after recovery from acute illness. (3) The third group exhibit
profound hypogammaglobulinemia before or after infection (Kuis et al., 1985). An
inadequate antibody response to the viral capsid antigen (VCA) and nuclear antigens
(EBNA-1 and -2) are characteristic of this form of the disease (Masucci et al., 1981).
1.2.1.3. Burkitt's lymphoma
Denis Burkitt first described a tumor involving the jaw among African children in
1958 which was later termed Burkitt's lymphoma (BL). It is a malignant lymphoma
of children occurring in endemic and sporadic form. The endemic form occurs in
central parts of Africa, New Guinea and localised areas of tropical South America,
where it is associated with holoendemic malaria. Children over 2 years old and adults
under 20 years old are primarily affected and the tumor most often involves the jaw
and the abdominal organs. There is strong epidemiological evidence to suggest that
EBV plays a critical causal role in the pathogenesis of BL (deThe et al., 1978).
World wide, BL has a striking male predominance and rarely occurs in adults except
in association with AIDS. Nearly 80% of 2-4 year olds have antibodies to viral
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capsid antigen (Henle et al., 1969). The major factors involved in the pathogenesis
of African BL are holoendemic malaria, EBV infection with B-cell transformation in
infancy, chromosomal translocations, and activation of c-myc and other oncogenes
(Evans, 1985).
1.2.1.4. Nasopharyngeal carcinoma (NPC)
NPC is another example of a close association between EBV and a human tumour,
but the role of EBV in NPC is not yet fully understood. Undifferentiated carcinomas
of the nasopharynx occur with unusually high frequency in residents of southeast
China, and in emigrant Chinese elsewhere (Ablashi et al., 1983). EBV DNA can be
detected in fresh NPC biopsies and histopathologic sections of fixed NPC tissues
(Brooks et al., 1992). The incidence of NPC clearly shows a male preponderance and
is closely related to occupation. Highest risk has been noticed in those who are
engaged in salt production, national defence, public service, and mining (Crawford,
2000). Salted fish can be linked to the development of NPC since it is a traditional
food consumed by southern Chinese from early childhood and it contains appreciable
quantities of nitroso-dimethylamine (Huang et al., 1978).
There are three different clinical forms of the disease: metastatic, invasive, and
combined. The combined type constitutes about 59% of all cases, and is
characterised by a combination of direct spread of the primary tumour and
appearance of cervical nodal metastases. Survival is longest with the metastatic type
which represents 33% of all cases (Teo et al., 1991).
16
CHAPTER 1 INTRODUCTION
1.2.1.5. Latency and cellular transformation by EBV
Like all herpesviruses, EBV expresses a highly restricted subset of genes during
latent infection. The latency-associated genes encoded by EBV are unique genes and
no homologues have been found in other herpesviruses (Virgin et al., 1997). Several
distinct patterns of gene expression have been observed in different in vitro and in
vivo circumstances and have been assigned to three groups: latency type I, II and III.
Latency type I is the pattern of expression detected in biopsy samples in cases of
endemic BL. In these cells, only EBNA-1, the EBERs and the BARTS are expressed.
Latency type II is observed in NPC and Hodgkin's lymphomas (Young et al., 1988;
Brooks et al., 1992; Deacon et al., 1993; Hamilton-Dutoit et al., 1993). Expression
is limited to EBNA-1, LMP-2A, LMP-2B, the BARTs and in some cases, LMP-1. In
persistently infected resting B cells of seropositive immunocompetent hosts, only
LMP-2A and the EBERs are detectable. The full array of latent genes is expressed in
latency type III: six EBV nuclear antigens (EBNAs), EBNA-1, 2, 3A, 3B, 3C and
LP (leader protein); three latent membrane proteins (LMP), LMP-1, 2A and 2B; two
EBV infected cell RNAs known as EBERs and a group of un-characterised
transcripts designated as the BARTs to denote the region of the genome they
originate from (Brooks et al., 1993). This pattern of expression is observed in LCLs,
infectious mononucleosis and post-transplant lymphomas.
EBNA-1 is a DNA-binding protein that binds to specific sequences in the latent viral
origin of replication (oriP) and is required for maintenance of the viral episome. It
also transactivates expression of the other latency genes and has a role in tethering
the virus genome to host chromosomes thus ensuring equal partitioning during cell
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division (Levitskaya et al., 1995). EBNA-2 is essential for immortalisation of B cells
in vitro (Cohen et al., 1989) and has been shown to transactivate the LMP genes and
the cellular oncogenes c-fgr and bcl-2. EBNA-3A, B and C originate from a single
open reading frame and their functions are less well characterised, although EBNA
3A and C are also necessary for immortalisation (Tomkinson et al., 1993). LP is not
essential for immortalisation but may have a potential role in controlling cell
proliferation. LMP-1 is an integral membrane protein and a classical viral
oncoprotein (Kaye et al., 1993). LMP-1 induces activation of the cellular
transcription factor, NFkB, and up-regulates the anti-apoptotic protein, Bcl-2
(Henderson et al., 1993). LMP-2A and 2B are also transmembrane proteins. LMP-
2A interacts with the src family of tyrosine kinases and may be involved in
suppressing reactivation (Miller et al., 1995). The EBERs are dispensable for viral
replication but may have a role in transformation of Akata cells (Komano et al.,
1999).
1.2.1.6. EBV lymphomas and immunodeficiency
Individuals with immunodeficiencies may develop uncontrolled proliferation of
EBV-immortalised cells involving a polyclonal expansion of the normal B-cell
population, leading to an acute and usually fatal lymphoblastic sarcoma. This may
occur either during a primary infection, such as IM or in reactivated infections. The
three groups at highest risk to these lymphoproliferative disorders are those with a
genetically determined immunodeficiency, such as XLP, patients given
immunosuppressive drugs as in renal transplant patients and patients with
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immunodeficiency involving CD4+ helper T cells destroyed by chronic infection
(Penn, 1991).
1.2.2. Kaposi's Sarcoma-Associated Herpesvirus (KSHV)
KSHV also called human herpesvirus type 8 (HHV-8), is a novel member of the
lymphotropic human herpesvirus family. Two small fragments of the KSHV genome
were identified initially in Kaposi sarcoma lesions of AIDS patients by
representational difference analysis (Chang et al., 1994). Since then, many groups
have reported that the KSHV genome can be detected in all epidemiological forms of
KS by Southern blot or PCR (Moore and Chang, 1995; Chang et al., 1996; Russo et
al., 1996; Schulz,1998). The KSHV genome has since been fully cloned and
sequenced and classified as a gammaherpesvirus of the genus Rhadinovirus (Moore
et al., 1996; Russo et al., 1996).
KS is a hyperproliferation of poorly differentiated endothelial cells and is associated
with extreme neovasularisation. To date, a wealth of epidemiological evidence points
to a central role of KSHV in the development of KS (Ganem, 1997; Schulz, 1998).
KS was a relatively uncommon disease affecting older men of eastern European and
Mediterranean descent. Later, with the AIDS epidemic there was a large increase in
its incidence especially in children in indigenous black populations across eastern
Africa. It is 20,000 times more common in persons with AIDS than in the general
population (Beral, 1991). There are four known epidemiological forms of KS: classic




The size and organisation of KSHV genome is very similar to that of other
rhadinoviruses (Renne et al., 1996a; Russo et al., 1996; Neipel et al., 1997). The
unique region of the genome is 140.5kb in length and is flanked by two high GC
content (85%) 801bp terminal repeats. There are 81 ORFs, of which 60-share
homology with HVS.
1.2.2.2. Diseases associated with KSHV
KSHV is associated with three neoplastic disorders: KS, primary effusion lymphoma
(PEL), also known as body cavity-based lymphoma (BCBL), and multicentric
Castleman's disease (MCD). As the name indicates, BCBL is a malignant lymphoma
that is exclusively or mainly localised to the body cavities such as pleura, peritoneum
and pericardium and is usually associated with AIDS. Most cases of BCBL are
dually infected with EBV and KSHV (Cesarman et al., 1995a; Gessain et al., 1997).
However, occasional cases of EBV negative BCBL have been reported (Carbone et
al., 1996; Cesarman et al., 1996a). MCD is an atypical lymphoproliferative disorder.
KSHV DNA is frequently detected in most cases of MCD in HIV infected patients,
whereas it is less common in HIV negative patients (Soulier et al., 1995). Several
skin cancers as well as multiple myeloma have also been reported to contain KSHV
DNA sequences (Rettig et al., 1997).
1.2.2.3. KSHV tropism and gene expression
KSHV has been detected in endothelial and spindle cells of KS lesions, in circulating
endothelial cells, B-cells, CD8+ T-cells, macrophages and prostatic glandular
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epithelium (Ambroziak et al., 1995; Li et al., 1996; Harrington et al., 1996; Sirianni
et al., 1997). Like EBV, KSHV is a B-cell tropic virus and several latently infected B
cell lines have been derived from the peripheral blood mononuclear cells of BCBL
patients (Cesarman et al., 1995b; Cesarman et al., 1996b; Gaidano et al., 1996;
Renne et al., 1996b). However, KS is a vascular tumour consisting of bundles of
spindle cells, which belong to the endothelial lineage but often express markers
characteristic of endothelial, macrophage and smooth muscle cells. In situ
hybridisation analysis has detected the presence of KSHV-specific transcripts in the
majority of these cells (Staskus et al., 1997). There is a restricted pattern of KSHV
gene expression in both spindle cells and in B-cell lymphoma derived cell lines such
as BC-1, indicative of a latent infection. As in the case of EBV, lytic replication can
be induced by addition of phorbol esters or butyrate (Miller et al., 1995; Miller et al.,
1997).
Transcriptional analysis of KSHV in the BC-1 cell line has led to the grouping of
KSHV genes into three classes: constitutively transcribed latent transcripts that are
unaffected by phorbol ester (class I); genes that are up-regulated by phorbol ester and
sodium butyrate (class II); transcripts that are only detectable following induction
(class III, Sarid et al., 1998). Class I genes include the latency associated nuclear
antigen (LANA), a DNA-binding protein which is thought to have a function similar
to that of EBV EBNA-1. In addition, KSHV encodes a relatively large number of
cellular homologues, two of which, v-cyclin and v-FLIP, are transcribed during
latency. The KSHV GPCR (ORF74) is a class III gene, with transcripts only
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observable following induction of productive infection in latent cell lines (Talbot et
al., 1999).
1.3. Animal herpesviruses
Animal viruses have provided useful systems for the study of DNA virus replication
in eukaryotic cells. Animal gamma herpesviruses such as HVS, MHV-68, and
A1HV-1 are closely related to the clinically important gammaherpesviruses, EBV and
KSHV. The restricted host range of EBV and KSHV and their limited ability to grow
in vitro has hampered further study of these viruses. In addition, studies of
gammaherpesviruses in humans are constrained by the frequent asymptomatic nature
of the acute infections, delay between infection and clinical presentation, and the
absence of typical animal model systems (Finerty et al., 1992). Animal
gammaherpesvirus infections closely resemble that of human conditions. It is
possible to manipulate the virus genome in vitro and investigate its effects in vivo
using molecular techniques. Hence, animal gammaherpesviruses could be used as
amenable animal model systems for the study of human gammaherpesvirus infection
and its associated pathology.
1.3.1. HVS
HVS is a T-cell tropic rhadinovirus whose natural host is the Squirrel monkey. In
other species of New World primate, HVS infection leads to the development of fatal
T cell lymphomas (Falk et al., 1972; Fleckenstein and Desrosiers, 1982). The unique
region of the HVS genome (112.9kb) is flanked by 1.4kb GC rich repeats and
contains at least 76 major open reading frames, of which 60 have homologues in
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other herpesviruses (Albrecht et al., 1992). There are three different strains of HVS
(A, B, C) based on the extent of DNA sequence variation at the left end of L-DNA.
Strains A and C are highly oncogenic and both immortalise common marmoset
peripheral blood leucocytes in vitro to interleukin 2-independent growth (Medveczky
et al., 1984; Desrosiers et al., 1986). Highly oncogenic subgroup C strains also
immortalize human, rabbit, and rhesus monkey lymphocytes and can produce
fulminant lymphoma in rhesus monkeys and New World primates (Medveczky et al.,
1989; Duboise et al., 1998).
1.3.2. MHV-68
MHV - 68 is a naturally occurring herpesvirus of small free-living rodents, the bank
vole (Clethrionomys glareolus) (Blaskovic et al., 1980). The MHV-68 genome
consists of a unique region of 118 kb flanked by variable copies of 1.23 kb repeats.
The genome organisation of MHV-68 is colinear with that of EBV and HVS. There
is a marked reduction in the frequency of CpG dinucleotides and it establishes latent
infection in B-lymphocytes (Sunil-Chandra et al., 1992). Approximately 80 open
reading frames (ORFs) have been determined, of which 60 are homologues of HVS
or KSHV genes. Comparison of the identity of MHV-68 ORFs to those of other
gammaherpesviruses indicates that MHV-68 is more closely related to HVS and
KSHV than to EBV, indicating that MHV-68 belongs to the y2 herpesvirus (Virgin et
al., 1997; Nash et al., 2001).
The pathogenesis of MHV-68 in laboratory mice resembles that of EBV in humans.
It produces an acute infection similar to infectious mononucleosis and is also
23
CHAPTER 1 INTRODUCTION
associated with lymphoproliferative disease. Long-term infection of inbred mice with
MHV-68 is associated with the development of tumours. Lymphoproliferative
disease occurred in 9% of chronically infected mice following intranasal infection, of
which 50% were high grade lymphomas. Lymphomas were associated with both
lymphoid and non-lymphoid tissue (lung, liver and kidney). When the mice were
treated with the immunosuppressive drug cyclosporin - A there was a significant
increase in the development of lymphoproliferative disease. The lymphomas were of
mixed B and T cell origin (Sunil-Chandra et al., 1994).
1.3.3. AIHV-1
A1HV-1 is the etiological agent of wildebeest-associated malignant catarrhal fever
(WA-MCF) (Plowright et al., 1960). It comes under the family Herpesviridae,
subfamily Gammaherpesvirinae and genus Rhadinovirus (Bridgen et al., 1989;
Ensser et al., 1997). AIHV-1 is similar to many y-herpesviruses such as KSHV,
MHV-68, HVS, bovine herpesvirus-4 (BHV-4), EHV-2, herpesvirus ateles (HVA)
and the prototype lymphocryptovirus EBV (Ensser et al., 1997).
1.3.4. OvHV-2
Ovine-herpesvirus-2 (OvHV-2) is the etiological agent of sheep associated malignant
catarrhal fever (SA-MCF). Both sheep sera and cattle with SA-MCF were found to
contain antibodies that were reactive to AIHV-1 (Rossiter, 1981; Rossiter 1983). This
suggested that SA-MCF and WA-MCF were caused by very similar, but not identical
agents. Subsequently OvHV-2 has been implicated as the causative agent of SA-
MCF (Baxter et al., 1993). Unlike AIHV-1, OvHV-2 has not been isolated although
24
CHAPTER 1 INTRODUCTION
it has been partially characterised (Baxter et al., 1997). Lymphoblastoid cell lines
(LCL) have been propagated from cattle, deer and rabbits with SA-MCF. Although
these cells did not show any evidence of viral particles or antigens, they contained
DNA sequences homologous to those of A1HV-1 (Bridgen and Reid, 1991). A PCR
test has been developed to detect OvHV-2 specifically, which does not amplify DNA
from A1HV-1 or other related viruses (Baxter et al., 1993). Recently, it has been
possible to clone almost the entire genome of OvHV-2 in cosmids and the
sequencing studies are progressing (Rosbottom et al., pers. comm.).
1.4. MCF
MCF is a serious, globally distributed viral disease of cattle, sheep, deer and other
ruminants. It is of great economic importance in domestic cattle and can inflict
serious losses in exotic and wild ruminants on game farms and zoos. It is generally
sporadic, although severe herd outbreaks have been reported in feedlot, dairy and
range cattle, zoos and game farms (Plowright et al., 1960; Hoffman and Young,
1989; Howard, 1993; Jones et al., 1997; Reid, 2000). Clinically, the course of the
disease may be per acute, acute or chronic. In general, disease in the more
susceptible species follows an acute or per acute course. The per acute disease is
characterised by rapid onset of depression and high fever with death occurring 12-
24h after onset (Reid et al., 1984). It has been reported from all continents and
almost all countries.
There are three different epizootiological forms of the disease: (1) WA-MCF, which
is the common form in Africa, (2) SA-MCF, which is worldwide in distribution and
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(3) North American form- this type of MCF is found in North America in feedlot
cattle which have no contact with sheep. It is more difficult to transmit in
experimental conditions and the causative agent is unknown (Pierson et al., 1979;
Fenner et al., 1993).
1.4.1. Aetiology
The aetiological agent of WA-MCF, A1HV-1 was first isolated by Plowright et al.,
(1960) in Kenya from blue wildebeest (Gorgon taurinus taurinus). The aetiological
agent of SA-MCF is OvHV-2 and it appears to be the predominant form of the
disease throughout the world. Antibodies to A1HV-1 have been detected by indirect
immunofluorescence (Rossiter, 1981, 1983) or by immunoblotting (Herring et al.,
1989) in sera from cattle with SA-MCF, and from hamsters experimentally infected
with SA-MCF (Reid et al., 1989b). However, the attempts to isolate OvHV-2 have
consistenly failed.
In addition to A1HV-1 and OvHV-2, there is evidence for an extensive group of
related gammaherpesviruses that can cause MCF. Viruses isolated from topi (Mushi
et al., 1981) and red hartebeest (Reid and Rowe, 1973) have been designated as
Alcelaphine herpesvirus-2. Of these two viruses, only the virus from red hartebeest
produced MCF following inoculation into cattle and rabbits. Another virus has been
recovered from roan antelope and designated as hippotragine herpesvirus-1 (HiHV-
1). This virus produced MCF in rabbits however the pathology was distinct from
MCF produced by A1HV-1 or OvHV-2 (Reid and Bridgen, 1991). MCF cases caused
by a new virus has recently been recognised in white-tailed deer (Li et al., 2000). It is
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a higly virulent virus, genetically related to A1HV-1 and OvHV-2 and has been
named as MCFV-WTD. In addition, Li et al., (2001) recently identified a novel
gammaherpesvirus in goats tentatively designated as caprine herpesvirus-2 (CpHV-
2). Based on the sequence analysis of the DNA polymerase gene from CpHV-2, it
was found to be 67% identical to A1HV-1, 71% identical to OvHV2, and 73%
identical to the white-tailed deer virus.
1.4.2. Reservoir hosts and transmission
1.4.2.1. WA-MCF
The main reservoir host for WA-MCF include both the blue and the white-bearded
variety of wildebeest (Connochaetes taurinus) in East Africa and the black
wildebeest (Connochaetes gnu) in South Africa (Castro et al., 1984). Neither free-
living nor captive wildebeest infected with A1HV-1 show clinical or pathological
signs attributable to the virus. Although there are serologically related viruses in
hartebeest (Reid and Rowe, 1973), topi (Mushi et al., 1981) and oryx (Reid et al.,
1975), there is no epidemiological evidence for their natural transmission to cattle.
Wildebeest are infected with A1HV-1 in utero and A1HV-1 has been shown to be
present in foetal spleen but not in wildebeest foetal membranes and fluid released
during parturition (Rossiter et al., 1983). Natural transmission of A1HV-1 from
wildebeest to cattle occurs almost entirely during the first 3-4 months of life of the
wildebeest calf. Transfer occurs mainly on common grazing lands. Very rarely,
transmission takes place from adult wildebeest and that may be under laboratory
conditions (Plowright, 1981). Virus has been recovered from nasal and ocular
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secretions of wildebeest calves suggesting that the respiratory tract could be a likely
route of spread (Mushi et al., 1980). In nasal and ocular secretions the virus titres
may reach 103 TCIDso/ml. After 3 months the secretions contain neutralizing
antibody, predominantly IgA, indicating a rapid decline in virus excretion and loss of
ability to transmit infection (Mushi and Rurangirwa, 1981). MCF virus was also
isolated from a few calves born to a MCF recovered cow over a period of 80 months
(Plowright et al., 1972). This indicates the possible occurrence of congenital
transmission in cattle. There were several reports of a high incidence of MCF
following the widebeest calving season suggesting a seasonal occurrence for the
disease (Mushi et al., 1980). In South Africa there were reports of MCF occurring in
cattle widely separated from infected cattle suggesting the role of arthropod vectors
in the spread (Barnard and Van-De-Pypekamb, 1988).
1.4.2.2. SA-MCF
A possible seasonal occurrence of SA-MCF has been suggested with a high
incidence of the disease occurring during lambing season (Baxter et al., 1997). As
with WA-MCF, OvHV2 is transmitted from the natural host, the sheep, to
susceptible hosts such as cows and deer (Reid, 2000). Recently, there were reports of
multiple cases of MCF in different parts of the world and the investigators failed to
incriminate sheep as the reservoir host. However, the possibility of other species




The pioneering work on transmission was carried out by Mettam (1923) using the
virus derived from the black wildebeest in South Africa. He successfully transmitted
the disease to cattle by the inoculation of infected blood. As with A1HV-1,
transmission of SA-MCF from naturally affected animals to cattle and deer has been
achieved using large volumes of intact cells derived either from blood or
disaggregated lymph node or spleen (Selman et al., 1978). Experimental
transmission of SA-MCF from affected deer to other deer and rabbits was also
successful (Reid et al., 1984). A series of studies have been carried out to investigate
experimental transmission of SA-MCF in adult sheep and lambs and found that both
of them were susceptible to OvHV-2 infection (Li et al., 1999).
WA-MCF has been experimentally transmitted to laboratory Syrian hamsters,
rabbits, rats and guinea pigs (Jacoby et al., 1988). Buxton and Reid (1980) have
reported the transmission of SA-MCF to rabbits. The clinical and the pathological
changes developed by these rabbits were indistinguishable from the response of
rabbits to infection with A1HV-1. Both WA-MCF and SA-MCF have been well
adapted to rabbits. The clinical symptoms and lesions in rabbits infected with the
virus, or virally-infected materials, were similar in all respects to those seen in the
natural disease (Buxton and Reid, 1980; Reid et al., 1984). Mice were refractory to
both forms of the disease. Hamsters are highly susceptible to both WA-MCF and




MCF is usually sporadic, with only one to a few cases occurring at a given time.
Severe outbreaks with very heavy losses are however not uncommon (Hamilton,
1990; Collery and Foley, 1996). In North Dakota, there were problem farms where
owners had been forced out of business by losses up to 50% of the herd. Similar
incidences were also reported by Clark et al., (1970) and Pierson et al., (1973) where
65% and 37 % losses were recorded. In Kenya (Masailand) severe outbreaks due to
SA-MCF and a low level of constant annual loss due to WA-MCF were also reported
(Plowright et al., 1975). A similar scale of loss has been recorded in Indonesia
(Daniels et al., 1988a).
Most ruminant species are susceptible to infection with A1HV-1 (Heuschele et al.,
1988). However, the nature and the impact of infection varies from totally subclinical
in well-adapted reservoir species, to lethal in susceptible species. Serological tests
have identified antibodies that react specifically to A1HV-1 in six subfamilies of the
family Bovidae. They include Alcelaphinae, Hippotraginae, Caprinae, Ovibovinae,
Cervinae and Odocoilinae (Heuschele and Fletcher, 1984). In addition to wildebeest,
(Connochaetes taurinus taurinus) red hartebeest {Alcelaphus buselaphus), topi
(Damaliscus korrigum) and blesbok (Damaliscus dorcas phillipsi) come under
alcelaphinae. The caprinae include all sheep and goats; ovibovinae includes the musk
ox (Ovibos moschatus); and the hippotraginae include the oryx species, roan
(Hippotragus equinus) and sable antelope (Hippotragus niger). Cervinae includes
deer and Odocoilinae includes moose, elk, reindeer and duikers.
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Cattle are relatively resistant to SA-MCF, but sporadic outbreaks affecting many
animals have been recorded (Pierson et al., 1973; Hamilton, 1990; Bonn, 1990).
Other species such as Bali cattle (Bos javanicus), the domestic water buffalo
(.Bubalus bubalis) (Ramachandran et al., 1982) and Pere David's deer (Elaphurus
davidianus) (Reid et al., 1987) are susceptible to SA-MCF. In domestic cattle the
outbreak is usually sporadic and is usually associated with intimate direct contact
with sheep, transient indirect contact or sometimes no obvious contact can be
established (Reid et al., 1986). An enzootic outbreak of SA-MCF in black beef cattle
was reported from Japan (Taneichi et al, 1986). Desmecht et al., (1999) reported few
cases of SA-MCF in cattle in Belgium.
In Scandinavian countries pigs appears to be a targeted host for SA-MCF. The first
report of MCF in pigs was from Germany in 1950. Further incidences of MCF
affecting pigs was reported from Norway, Switzerland and Sweden. The natural
disease has mostly occurred sporadically, affecting a single pig or two to three pigs,
and sometimes several animals on one farm. Recently three cases of MCF in pigs
were reported from Norway (Loken et al., 1998).
In North America SA-MCF proves to be a common cause of mortality in bison
(Schultheiss et al., 1998).
A very high incidence of infection was reported in Rusa deer (Cervus timorensis)
from Australia (Denholm and Westbury, 1982). In Europe and New Zealand a
similar high incidence was observed among red deer (Cervus elaphus) (Reid et al.,
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1979; Oliver et al., 1983). It is now apparent that deer are highly susceptible to both
forms of the disease, but the sheep-associated form poses a serious threat to farmed
deer (Reid et al., 1984). Farming systems where Pere David's deer were kept have
also suffered huge losses due to severe infection (Reid et al., 1987; Orr and
Mackintosh, 1988).
1.4.4. Clinical signs
The clinical and pathological signs in MCF caused by both viruses appear to be very
similar and indistinguishable. The incubation period in natural as well as
experimental infection can be quite variable and usually ranges from 10-60 days. The
different clinical forms of MCF are characterised as (1) per acute with generalised
disease, (2) intestinal, (3) head and eye, and (4) a catarrhal form with mild symptoms
of catarrh. The per acute form is the most severe and animals can die within a few
hours (Reid et al., 1984).
Initially, there is high fluctuating fever and depression, accompanied by an absolute
increase in circulating medium-sized and large granular lymphocytes, followed by
eosinopenia in the terminal stages. There is potentially wide variation in the clinical
signs exhibited by the affected animals. Quite consistently, affected animals have
enlarged lymphnodes, and there is usually some degree of oral and ocular disease,
and exudative dermatitis. Corneal ulceration occurs in some cases (Fig. 1.3). In few
cases there are nervous signs, such as hyperesthesia, head pressing, trembling,
nystagmus, incordination and behavioural changes. Some animals may have
gastroenteritis with diarrhoea, which in acute cases become bloody (Reid et al.,
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Fig. 1.3. Symptoms of malignant catarrhal fever
A - dry, cracked and encrusted appearance of muzzle, bilateral mucopurulent nasal
discharge and hypersalivation.
B - Corneal opacity
Reproduced with kind permission from The Veterinary Record, A clinicopathological
study of bovine malignant catarrhal fever in Great Britain by Seman et al., (1974).
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1979). This is most commonly seen in deer. The disease may take an acute course of
about 1-3 days, particularly in animals with hemorrhagic enteritis. Those with less
severe gastroenteritis, central nervous system signs, or generalised disease may
linger for as long as 9-10 days.
During experimental infection, the clinical signs include high fever, catarrhal
conjunctivitis and rhinitis. The cornea becomes opaque in the final stages, the skin of
muzzle is eroded, and the nasal passages are obstructed by mucopurulent exudates.
Buccal mucosae is congested, but in some cases erosions develop inside the cheeks
and on the roof of mouth that are reported to be grossly indistinguishable from the
erosive and oral lesions of rinderpest. Diarrhoea is common, and nervous
manifestations are seen in the final stages. Emaciation develops rapidly. The disease
is almost invariably fatal (Liggit et al., 1978).
There was a report on an unusual case of MCF in a 12-month old bull exhibiting
none of the usual features but showing marked skin pathology (Holliman et al.,
1994). The animal was pyrexic. Nasal, ocular and enteric signs were absent. The skin
and hair over most of the body were moist with exudates, the neck, back and flanks
being worst affected. Within two weeks the skin changes became more pronounced
resulting in multiple Assuring of the skin, most markedly on the neck. When the
exudates had dried and crusted the skin felt hard to touch. Despite daily iodine
scrubs, the skin became foul smelling, as a result of secondary bacterial infection.
The animal died 17 days after the initial onset of symptoms. The histopathological
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lesions suggested MCF as the cause of death and later, it was confirmed by the
presence of antibody to A1HV-1 by serological test as well as by PCR.
1.4.5. Outcome of the disease
It is generally assumed that most or all cattle with signs of MCF die after a short
clinical illness (Smith, 1996). There are, however, reports of mild disease in
domestic cattle followed by complete recovery, recovery with recrudescent disease,
or chronic MCF (Daubney and Hudson, 1936; Daniels et al., 1988b; Hamilton, 1990;
Milne and Reid 1990; Baxter et al., 1993; Michel and Asperling 1994; O'Toole et
al., 1997). Chronic and/or recrudescent MCF also occurs in sika deer (Cervus
nippon) and bison {Bison bison) (Heuschele et al., 1985).
1.4.6. Target cells
Extensive studies were carried out to examine the target cells involved in MCF.
Lymphoblastoid cell lines have been derived from both A1HV-1 and OvHV-2
infected animals, such as cattle, deer and rabbits. These have the characteristics of
large granular lymphocytes (LGLs). LGLs can either be natural killer cells (NK) or
cytotoxic T-cells (Abbas et al., 1994). Following addition of IL-2, the LGLs acquire
T-cell markers (Reid et al., 1989). Based on the surface markers, the LGLs from
infected cattle and deer have been grouped and they are mainly CD4+/CD8-, CD4-
/CD8+ and CD4-/CD8-. Among these only the latter group is found to be involved in
the pathogenesis of MCF (Burrels and Reid, 1991). In rabbits infected with A1HV-1,
the T-cell hyperplasia found in the spleen and lymphnodes was due to a CD8+ T-cell
expansion (Nakajima et al., 1992; Schock and Reid, 1996). Based on studies
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conducted by different groups, it has been proposed that virus infection of LGLs
disrupts their normal function and leads to polyclonal T-cell hyperplasia (Cook and
Splitter, 1988, Reid et al., 1989). This indicates that the main target cell for MCF
virus infection in cattle is T-cell. However, some infectivity has been detected in
macrophages and monocytes in rabbits (Rurangirwa and Mushi, 1982). These cells
may act as carriers of virus to facilitate the virus spread and can lead to
immunosuppression by compromising their important functions of antigen
presentation and phagocytosis (Mushi and Rurangirwa, 1981).
1.4.7. Pathogenesis
Despite the severe pathological changes that occur in animals affected by MCF the
pathogenic mechanisms remains unclear. In lesions from affected animals there is no
evidence of typical herpesvirus cytopathic effects and very little evidence of viral
antigen is observed (Bridgen et al., 1992). Though the presumed natural portal of
entry in MCF is the upper respiratory tract, the precise site is not clear and is
believed to be the nasal mucosae and/or tonsil. A long incubation period is
characteristic for both WA-MCF and SA-MCF and it ranges from 10-60 days
(Plowright, 1968). However, in practise it is essential to wait for at least 2 months
before concluding that an animal has not been infected.
In rabbits, infectivity was present in pooled lymphoid tissues 2-4 days after
intraperitoneal infection and in spleen 4 days after intravenous infection (Edington et
al., 1979). Sites particularly involved were the splenic redpulp, paracortical areas of
lymph nodes and cortex and medulla of the thymus. These locations suggest an
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involvement of T lymphocytes and it appears that in the rabbit there is a rapid
establishment of infection in spleen. There is no evidence of epithelial involvement
at the site of mucosal penetration and little evidence for the infection of other cell
types, except macrophages (Plowright, 1984).
Based on the pathological changes in the affected tissues, there is increasing
evidence that the disease is an immunopathological condition. Plowright (1968)
suggested that hypersensitivity to viral or viral-induced antigens was involved and
responsible for the pathogenesis. Subsequently, Rweyemamu et al., (1976)
hypothesized that the lesions may be due to a type III or Arthus-like hypersensitivity
reaction with deposition of antigen-antibody complexes or to a combination of this
with type IV, delayed T-cell mediated response. However, the absence of a
hypergammaglobulinemia and failure to demonstrate IgG or complement in the walls
of blood vessels and glomeruli do not lend support to the above idea (Plowright,
1984). Liggit et al., (1978) observed strong histological resemblance of MCF to the
lesions seen in graft-versus-host disease and speculated that it was a virus induced
autoimmune and lymphoproliferative condition. Later, Reid et al., (1983) and Reid
and Buxton, (1985) suggested that the essential defect in MCF pathogenesis appears
to be immune deregulation attributable to virus infection causing dysfunction of
natural killer cells and uncontrolled proliferation of lymphoblastoid elements.
1.4.8. Pathology
Gross pathological changes may not be present in animals, which die of per acute
MCF. The most consistent lesion in almost all organs is a marked perivascular and
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intramural infiltration of mononuclear cells, chiefly lymphocytes.
Arteries and arterioles in almost all organs are affected, and often there is medial
necrosis and endothelial swelling. The carcass is dehydrated and emaciated.
Conjunctivitis is evident. The muzzle and nares are heavily encrusted and often
reveal irregular raw surfaces, with slight serous discharge. Cutaneous lesions are
common in SA-MCF. There may be generalised exanthema and patchy loss of hair.
In severe cases, the horns and hooves may slough.
Respiratory lesions are more severe in WA-MCF compared to the sheep-associated
disease. Congestion and oedema of the lungs and a patchy bronchopneumonia, with
slight pleural exudates, are present in about 40% of animals. Congestion with
necrosis, diphtheritic membranes, erosion and hemorrhagic areas are present on the
turbinates and septum especially in the head and eye form of the disease. The
pharyngeal and laryngeal mucosae are hyperaemic and swollen and later develop
multiple erosions or ulcerations and are often covered in part by greyish-yellow
pseudomembranes. The tracheobronchial mucosa shows petecheal hemorrhages.
Epithelial necrosis and erosions followed by ulcerations occur in the pharynx,
oesophagus, on the folds of reticulum and the pillars of rumen. The abomasal mucosa
is oedematous and hyperaemic. The wall of the small intestine may be firm and
thickened by oedema. The serosa is dull, finely granular with petechiae. Intestinal
contents may be mucoid or hemorrhagic, and the mucosa thickened with petechial
hemorrhages. Similar lesions also occur in the large intestine. Intestinal lesions tend
to be more severe in deer. The liver is enlarged and mottled with periportal
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accumulations of mononuclear cells. There may be numerous small hemorrhages and
a few erosions on the mucous membrane of the gallbladder.
The urinary system exhibits some characteristic lesions. There may be infarcts or foci
of non-suppurative interstitial nephritis. These may be numerous enough to produce
a mottled appearance. Similar lesions are also present in the urinary bladder.
Vaginitis with congestion, necrosis and erosion of the mucosae and slight
mucopurulent exudate is also observed.
Enlargement of lymphnodes is the characteristic lesion of MCF and is present in
about 80% of cases. All nodes may be involved but this is particularly marked in the
head and neck region and in visceral nodes such as the bronchials or renals. They
may be many times the normal size, firm, fleshy and surrounded by gelatinous
oedema. Some nodes may be hemorrhagic or congested especially in cattle. The
spleen is slightly enlarged, and the lymphoid follicles are prominent.
In the brain there is an excess of cerebrospinal fluid, which contains more protein
and a moderate number of mononuclear cells. Scattered petecheal hemorrhages can
be seen in the meninges (Liggit et al., 1980).
1.4.9. Histopathological changes
Histopathological changes must be relied on for the diagnosis of MCF, and its
differentiation from similar diseases. In the genesis of the widespread and severe
lesions which characterise MCF, there are three essential components: 1) destruction
38
CHAPTER 1 INTRODUCTION
of lymphocytes especially in the lymphopoietic tissues, 2) proliferation and
infiltration of larger lymphoblastoid cells in many organs especially in perivascular
locations, 3) an angitis involving all components of the walls of arteries and veins.
The characteristic changes are found in lymphoid tissues and in the adventitia and
walls of medium-sized vessels, especially arteries in any organ.
The vascular lesions are an accumulation of mainly mononuclear cells in the
adventitia, and fibrinoid necrotizing vasculitis. These changes may be focal or
segmental, and may involve the full thickness of the wall (Liggit and Demartini,
1980). The perivascular accumulation of cells is particularly characteristic. The cells
are mainly lymphoid cells with large nuclei and prominent nucleoli; occasionally
small lymphocytes and plasma cells may be present. These changes in the blood
vessels may be present in all cases of MCF whether per acute, acute, or mild with
recovery. The best organs to examine for the vascular lesions are the brain and
leptomeninges, carotid rete, kidney, liver, the adrenal capsule and medulla, salivary
gland, and any area of skin or alimentary tract showing gross lesions (Liggit et al.,
1978; Liggit and DeMartini, 1980).
The lymphnodes show active proliferation of lymphoblasts, which form extensive
homogeneous populations of cells in the T cell-dependent areas of the interfollicular,
cortical and paracortical zones. There is necrosis of small mature lymphocytes,
especially in the follicles. Focal areas of hemorrhage and necrosis associated with
arteritis may be seen in all areas of the nodes. The lymphoid reaction in the spleen
varies from marked lymphoid cell hyperplasia, in the periarteriolar sheaths, to
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atrophy and depletion of lymphocytes. In a variety of organs, there is marked
proliferation and infiltration of lymphocytic and lymphoblastic cells, mainly
perivascular in distribution. The lymphoreticular proliferation may become so severe
in some organs that it is difficult to determine whether it is hyperplastic or neoplastic.
Microscopic arteritis similar to that in other organs also occurs in the nervous
system. Necrotising arteritis, plasma exudation into the meninges or Virchow-Robin
space and the predominantly adventitial lymphocytic response in the brain of cattle
are unique to MCF.
The lesions in the skin and squamous mucosae of the alimentary tract are
histologically similar. The dermis is diffusely infiltrated with lymphocytes. Groups
of epithelial cells become necrotic, swollen and ultimately the full thickness of
epithelium in affected areas undergoes necrosis and erosion.
1.4.10. Immune response
Cattle that survive an infection with WA-MCF are resistant to parenteral challenge
for several years. In a few cases, there were reports of protection by attenuated live
virus (Reid and Rowe, 1973). However, they succumbed to a modified form of the
disease after a prolonged interval (Rweyemamu et al., 1976). Passively acquired
antibody does not protect the young against natural infection. Immunological cross-
reactions occur between this virus and other bovine viruses such as BHV-1 and
BHV-3 (Rossiter et al., 1988). Although little is known about cell mediated
immunity (CMI) in MCF, the failure of neutralising antibodies to protect suggests
that it is the most important part of the immune response. Delayed hypersensitivity to
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MCF antigens injected intradermally and lymphocyte-mediated cytolysis of MCF
infected cells has been reported (Rossiter, 1985).
1.4.11. Diagnosis
The initial diagnosis of MCF usually rests on clinicopathological data. The
histopathological changes are fortunately unique and pathognomonic irrespective of
the wide spectrum of clinical manifestations (Reid et al., 1984). A history of contact
with wildebeest or sheep generally favours the diagnosis. However, recent
developments in molecular biological techniques have become an added advantage
in confirming the diagnosis.
A variety of serological tests for detection of antibody have been described for
A1HV-1. A neutralisation assay using the cell-free WC 11 strain seems to be highly
specific but indirect immunofluorescence tests are more rapid, although, there can be
some cross reactions with bovine herpesvirus 4 antibody (Rossiter, 1981). Li et al.,
(1994) have developed a competition inhibition enzyme-linked immunosorbent assay
(CI-ELISA) using a monoclonal antibody raised against the Minnesota isolate of
OvHV-2. Evidence of cytopathic effects in monolayers of bovine or ovine origin
(bovine thyroid cell culture is preferred generally) co-cultivated with peripheral
blood leukocytes or cells from affected tissues can serve as another diagnostic tool.
The knowledge of the complete sequence of A1HV-1 genome made it possible to
design primers for detecting viral DNA in affected tissues or peripheral blood
leukocytes. Some investigators have tried this method but with limited application
(Hsu et al., 1990; Katz et al., 1991).
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In SA-MCF, since the virus has not been isolated, the diagnosis is mainly based on
histopathological confirmation or detection of antibody that cross-reacts with A1HV-
1. Recently, a CI-ELISA has been developed and was on trial under field conditions
but proved to be less sensitive than the immunofluorescence tests (Muller-Doblies et
al., 1998). OvHV-2 specific PCR has been developed and has been assessed as a
diagnostic tool in several European countries (Muller-Doblies et al., 1998), North
America (Li et al., 1995), Australia (Ellis and Masters, 1997), New Zealand, Africa
(Mirangi and Kang-ee, 1997) and Indonesia (Wiyono et al., 1994).
The sporadic occurrence of the disease with typical clinical signs and lesions of MCF
together with a history of close contact with sheep or wildebeest is sufficient to give
a presumptive diagnosis. However, several other disease conditions in cattle such as
rinderpest, mucosal disease, infectious bovine rhinotracheitis, infectious bovine
keratoconjunctivitis, theileriosis, and foot-and-mouth disease exhibit similar clinical
signs and complicate the differential diagnosis. Hence it is advisable to do laboratory
tests before reaching conclusive diagnosis.
1.4.12. Prophylaxis and control
A number of attempts using inactivated virus preparations have been made to protect
cattle and rabbits against challenge with virulent virus. In cattle, although very high
levels of neutralising antibody developed, there was no resistance to parenteral
challenge by cell-free or cell-associated virus (Plowright et al., 1975). In rabbits,
similar inactivated antigens have provided protection against cell-free virus given
intravenously, but not against virulent spleen-cell suspensions (Edington and
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Plowright, 1980; Russel, 1980). Subsequently, attempts to protect cattle and rabbits
against parenteral challenge using cell-associated virus by vaccination with fixed
virulent tissue suspensions, or even live attenuated cells have consistently failed, in
spite of the development of high-titre antibodies and delayed cutaneous
hypersensitivity (Rossiter, 1985).
In the absence of a vaccine, the prevention of MCF rests simply and reliably on the
prevention of close contacts between susceptible and reservoir hosts. In Zoological
collections where severe losses occur due to MCF, the only practical solution is to
separate the reservoir host from the susceptible species.
1.5. AIHV-1 genome
The genome of AIHV-1 has been sequenced completely. It consists of approximately
130 kb low GC content L-DNA flanked by 20-25 repeats of a 1.1 kb sequence with
high GC content (Ensser et al., 1997). The genome organisation of AIHV-1 is shown
in Fig. 1. 4. Gammaherpesvirus genomes are organised into blocks of genes that are
conserved across all gammaherpesviruses. The herpesvirus conserved "core" genes
within members of a herpesvirus subgroup appear in equivalent locations within
appropriately aligned genomes, and in the same relative orientation (McGeoch et al.,
1988; McGeoch, 1989; Bublot et al., 1992; Albrecht et al., 1992). In addition to the
core genes, each herpesvirus contains unique "virus specific genes". One notable
feature of the gammaherpesviruses genomes is that they have a low frequency of
CpG dinucleotides (Honess et al., 1989). An exception for this feature is the recently
























































The L-DNA contains 70 ORFs, 61 of which show homology to the rhadinovirus
prototype HVS genes. These conserved genes are arranged into distinct blocks (I-V)
and the position, content and orientation of these blocks are conserved among the
other gammaherpesviruses (Fig. 1.5). The genes in block I, II and IV are well
conserved throughout all the subfamilies of herpesviruses. They include ORFs 9
(DNA polymerase), ORF 21 (thymidine kinase), and ORF 25 (viral capsid protein).
Blocks III and V contain genes that have homologues only among the
gammaherpesviruses. These include ORFs 48, 50, and 75. A1HV-1 is the only
sequenced gammaherpesvirus that does not possess an ORF 49 homologue. ORF 50
is present in a similar location in all the fully sequenced gammaherpesviruses. It is
homologous to ORF 50 of EBV, HVS, KSHV and MHV-68. Throughout the
herpesvirus family, the blocks of conserved ORFs are interspersed with variable
regions and they contain two different groups of ORFs: 1) genes that are conserved
in some but not all members of a subfamily [e.g. ORF 72 encoding cyclin D and
ORF 73 encoding latency-associated nuclear antigen (LANA)]. 2) genes that are
unique to that particular virus. In A1HV-1 genome, 10 such genes are identified and
they are likely to play a part in determining the particular cell tropism of the virus,
establishment of latency, transformation of the host cells and other virus-host
interactions.
ORF A lis the positional homologue of saimiri transformation protein-A (STP-A) of
HVS (Damania et al., 2000) and Ml of MHV-68 (Clambey et al., 2000). ORF A2 is
the positional equivalent to STP-C, a transformation-associated gene of HVS strain C
(Jung et al., 1999). A3 shows homology to the genes that encode the semaphorin
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proteins and it is the only example of a semaphorin encoded by a member of the
herpesvirus family. Semaphorins were found to play an important role in tumour
suppression and immunoregulation by interacting with the host's immune system
(Ensser and Fleckenstein, 1995; Roche et al., 1996). A4 possess a putative signal
sequence but it does not exhibit homology to any sequence in the databases. A5 has
been predicted to encode a protein with seven transmembrane helical domains
characteristic of the G-protein-coupled receptors. In MHV-68, KSHV and HVS the
GPCR like ORF 74 product act as functional IL-8 receptor and it appears to act as an
oncogene (Bais et al., 1998; Wakeling et al., 2001). A6 shows weak homology to Zta
of EBV and K-bZIP of KSHV (Chang et al., 1990; Gruffat et al., 1999). This ORF
lies in a region of the A1HV-1 genome which has been reported to undergo re¬
arrangements following serial passage in cell culture, producing a virus that can no
longer cause disease in animals (Handley et al., 1995). A7 is the positional
homologue of EBV BZLF2 which encodes for a glycoprotein and is found to be
essential for the penetration of B-cell membrane (Li et al., 1995b; Wang and
Huttfletcher, 1998). A8 shows weak homology to EBV gp350/220 (glycoprotein),
the major EBV surface antigen and is the principal target of virus-neutralizing
antibodies in EBV positive serum (Hoffman et al., 1980). In MHV-68, the gp 150
has also shown to protect against virus induced mononucleosis (Stewart et al., 1999).
A9 encodes a homologue of cellular Bcl-2, an inhibitor of apoptosis and all the
gammaherpesviruses have been shown to encode this homologue. ORF A10 also
codes for a glycoprotein which is specific to A1HV-1 (Ensser et al., 1997).
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Since the OvHv-2 viral particles have not been isolated, little is known about the
structure and organisation of the genome. However, from the lymphoblastoid cell
lines derived from animals with SA-MCF a clone was identified, which hybridises to
a portion of A1HV-1 DNA. The sequence derived from this clone represented the
first OvHV-2 sequence and it showed homology to ORF 75 in other
gammaherpesviruses. This sequence was the basis for the development of a PCR test
to detect the presence of MCF in a variety of species (Bridgen and Reid, 1991;
Baxter et al., 1993). Another sequence having similarity to DNA polymerase gene
(ORF 9) has also been amplified from cell lines derived from MCF-affected animals
(Rovnak et al., 1998).
The unique genes of A1HV-1 include homologues of cellular genes and as in the case
of other gammaherpesviruses are presumably acquired by the virus from the host
genome during their co-evolution. Hence, they are likely to be responsible for the
dramatic pathological picture associated with MCF. Now, with the knowledge of
complete sequence of A1HV-1, it would be possible to investigate in detail the viral
gene transcription and expression pattern throughout the course of infection and this
might presumably help to elucidate the series of events in MCF starting from viral
entry to the production of disease including the interactions between viral and
cellular proteins.
1.6. Gammaherpesvirus transactivators
Herpesviruses encode transactivator proteins in their early stages of lytic replication
which regulate the gene expression cascade. The main purpose of viral gene
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expression is to facilitate the production of multiple copies of the virus genome and
infectious virions. Viral gene expression is a highly regulated process and the viruses
exploit cellular regulatory processes to support it. They use a variety of mechanisms
to promote or repress cellular gene expression, in order to create a favourable cellular
environment for the replication of its nucleic acid. The transactivator proteins must
ensure efficient transcription of early, delayed-early, and late genes. They often
contain at least two essential domains: one directs the protein to its target (e.g., DNA
binding domain), and the second facilitates initiation of RNA transcription
(activation domain) presumably by interacting with cellular factors at the promoter
region.
1.6.1. Transactivator proteins of EBV
EBV infects and immortalizes human B lymphocyte in vitro resulting in the
establishment of a latent infection (Pope et al., 1968). During latency only a
restricted set of viral genes are expressed which includes nuclear antigens (EBNAs),
latent membrane proteins (LMPs), and two small EBV encoded RNAs (EBERS)
(Dambaugh et al., 1986). Disruption of latency, leading to activation of the virus can
be achieved in vitro by treating with tumour promoter 12-O-tetradecanoylphorbol-
13-acetate (TPA) or chemical inducers such as n-butyrate and halogenated
pyrimidines (Ito, 1986). In addition, the replicative cycle can also be initiated by the
coordinate expression of regulatory proteins which function as transactivator proteins
for their respective early viral genes. EBV encodes several transactivators, Zta
(BZLF1, ZEBRA, Z, EB1), Rta (BRLF, R), Mta (EB2, M, SM, BMLF1), EBNA-1
and -2. Zta, Rta and Mta are the key EBV gene expression regulators (Farrel, 1989;
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Semmes et al., 1998). Zta is a bZIP family transcriptional activator and is identified
in the gamma 1 class of herpesviruses (Baer et al., 1984). In gamma 1 herpesviruses,
it has been extensively studied and fully functionally characterised. A structural
homologue of Zta has been recently identified in KSHV (Gruffat et al., 1999). The
Rta transcriptional activator has homologs encoded within both yl and y2
herpesviruses (Nicholas et al., 1992; Russo et al., 1996). Homologs of the Mta
protein are encoded by a, (3, and y herpesviruses (Nicholas et al., 1988; Zhao et al.,
1995; Singh et al., 1996; Whitehouse et al., 1998a).
1.6.1.1. Zta
Zta, a bZIP-like transcriptional activator, binds as a homodimer to ZEBRA-
responsive elements (ZREs) which are located upstream of specific EBV genes and
also within the oriLyt region (Lieberman et al., 1989). It performs a dual role in the
EBV life cycle, functioning both as a transcriptional activator of viral gene
expression and as an origin binding protein essential for EBV DNA replication
(Fixman et al., 1992, 1995). Zta is unique in its ability to trigger the entire lytic
cascade (Chevallier-Greco et al., 1986). It is a DNA-binding protein that is partially
homologous to c-Fos, binds specifically to Apl sites, and can induce the lytic cycle
in latently infected B lymphocytes. It can also induce c-Fos expression through AP-1
and AP-1-like sites present in the c-Fos promoter and this may be necessary for the
expression of other viral lytic genes and cellular genes whose products are required
for viral replication (Flemington and Speck, 1990). It has been shown to interact with
a variety of cellular proteins, including TBP, TFIIA, the retinoic acid receptor, NF-
kB/p65, and p53 (Gutsch et al., 1994; Zhang et al., 1996). The promoters of Zta and
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Rta can be activated by both Zta and Rta but not by TPA and the induction of Akata
(EBV-positive Burkitt's lymphoma) cells in response to anti-immunoglobulin seems
to involve simultaneous expression of both the transcripts as early as lh (Sinclair et
al., 1991).
Carey et al., (1992) have hypothesized that synergy is important for efficient
transcriptional stimulation by Zta in vivo. Their study have shown that 9 out of 23
potential or known Zta-responsive EBV genes contained two or more upstream
binding sites and Zta can stimulate transcription synergistically. This phenomenon
was observed in both uninfected and EBV-infected B-lymphoid cells and in vitro in a
HeLa cell nuclear extract. Le Roux et al., (1996) have demonstrated that Zta which is
overexpressed and competent for transcriptional activation of the EBV transcription
units in the viral genome, did not activate its own promoter either in the viral genome
or carried by a plasmid in EBV-positive cells. However, transfected Zta induced the
transcription of both Zta and Rta but only Rta is efficiently translated. Askovic and
Baumann (1997) have shown that the activation domain of Zta is not unique and can
be replaced by a heterologous acidic, proline-rich, or glutamine-rich activation
domain which, still retains its native abilities. This indicates that its separate
activities are not attributable to specific subdomains but are spread throughout its N
terminus and therefore cannot be inactivated by deleting localized regions.
1.6.1.2. Rta
Hardwick et al., (1988) were the first to identify this EBV transactivator capable of
activating the expression of a cytoplasmic early antigen (EA-R) encoded by BHRF1.
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Rta can activate the expression of most of the EBV promoters tested. It is a
particularly potent activator of two genes, the transactivator Mta and BHRF1.
BHRF1 encodes an intracellular membrane protein with sequence homology to the
bcl-2 oncogene (Pearson et al., 1987). Rta also activates the transcription of several
other genes, including the EBV DNA polymerase and c-myc genes (Gutsch et al.,
1994). Deletion of sequences near the C-terminal end of Rta abolished
transactivation activity without affecting its ability to bind DNA. This suggest that
the domain of Rta which contacts cellular transcription factors to facilitate initiation
of RNA transcription is located at the C terminus. This complex activation domain of
Rta is composed of several hydrophobic subdomains, as well as an adjacent domain
which confers cell type specificity (Hardwick et al., 1992).
In addition to their individual actions, Rta and Zta can act co-operatively to enhance
the expression of several EBV promoters in transient expression assays (Gruffat et
al., 1990). This co-operative transactivation by the Zta-Rta combination appears to
be mediated by direct binding of both Z and R transactivators to responsive promoter
elements, and interactions between R, Z and cellular transcription factors (Quinlivan
et al., 1993). Gruffat and Sergeant, (1994) have characterized the DNA-binding site
repertoire for Rta and it can be represented as 5'-CC N9 GG-3'.
Apart from its role as a transcriptional activator, Rta has profound effects on key cell
cycle regulatory proteins. It dramatically increases the level of cellular E2F1 while
simultaneously decreasing the expression of Rb family members, a crucial cell cycle
suppressor. The induction of E2F1 is accompanied by S phase entry and subsequent
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apoptosis, thereby promoting maximally efficient replication of this virus. Thus,
modulation of E2F function may be a requirement for efficient lytic replication of
herpesviruses (Swenson et al., 1999). Recently, Feng et al., (2000) identified the
significant role played by Rta in NPC pathogenesis. They have observed the
expression of EBV lytic genes Zta, BALF2 and BCLF1 in nasopharynx biopsies
obtained from NPC and EBV +ve control individuals. However, Rta was detected in
NPC biopsies only, indicating its use as a diagnostic parameter of NPC. They have
also identified the antibody-binding regions in Rta. Hence, the IgG antibodies
directed against Rta can serve as a serological parameter for NPC diagnosis as well
as screening in a susceptible population.
1.6.1.3. Mta
EBV Mta was first identified as a promiscuous non-specific transactivator by
Lieberman et al., (1986). It transactivated not only EBV promoters, but also those
from unrelated viruses such as the HSV thymidine kinase gene, the E3 gene of
adenovirus, and the SV 40 early promoter. They have also shown that Mta is capable
of positive autoregulation. Transfection of an expression vector containing the Mta
coding sequence resulted in the synthesis of a 50 kDa protein. A 60 kDa protein was
specifically induced by the transactivator Zta; whereas, chemical induction of
lymphocytes latently infected with EBV resulted in the synthesis of both 60- and 50
kDa forms of Mta. This suggests that alternative forms of this protein can be induced
by alternate splicing patterns (Wong and Levine, 1989).
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In contrary to the earlier observation, Kenney et al., (1989a) have reported that the
Mta transactivation effect is reporter-gene dependent. It was capable of
transactivating latent (latent membrane protein), IE (Mta and Zta), E (early antigen
diffuse gene) and late (the major envelope glycoprotein, gp350/220) EBY promoters
when linked to chloramphenicol acetyl transferase (CAT) reporter gene, whereas
these promoters were unaffected when it is linked to the human growth hormone
gene. They have also shown that the CAT mRNA level was not increased in
proportion to the level of observed CAT activity. This suggests that the mechanism
of transactivation by Mta is partly posttranscriptional. In another experiment they
have proved that the expression of Mta promoter can be enhanced by Zta in EBV
positive but not in EBV negative B cells (Kenney et al., 1989b). This indicates that
the effect of Zta may be mediated through another EBV gene product. In support of
this view, they have also observed that the Mta was transactivated by Rta in both
EBV positive and negative B cells. The above observations clearly show the
presence of an enhancer element in the Mta promoter which is responsive to the Zta
and Rta transactivators (Kenney et al., 1989c). In addition to its role as a
transactivator, Mta has also been implicated in the regulation of replication gene
expression via the lytic origin of replication, oriLyt. It increased the cytoplasmic
accumulation of BALF2 (single-stranded DNA binding protein), BALF5 (DNA
polymerase), BSLF1 (primase), and BBLF4 (helicase) genes (Semmes et al., 1998).
1.6.2. Transactivator proteins of HVS
The immediate early transcripts in HVS are encoded by ORF 14, ORF 50 and ORF
57. The major IE transcript is ORF 14 and the analysis of sequence shows that it does
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not exhibit any homology with any EBV encoded proteins, but it contains local
homology with a putative superantigen. However, its function remains to be
established (Randall et al., 1984; Nicholas et al., 1990; Albrecht et al., 1992;
Whitehouse et al., 1998a). Gene expression during the HVS lytic replication cycle is
controlled by the products of the two major transcriptional regulatory genes encoded
by ORFs 50 and 57. No Zta homologue has yet been identified (Nicholas et al.,
1991; Whitehouse et al., 1997a&b; 1998a&b).
1.6.2.1. ORF 50
HVS ORF 50 is homologous to Rta of EBV (Nicholas et al., 1991). Whitehouse et
al., (1997a) have characterised the intron-exon structure of ORF 50 and
demonstrated that two transcripts were produced from two separate promoters, which
were active at different stages of the virus replication cycle. Among the two, one is
spliced (50a) and the other is unspliced (50b). The spliced transcript is detected at
early times during productive virus replication in Owl Monkey Kidney cells (OMK),
whereas the unspliced transcript is detected at later time points. They have also
shown that the spliced transcript is more potent in activating delayed early ORF 6
promoter (DNA binding protein gene) in transient transfection assays. Further, they
have elucidated the HVS ORF 50 responsive element in the ORF 6 promoter and
found that it shows homology to the EBV response element consensus sequence, 5'-
CC Ng GG- 3' (Whitehouse et al., 1997b). In transient transfection assays, as in the
case of EBV, the HVS ORF 57 gene was also transactivated by the ORF 50a gene
product (Whitehouse et al., 1998b).
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Thurau et al., (2000) performed a structural and functional analysis of the ORF 50
gene of strain C488. The strain C488 of group C carries two genes at the variable left
hand end: stp C and tip. Tip codes for a tyrosine kinase interacting protein which
interacts with the T-cellular protein kinase Lck (Biesinger et al., 1990, 1995). As in
the case of stp A in All strain, stp C of C488 strain also encodes for transforming
proteins (Jung et al., 1991). In contrast to virus strain All, C488 is capable of
transforming human T cells to stable growth in culture (Biesinger et al., 1992). The
structural analysis of ORF 50 of C488 revealed considerable sequence divergence
with ORF 50 of All strain. The transactivation capability is also significantly
different between two strains. In contrast to strain All, the short unspliced ORF 50b
displayed complete transactivation of ORF 6 and ORF 57 promoters.
Goodwin et al., (2001) investigated the role of HVS ORF 50 proteins in the latent-
lytic switch using a persistently HVS-infected cell line A549. They observed that the
spliced ORF 50a gene product, when expressed under the control of a constitutively
active promoter (CMV IE) rather than from its cognate promoter, was sufficient to
reactivate the entire HVS lytic replication cycle. Although, the HVS strains A and C
ORF 50 proteins are structurally divergent, both of them were capable of inducing
the lytic replication cycle in this model of HVS latency.
1.6.2.2. ORF 57
The IE 52-kDa protein of HVS has been mapped to the EcoRI-I/E fragments of the
HVS strain All genome and was found to be structurally and functionally
homologous to Mta of EBV (Nicholas et al., 1991). In transient transfection assays it
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can substitute with comparable efficiency for the Mta gene product of EBV in the
Zta -dependent activation of the EBV DR promoter (Nicholas et al., 1988). This
suggests that HVS ORF 57 can act as a transactivator protein capable of activating
CAT gene expression from heterologous promoter-CAT constructs. Subsequently
Whitehouse et al., (1998a) have demonstrated that ORF 57 gene product activates
the HVS ORF 50b (unspliced transcript), but it represses the transactivating
capability of the ORF 50a gene product (spliced transcript). This suggested that the
ORF 57 regulation is dependent on the presence of introns in the target gene
encoding region.
In addition, it can also activate a range of HVS promoters for the genes encoding
DNA polymerase, thymidine kinase, major capsid protein, and glycoprotein B,
although there is a difference in the rate of activation of CAT and P-Gal constructs
driven by same promoters. However, the increase in the CAT and P-Gal activity was
not correlated with a similar increase in CAT and P-Gal RNA levels in the presence
of ORF 57. This suggested that ORF57 regulates gene expression through a post-
transcriptional mechanism. Cooper et al., (1999) demonstrated that HVS infection of
COS-7 cells induced a reorganised distribution of the spliceosome component SC-35
and snRNP U2 and that the expression of ORF 57 alone was sufficient to cause this
effect. This indicates that the mechanism of down-regulation of intron containing
genes by ORF 57 and the redistribution of spliceosome complex are inter-related.
Goodwin et al., (2000) investigated the domains responsible for its functional
activities and observed that the carboxy terminus is required for ORF 57
transactivation, repression and an intense nuclear spotting. They have also identified
55
CHAPTER 1 INTRODUCTION
two highly conserved motifs; a zinc finger-like motif and a highly hydrophobic
domain and showed that these are involved in transactivator and repressor properties
of ORF 57.
1.6.3. Transactivator proteins of MHV-68
MHV-68 possesses homologues of EBV Rta and Mta. Like the homologues of Rta in
other gammaherpesviruses such as EBV and HVS, MHV-68 Rta also functions as a
transcriptional activator. Wu et al., (2000) studied the kinetics of MHV-68 Rta
transcription during lytic infection and the function of MHV-68 Rta in reactivation
using a B-cell line harbouring latent MHV-68. Their results indicate that Rta is
expressed as an immediate early gene during lytic infection and transfection of an
Rta expression plasmid can induce the expression of early and late viral RNAs and
proteins, activate lytic replication of viral DNA, and can lead to the production of
infectious viral particles. MHV-68 ORF 50 has two transcripts and it has been shown
to activate the ORF 57 promoter (Liu et al., 2000). Rochford et al., (2001) have also
shown that Rta is capable of disrupting latency and activating virus replication
resulting in a complete lytic cycle and production of infectious virus particles. The
gene encoding the Mta homologue of MHV-68 is also like that of EBV and HVS and
is composed of two exons (Mackett et al., 1997).
1.6.4. Transactivator proteins of KSHV
KSHV encodes for Rta, Mta and Zta homologues. Of these, Rta and Mta act as
transcriptional activators capable of reactivating the virus from latent to lytic stage.
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The Zta homologue is the structural homologue and designated as ORF K8. It has not
been fully functionally characterised (Gruffat et al., 1999).
1.6.4.1. ORF 50
KSHV ORF 50 is capable of activating KSHV early lytic genes, including virus-
encoded interleukin 6 and poly-adenylated nuclear RNA (PAN-RNA), and a late
gene, small viral capsid antigen. However, in cells dually infected with EBV and
KSHV, it activated only autologous lytic cycle genes (Sun et al., 1998). Lukac et al.,
(1998) have demonstrated that ORF 50 was able to selectively upregulate delayed-
early viral genes, sufficient to disrupt latency, and induce the lytic gene cascade.
They also explored several aspects of expression, structure, and function of this
protein and have established that it plays an essential role in KSHV lytic replication,
acting as a putative molecular switch controlling the induction of virus from latency
(Lukac et al., 1999). Similar observations were also made by Gradoville et al.,
(2000) in a newly established primary effusion lymphoma (PEL) cell line HH-B2,
transfected with a KSHV ORF 50 expression plasmid. They have shown that KSHV
ORF 50 auto-stimulated its own expression in cultured PEL cells.
Chen et al., (2000) reported that ORF 50 was capable of transactivating viral
interferon regulatory factor (vIRF) and DNA polymerase promoters in BCBL-1,
293T, and CV-1 cells. Using deletion analysis and competition gel shift assays, they
identified the domains in the vIRF promoter important for transactivation by ORF
50, as Spl binding sites. Sakakibara et al., (2001) have shown that ORF 50
autoregulated its own expression. They have identified the promoter element
required for it and an electrophoretic mobility shift assay indicated that the octamer
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binding protein-1 (Oct-1) bound to this element. Furthermore, mutations in the
octamer-binding motif resulted in refractoriness of the ORF 50 promoter to
transactivation by ORF50 whereas the Oct-1 expression enhanced this
transactivation. This auto-upregulation is thought to be an important mechanism for
efficient lytic viral replication.
In addition to this transactivator property, ORF50 also possesses a repressor function.
Transient transfection assays carried out in 293T cells using a p53 expression vector
have shown that ORF50 represses the transcriptional activity of p53 and p53 induced
apoptosis (Gwack et al., 2001). Recently, the target site of ORF 50 transactivation in
the ORF 57 promoter was mapped to a 40bp fragment encompassing nt 81904 to
81943 (Duan et al., 2001). Lukac et al., (2001) also identified and characterised the
DNA sequence of the ORF 57 promoter required for activation by ORF 50 and
showed that it is homologous to an element in the K-bZIP promoter and it can be
directly bound by ORF 50 protein. This binding site consists of a 12bp partially
palindromic sequence, 5' -AACAATAATGTT -3', together with several 3'flanking
nucleotides. Caselli et al., (2001) analysed the effects of ORF 50 and 57 on the
activation of the human immunodeficiency virus type 1 (HIV-1) LTR. They have
found that ORF 50 interacted synergically with HIV-1 tat inducing a 10-fold
enhancement of HIV-1 LTR transactivation in both BCBL-1 cells (latently infected
with KSHV) and HL3T1 cells (an epithelial cell line non-permissive to KSHV).
When both ORF 50 and 57 are expressed, the enhancement of transactivation





KSHV ORF 57 gene is spliced, contains a single intron and encodes a protein of 455
amino acids (Bello et al., 1999). Kirshner et al., (2000) have examined the
expression of this gene and found that it is expressed very early in infection from a
1.6kb spliced RNA. In transient transfection assays, ORF 57 had little effect on the
expression of reporter genes driven by a variety of KSHV and heterologous
promoters. It acts through posttranscriptional regulation to enhance accumulation of
certain virus transcripts, including ORF 50, ORF 59 and PAN-RNA. Kirshner et al.,
(2000) have also observed synergistic effect of coexpression of ORF 50 and ORF 57
on some of the promoters tested. Caselli et al., (2001) observed that ORF 57
enhanced tot-induced transactivation of HIV-1 LTR in KSHV latently infected cell
line BCBL-1 but, not in an epithelial cell line non-permissive to KSHV infection.
This suggests that the transactivation by ORF 57 was likely mediated by the
induction of ORF 50 or other KSHV viral functions.
1.7. Nuclear shuttling proteins
It has become apparent that some nuclear proteins are not confined to the nucleus
and they continuously shuttle between the nuclear and cytoplasmic compartments.
They include some of the heterogeneous nuclear RNP (hnRNP) proteins (Pinol-
Roma and Dreyfuss, 1992; Flach et al., 1994), the human immunodeficiency virus
type 1 (HIV-1) Rev protein (Meyer and Malim, 1994; Kalland et al., 1994), several
nucleolar proteins (Borer et al., 1989; Meier and Blobel, 1992), U1 small nuclear
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RNP-specific protein U1A (Kambach and Mattaj, 1992), steroid hormone receptors
(Guiochon-Mantel et al., 1991), heat shock related proteins (Mandell and Feldherr,
1990), and the protein kinase A inhibitor peptide (PK1) (Fantozzi et al., 1994). The
capacity of a nuclear protein to shuttle demonstrates that its nuclear import is
counterbalanced to some extent by its nuclear export. Though much has been
elucidated with respect to nuclear protein import, the process of nuclear protein
export is less well understood (Moore, 1996; Nigg, 1997).
There are two important pathways proposed for the nuclear protein export - an active
process and a passive process (Michael et al., 1995). The passive process occurs for
nuclear proteins, which do not have a means of nuclear retention (Laskey and
Dingwall, 1993; Schmidt-Zachmann et al., 1993). Some nuclear proteins possess
specific nuclear export sequences (NESs), which mediate their active export, via
interactions with cellular transport machinery. Such sequences have been identified
in Rev (Fischer et al., 1995; Meyer et al., 1996), PK1 (Wen et al., 1995) and hnRNP
Al (Michael et al., 1995). The Rev and PK1 NESs consist of short leucine-rich
segments, whereas the hnRNP Al NES, termed M9 is a 38-residue sequence which
contains no leucine residues and is glycine-rich. In general, NES-containing proteins
exhibit rapid nuclear shuttling, whereas the shuttling of proteins lacking NESs is a
slower process. The NES has recently been shown to interact with a protein, CRM1
or exportin 1, which is related to the karyopherin [3 family of nuclear import proteins
(Ossareh-Nazari et al., 1997; Seedorf and Silver, 1997). Exportin 1 interacts with the




Import of a protein into the nucleus occurs in two distinct steps. Different groups of
proteins are imported into the nucleus by specific nuclear import receptor systems. In
the classical system of import (Fig. 1.6), proteins containing basic nuclear
localisation signals (generally lysine-rich) are initially recognised by a cytoplasmic
nuclear localisation signal receptor importin- a, or karyopherin a, which forms a
heterodimeric complex with importin-P (karyopherin P) (Weis et al., 1995). Importin
P functions as a transport adapter molecule binding to the nuclear pore complex, via
a direct interaction with specific nucleoporins (Weis et al., 1996). Translocation of
the protein through the nuclear pore complex into the nucleus requires additional
transport proteins, including a small GTP-binding protein termed Ran and
nucleoporins. Once in the nucleus, binding of Ran-GTP to importin p causes
dissociation of the import complex (Gorlich et al., 1996). How these components
work together to move the import substrate is not yet clearly understood. It is
believed that guanosine nucleotide concentration differences, with GTP most
abundant in the nucleus and GDP most abundant in the cytoplasm, drives GDP-GTP
exchange in the nucleus and provides the driving force for transport. Some proteins
lack this nuclear localisation signal but still get transported into the nucleus as in the
case of P-catenin (Eleftheriou et al., 2001) and HSV-1 VP22 (Pomeranz and Blaho,
1999). However, the exact mechanism of how this happens is still unclear. The
combined presence of a NES and a nuclear localisation signal allows RNA transport
proteins to shuttle between nucleus and cytoplasm.
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Cellular Apoptosis Susceptibility gene (export factor)
Ran Ran
GPP GTP - Two different forms of Ran protein; Ran GTP is generated
within the nucleus; Ran GDP abundant in cytoplasm.
RanGAPI - Ran GTPase activating protein 1, which activates
the RanGTPase, leading to RanGDP.
RanBP1,2 - Ran binding protein 1&2, a soluble protein which
binds RanGTP and stimulates the activity of RanGAPI.
RCC1 - regulator of chromosome condensation 1, which is the
nucleotide exchange factor for Ran and generates RanGTP.
1. Import complex formation - (Importin a is the cytoplasmic receptor for
NLS-bearing proteins and it also binds to importin (3 to form a trimeric complex;
2. Transport and docking to the nuclear pore complex;
3. Ran and energy dependent transport of the import-complex into the nucleus;
4. Termination of the import reaction by the Ran GTP dependent dissociation of
the import-complex;
5. Export complex formation by RanGTP, CAS, and importin a;
6. Ran GTP dependent export of the export-complex and of importin (3;
7. RanGTP hydrolysis, stimulated by RanBPI and RanBP2 bound RanGAPI,
setting the importin proteins free for a new import cycle.
Fig 1,6: Schematic representation of the importin dependent
classical nuclear protein import pathway
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Although the significance of nuclear shuttling is not well known in all cases, some
shuttling proteins, which bind RNA, appear to have roles in mRNA export. The
shuttling protein hnRNP A1 is associated with RNA polymerase II derived
transcripts in both nucleus and cytoplasm and may directly mediate the
nucleocytoplasmic transport of these molecules (Pinol-Roma and Dreyfuss, 1992).
HIV-1 Rev mediates export of unspliced and incompletely spliced viral mRNAs;
binds to the Rev-responsive element in these mRNAs as an oligomer and directs
them to the cellular pathway for export of unspliced small RNAs via interactions
with cellular eIF-5a and exportin-1 proteins (Cullen, 1994; Fischer et al., 1994).
HSV-1 IE 63 (ICP 27) has been shown to possess RNA-binding activity, post-
transcriptional effects on viral and cellular gene expression and can effectively traffic
between nuclei in inter-species heterokaryons. Furthermore, it can also shuttle when
transiently expressed in uninfected cells, indicating that its shuttling does not require
viral infection or any other viral components (Mears and Rice, 1998). This suggests
that IE 63 facilitates nuclear export of HSV-1 transcripts, in addition to retaining
intron-containing transcripts in the nucleus.
1.7.1. Nuclear shuttling protein of EBV
The EBV nuclear protein Mta was capable of nucleo-cytoplasmic shuttling in a
heterokaryon assay (Semmes et al., 1998). Mta demonstrated the ability to shuttle
from the originally transfected HeLa cells to the RevM 10-staining nuclei of the
recipient cells. In an indirect immunofluorescence assay Mta showed intense nuclear
speckles and found to colocalise with the splicing factor SC35 indicating its presence
at sites adjacent to nascent mRNA synthesis and processing. GST-Mta was seen
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bound to BMRF1 and Mta transcripts but not to control cellular gene RNA. The
presence of a consensus leucine-rich nuclear export signal was also observed in Mta.
All these observations establish that Mta functions in RNA processing and transport,
mediates cytoplasmic accumulation of a number of EBV early mRNAs and has the
properties of a RNA export protein (Semmes et al., 1998). Subsequently it has been
demonstrated that Mta inhibited the expression of intron-containing genes, activated
the expression of intron-less genes, and efficiently transformed immortalised Rati
and NIH 3T3 cells. Using Mta deletion mutants it has been established that the C-
terminal region of the protein is involved in its effect on RNA splicing and transport.
The RNA binding domain of Mta has been located at the N-terminal region, between
aa 125 and 204, which is arginine-rich. As in the case of HSV-1 IE 63 and Rev, Mta
also has a leucine-rich region that contains a consensus NES. In the presence of Mta,
intron-containing and intron-less RNAs accumulate in the cytoplasm (Buisson et al.,
1999). Subsequently, Boyle et al., (1999) have reported that Mta mediated export of
intronless RNA and the intracellular localisation of Mta could be mediated by a
direct association with Crm-1.
Farjot et al., (2000) revealed different conclusions. Their experiments have clearly
demonstrated that, under conditions where Rev-mediated export of intron-containing
RNA is inhibited by inactivating the Crm-1 dependent pathway using Leptomycin-B
(LMB), the Mta mediated export of intron-containing RNA is unaffected. This
suggests that Mta is involved in nuclear export of RNA through a mechanism distinct
from that used by Rev protein. Moreover, unlike Rev shuttling, Mta nucleo-
cytoplasmic shuttling visualised by a heterokaryon assay is LMB resistant. Although
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a leucine-rich NES sequence has been identified previously in Mta, by site directed
mutagenesis and domain swapping, Farjot et al., (2000) showed that a Crm-1
independent pathway was utilised by Mta for nuclear export of RNAs.
1.7.2. Nuclear shuttling protein of HVS
Transfection of HVS infected COS-7 cells and 293T cells with ORF 57 expression
plasmid resulted in the re-distribution of SC-35 and snRNP U2 components of the
spliceosome. These re-distributed spliceosome components colocalise to regions in
the nucleus where the ORF 57 gene product is concentrated (Cooper et al., 1999).
Further, the expression of ORF 57 alone was sufficient to cause the re-distribution of
spliceosome components. Similarly, HSV-1 IE 63 has also been shown to re¬
distribute the snRNP components of the spliceosome (Phelan et al., 1993). The re¬
distribution of the spliceosome complex has a profound effect upon the splicing
capability of a cell and consequently on the processing of viral intron-containing
mRNA. Recent analysis has demonstrated that the ORF 57 protein has the ability to
bind viral RNA and shuttle between the nucleus and cytoplasm, and is required for
efficient cytoplasmic accumulation of virus mRNA (Goodwin et al., 1999). This
suggests that ORF57 plays a pivotal role in mediating the nuclear export of viral
transcripts.
Goodwin et al., (2000) have carried out detailed analysis of the functional properties
of ORF 57 gene product and the domains responsible for the different functions.
They have observed that the carboxy terminus is responsible for the transactivation,
repression and an intense nuclear spotting. They also located two important
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functional domains within the carboxy terminus designated as a zinc finger-like
domain and a highly hydrophobic domain (GLFF) and showed that the hydrophobic
domain is involved in nuclear localisation. Goodwin and Whitehouse (2001)
investigated the nucleo-cytoplasmic shuttling mechanism utilised by the HVS ORF
57 employing a yeast two-hybrid system to identify interacting cellular proteins
using ORF 57 as a bait. The results, as confirmed by co-immunoprecipitation
experiments using transfected and infected cells showed that ORF 57 interacts with
importin a isoforms 1 and 5. This interaction is mediated via the hydrophobic,
internal, importin a armadillo repeats. The ORF 57 amino-terminal arginine-rich
sequence, which functions as an NLS, is also required for this interaction. They have
also observed that the ORF 57 protein is responsible for the re-distribution of
importin a into the nucleoli.
1.7.3. Nuclear shuttling protein of KSHV
KSHV ORF 57 gene product has been shown to encode a nuclear protein implicated
in RNA processing and transport (Bello et al., 1999). A cellular localisation study
using the complete and truncated forms of the ORF 57 protein revealed that the full-
length protein exhibited a fluorescence pattern that was confined to the nucleus. The
punctate nuclear fluorescence also co-localised with the splicing factor SC-35,
similar to the observations with IE 63 and HVS ORF57. However, the N-terminal
truncated protein was confined to the cytoplasm indicating that the nuclear
localisation signal resides at the N-terminus. The shuttling ability of this nuclear
protein was investigated by two different methods and they found that though it was
capable of shuttling in the heterokaryon assay, it was resistant to Actinomycin D
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treatment. This feature has been observed with many shuttling proteins, including
the nucleo-cytoplasmic transport receptors such as cyclin Bl. To demonstrate
shuttling following Actinomycin D treatment, protein re-import into the nucleus has
to be transcription dependent (Hagting et al., 1998).
1.7.4. Nuclear shuttling protein of HSV-1
HSV-1 IE 63 is an essential viral regulatory protein which functions in the switch
from early to late gene expression during infection (McCarthy et al., 1989). It is one
of the two IE proteins essential for lytic virus replication and localises to the nucleus
(Sacks et al., 1985; Ingram et al., 1996). In transfection experiments, it has been
shown to function as both an activator and a repressor depending upon the target
gene (Sekulovich et al., 1988). At the posttranscriptional level, IE 63 has been shown
to bind RNA (Phelan et al., 1996) via an RGG binding motif (Mears and Rice, 1996).
Martin et al., (1987) observed that HSV-1 infection causes a redistribution of the
cellular splicing snRNPs from a diffuse speckled pattern to a highly punctate
expression in the nucleus and IE 63 was shown to be necessary and sufficient to
cause this effect. Moreover, IE 63 protein was shown to colocalise with the
redistributed snRNPs (Sandri-Goldin et al., 1995). This indicates that HSV-1
infection has a dramatic effect on splicing of cellular RNAs, and IE 63 has a key role
in this event. During HSV-1 infection, intron-containing viral transcripts were
retained in the nucleus whereas non-intron-containing transcripts were detected in
the cytoplasm (Phelan et al., 1996). It has also been shown to shuttle from the
nucleus to the cytoplasm during Actinomycin D treatment (Phelan and Clements,
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1997). This property suggests an essential role of this protein in facilitating virus
RNA trafficking from the nucleus.
1.7.5. IE63 Export pathways
Importin p family members have been thought of as the only proteins capable of
transporting cargoes across the nuclear pore. However, recent work suggests that
other proteins can also use the RanGTP system to transport cargoes. An endoplasmic
reticulum resident calcium binding protein (CRT), has been implicated in the nuclear
export of proteins with a leucine rich nuclear export signal (LRNES) (Holaska et al.,
2001). Recombinant CRT can stimulate export of the LRNES even in the presence of
leptomycin B (LMB), a specific inhibitor of CRM 1-dependent nuclear export,
showing that this pathway is distinct from the CRM1 pathway (Fornerod, et al.,
1997).
CRM1 mediates the nuclear export of a variety of proteins and RNAs including the
HIV-1 mRNAs and cellular small nuclear RNAs. CRM 1-independent export of
unspliced HIV-1 mRNA can be promoted by a constitutive transport element (CTE)
by interaction with TAP/NXF1 (Transporter associated with antigen processing/
Nuclear RNA export factorl (Braun et al., 1999; Kang and Cullen, 1999). TAP has
also been implicated in the export of cellular mRNA (Braun et al., 2001). TAP binds
the viral CTE specifically, whereas the interaction of TAP with cellular RNAs is
thought to be mediated by a conserved family of proteins called REFs (RNA and
export factor binding proteins) (Rodrigues et al., 2001). REFs are thought to




IE63 protein is an RNA export factor that stimulates viral but not cellular mRNA
nuclear export. For exporting viral mRNAs IE63 utilises the CRM1 independent
pathway. IE63 interacts directly with REF and forms a complex with REF and TAP
proteins invitro and in HSV-1 infected cells. IE63 recruits REF proteins to intronless
viral RNAs and escorts them to the cytoplasm using the same pathway proposed for
cellular mRNAs, via the interaction of REF with TAP (Koffa et al., 2001). This
describes a novel way by which intronless viral RNAs can access a conserved
cellular mechanism to promote viral mRNA export.
1.8. Project background
It has been observed that when AlHV-l is passaged through bovine cell cultures, it
changes from being cell-associated and virulent to cell-free and virulent after
approximately 10 passages and then becomes cell-free and attenuated after a further
20 passages. Genomes from the virulent and attenuated forms of the virus have been
analysed and it was proposed that an alteration had occurred in the genome (Handley
et al., 1995). ORF 50 has been implicated as one of the genes affected by the
rearrangement /or deletion.
The homologues of ORF 50 in other herpesviruses have been shown to play a key
role in reactivation of virus from latency, in inducing the cascade of gene expression
and it also affects cell cycle regulation. Transient transfection assays have shown that
AlHV-l ORF 50 transactivates the AlHV-l ORF 57 and ORF 6 promoters. Further, a
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113bp region, 409-522 bp upstream of the ORF 57 start codon, was shown to be
critical for transactivation by ORF 50 (Frame, 2001).
The ORF 57 homologues in other herpesviruses have been identified as an essential
nuclear protein which regulates viral early and late genes during infection. It plays an
important role in viral gene expression, being required for the progression of the viral
infection into the lytic phase. The role of A1HV-1 ORF 57 in the viral life cycle is
not yet known. Understanding the functions of ORF 57 gene product at the molecular
level will help to elucidate the fundamental information with regard to its role in
viral pathogenesis.
1.9. Aim of the project
The aim of this project was to characterise the A1HV-1 ORF 57 gene product and
investigate its role in the pathogenesis of the disease. Several approaches were taken
including analysis of the transcription pattern of the ORF 57 gene and the sub¬
cellular localisation of the protein. The potential transactivating function of the gene
was examined. Attempts were made to define the regulatory role of this protein at the
post-transcriptional level and its contribution to viral life cycle switch from latency
to lytic productive replication.
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2. Materials and methods
All chemicals were obtained from Sigma (Sigma-Aldrich Company Ltd., Fancy
Road, Poole, Dorset, BH12 40H, England) or ICN Biochemicals (ICN
Pharmaceuticals Ltd., 1 Elmwood, Chineham Business Park, Basingstoke,
Hampshire, RG24 8WG) unless otherwise stated. Milli-Q water (sterile and fdtered)
(Millipore) was used for preparation of all solutions, in all enzymatic reactions and in
the preparation of nucleic acid and protein samples.
2.1. Culture of cells and virus
2.1.1. Cell lines
All cells lines were cultured in sterile plastic-ware (Nunc) and incubated at 37°C in
equilibrium with humidified 5% CO2.
Bovine turbinate (BT) cells were grown in Iscove's medium (Gibco BRL, Life
Technologies) containing 10% (v/v) Foetal Calf Serum (FCS) (Globepharm), 70
pg/ml penicillin (Merck BDH), 10 fig/ml streptomycin, 2 mM L-glutamine (Merck
BDH) and 250 pg/ml Amphotericin B (an anti-fungal agent) (Merck BDH). BT cells
were provided by Miss Irene Pow, Moredun Research Institute, Edinburgh.
Baby Hamster Kidney (BHK-21) cells are a continuous fibroblastoid cell line from a
Syrian golden hamster (Macpherson and Stoker, 1961). BHK-21 cells were cultured
in Glasgow Minimum Essential Medium (GMEM) (Gibco BRL, Life Technologies)
supplemented with 10% (v/v) Tryptose Phosphate Broth (Life Technologies) and
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10% (v/v) Newborn Calf Serum (NBCS) (Life Technologies), 70 pg/ml penicillin,
10 pg/ml streptomycin and 2 mM L-glutamine.
2.1.2. Harvesting of cells
Adherent cells were maintained in sub-confluent growth and passaged by removing
them from the monolayer with trypsin. The medium was poured off and the
monolayer washed with 0.02% (w/v) versene (see section 2.6) for BT cells or sterile
PBS for BHK-21 cells. The monolayer was then incubated with 0.25% (w/v)
trypsin/EDTA (Life Technologies) until the cells detached from the surface of the
flask. The cells were resuspended in media by pipetting and seeded into a T 175 flask
at a density of 1 x 106 - 3 x 106 for BT cells or 2 x 106 - 6 x 106 for BHK-21 cells.
2.1.3. Long-term storage of mammalian cells
Cells were trypsinised and centrifuged at 4500 x g for 10 min. The pellet was
resuspended in freezing mix [90% (v/v) FCS, 10% (v/v) DMSO] at a concentration
of 1 x 106 cells/ml. One ml aliquots were transferred to cryovials, wrapped in cotton
wool for freezing at -70°C overnight. Cells were then stored in liquid nitrogen.
2.1.4. Preparation of virus stocks
The C500 strain of A1HV-1 was obtained from Dr. Hugh Reid and Miss Irene Pow,
Moredun Research Institute, Edinburgh. This virus was isolated from a blue
wildebeest and passaged several times through rabbits. A volume of 0.3 ml of very
low passage virus stock (A1HV-1 C500, cell associated virus) was added to a T 175
flask of BT cells at 80% confluence. Virus-infected BT cells were grown in medium
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containing 2% (v/v) FCS. Cells were incubated until signs of CPE were observed (~7
days), at which time they were harvested by scraping and pelleted by centrifugation
at 4500 x g for 10 min. The pellet was resuspended in 2 ml of medium and 1.8 ml
was used to infect ten T175 flasks of BT cells. The cells were incubated for 8 days
and then harvested and pelleted by centrifugation at 4500 x g for 10 min. The pellets
were resuspended in 90% (v/v) FCS and 10% (v/v) DMSO, pooled and aliquoted
into cryovials (0.5 ml), which were stored in liquid nitrogen.
A cell free attenuated virus was also obtained from Moredun Research Institute. One
ml of the virus stock was used to infect a T175 flask of 80% confluent BT cells.
Virus-infected BT cells were grown in 10 ml of medium containing 2% (v/v) FCS.
Cells were incubated until signs of CPE were observed (7-10 days), at which time
they were harvested by scraping and pelleted by centrifugation at 4500 x g for 10
min. The cell debris was removed and one ml of supernatant was used to infect one
T175 flask of BT cells. The cells were incubated for 7-10 days and then harvested as
before. Supernatant was aliquoted in one ml amounts and stored at -70°C.
2.1.5. Transfection of mammalian cells by electroporation
Cells were harvested as described in section 2.1.2, resuspended in medium lacking
serum and 800 pi aliquots of this cell suspension were added to 1.5 ml micro¬
centrifuge tubes containing DNA in a 50 pi volume. BHK-21 cells were used at 2 x
106 cells per sample. The DNA-cell mixture was placed in a 4 mm electroporation
cuvette (Flowgen) and electroporated at a capacitance of 1050 pF and a voltage of
300 V in an EquiBio EasyjecT Plus electroporator. After electroporation, cells were
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plated immediately onto 60 mm dishes containing 3 ml of Glasgow's medium with
10 % (v/v) NBCS and assayed after incubation at 37°C for 48 h.
2.1.6. Dual-luciferase reporter assays
The Dual-Luciferase Reporter Assay System (Promega) was used to assess the
function of the gene under study in transfected cells. Cells were washed with sterile
PBS and incubated for 15 min in 400 pi of proprietary lx Passive Lysis Buffer.
Lysates were harvested and transferred to a 1.5 ml micro-centrifuge tube and
centrifuged for 2 min at 3500 x g. The samples were assayed using proprietary firefly
Luciferase Assay Reagent II. Proprietary Stop & Glo Reagent was then added which
quenches the firefly luciferase signal and provides the substrate for the Renilla
luciferase. The luciferase activities were measured using a Luminoskan RT
luminometer.
2.2. Extraction and analysis of plasmid DNA
Molecular cloning was carried out as described previously (Sambrook et al., 1989).
2.2.1. Plasmid vectors
The following plasmid vectors were used.
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Promega 3018 Amp None
pEGFP-Nl N-terminal enhanced
green fluorescent protein vector
Clontech 4700 Kan/Neo CMV IE
pEGFP-Cl C-terminal enhanced
green fluorescent protein vector
Clontech 4700 Kan/Neo CMV IE
pGL2-Basic vector Promega 5100 Amp None
pGL3-Basic vector Promega 4818 Amp None
pGL3-Promoter vector Promega 5010 Amp SV40
pRL-SV40 vector Promega 3705 Amp SV40
pRL-TK vector Promega 4045 Amp HSV TK
pRL-CMV Promega 4079 Amp CMV IE
PRL-null Promega 3320 Amp None
Abbreviations used in table:
CMV IE - human cytomegalovirus immediate-early promoter, SV40 - simian virus 40. HSV TK -
Herpes simplex virus thymidine kinase promoter.
E.coli drug selection: Amp - Ampicillin, Kan - Kanamycin.
Mammalian cell selection: Neo - Neomycin.
EGFP - enhanced green fluorescent protein.
pEGFP CI and pEGFP N1 encode for green fluorescent protein with CI having multiple cloning sites
at the C-terminus of the GFP and N1 having multiple cloning sites at the N-terminus of the GFP to
allow the fusion of gene of interest. pGL2basic vector encodes a spliced firefly luciferase gene and
pGL3basic codes for an unspliced firefly luciferase gene. pRL vectors encode a spliced renilla
luciferase gene.
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2.2.2. Polymerase chain reaction (PCR)
Unless otherwise stated, PCR was usually carried out in a volume of 50 pi containing
1 ju.1 of 1 U/pl Taq polymerase (Boehringer Mannheim/Roche), 5 pi of lOx reaction
buffer (100 mM Tris-HCl, 15 mM MgCl2, 500 mM KC1 [pH 8.3]), 100 ng of each
primer, 10 ng of DNA template, 10 mM dNTP mix (Sigma), 1.5 mM MgCL and
dH20. PCR was carried out in thin-walled 0.2 ml Eppendorf tubes in a Hybaid
Omnigene PCR machine or Hybaid PCR sprint thermal cycler under the following
conditions: 1 cycle of 96°C for 2 min; 40 cycles of 96°C for lmin, 50°C for 1 min
and 72°C for 1 min and finally 1 cycle of 72°C for 7.5 min. Reactions were optimised
by varying annealing temperature, MgCl2 concentration, pH or by adding DMSO or
glycerol (Pomp and Medrano, 1991).
The annealing temperature varied for individual primer pairs and is stated
accordingly. All primers were obtained from MWG-Biotech. PCR products (25 pi)
were analysed by 1% (w/v) agarose gel electrophoresis. In some instances bands
were excised from the gel for purification.
The annealing temperature for each primer was calculated as follows:
[(No: of Gs + Cs) x 4] + [(No: of As + Ts) x 2] - 5 = annealing temperature
(Suggs et al., 1981). If a restriction endonuclease recognition site was incorporated in
the oligonuleotide primer, its sequence was not included in the above equation.
2.2.3. Agarose gel electrophoresis
PCR products or restriction endonuclease digested products (20 pi) were mixed with
6 pi of loading buffer (see section 2.6). Samples were loaded onto a horizontal 1%
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(w/v) agarose (Bioline) gel prepared using lx TAE buffer and containing 1 pg/ml
ethidium bromide. The gel was submerged in lx TAE buffer and samples were
electrophoresed at constant voltage (13 cm x 15 cm gels at 100 V or 6 cm x 7 cm
gels at 80 V). DNA bands were visualised using a short wave UV transilluminator
(UVP inc.) at a wavelength of 302 nm. The size of DNA bands was estimated by
comparison with DNA molecular weight markers. The DNA markers used were
iscoRI and HindlU fragments of bacteriophage lambda DNA (sizes in bp: 21226,
5148, 4973, 4268, 3530, 2027, 1904, 1584, 1375, 947, 831, 564, 125) (Promega) and
a lOObp DNA Ladder (Sizes in bp: 1500, 1000, 900, 800, 700, 600, 500, 400, 300,
200, 100) (Promega).
2.2.4. Extraction of DNA fragments from agarose gels
DNA bands were excised from agarose gels using a clean scalpel blade and placed in
a micro-centrifuge tube. DNA was extracted from agarose gels using the QIAquick
gel extraction kit (Qiagen) as per manufacturer's instructions. Briefly, Buffer QG
was added and incubated for 10 min at 50°C with occasional vortexing for
solubilisation of the gel. The sample was then added to a QIAquick column
containing silica membrane to which the DNA gets adsorbed in the presence of high
salts. The contaminants were washed through the column by addition of Buffer PE,
which contains ethanol. The DNA was eluted in 10 mM Tris-HCl pH 8.5.
2.2.5. Quantification of DNA
Plasmid DNA was quantified using a CECIL spectrophotometer. To 98 pi of TE
buffer, 2 pi of plasmid DNA was added and optical density (OD) was measured at
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260 nm and 280 nm. The figure obtained at 260 nm was multiplied by 50 to account
for the dilution of the DNA and by 50 again to obtain the concentration per ml. This
is based on the fact that 1 OD unit is equivalent to approximately 50 jag/ml of
double-stranded DNA. The ratio of OD values at 260 nm to 280 nm indicated the
purity of the DNA. A ratio of 1.8-2.0 was taken as the cut off mark for purity of
DNA (Sambrook et al., 1989).
2.2.6. Digestion of DNA with restriction enzymes
DNA restriction enzymes were obtained from New England Biolabs and used with
the supplied buffers according to the manufacturer's instructions. DNA restrictions
were usually carried out in a volume of 20- 50 pi with one U of enzyme per one pg
of DNA for a minimum of 2 h at 37°C. Digested DNA was analysed on a 1% (w/v)
agarose gel.
2.2.7. "Blunt-ending" of DNA fragments
DNA overhanging ends generated by restriction enzymes were filled in to facilitate
ligation with blunt-ended vector DNA. This was performed using Klenow
polymerase (DNA polymerase I large fragment) in reaction buffer (50 mM Tris-HCl
pH 8.0, 10 mM MgCf, 50 mM NaCl) (Gibco BRL Life technologies) with 33 mM
dNTPs (Sigma). This mixture was incubated at 37°C for 20 min. The reaction was
terminated by phenol extraction.
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2.2.8. De-phosphorylation of linearised DNA
In order to prevent self ligation of vector, the 5'-phosphate group on each end of
linearised vector DNA was removed by direct addition of 5 U of shrimp alkaline
phosphatase (SAP) (USB Life Science Research Products) to the restriction digest
mix. The mixture was incubated at 37°C for 1 h. SAP was heat inactivated by
incubating the reaction mix at 65°C for 15 min.
2.2.9. Ligation of DNA fragments
Ligations involving the pGEM-T Easy vector were carried out at 4°C overnight. 10
pi of the reaction mix contained 5:1 ratio of DNA fragment (PCR product) to be
inserted and linearised vector DNA, 1 pi of lOx T4 DNA ligase buffer (300 mM
Tris-HCl [pH 7.8], 100 mM MgCl2, 10 mM ATP, 100 mM dithiothreitol), and 3U T4
DNA ligase (Promega).
Ligations involving other vectors were carried out at 16°C overnight in a final
volume of 10 pi containing T4 DNA ligase (3U) and 1 pi of lOx T4 DNA ligase
buffer (660 mM Tris-HCl pH 7.5, 50 mM MgCl2, 10 mM dithioerythritol, 10 mM
ATP) (Boehringer Mannheim/Roche).
For blunt ended ligations, T4 DNA ligase (3U) and 2 pi of 5x T4 DNA ligase buffer
(250 mM Tris-HCl pH 7.6, 50 mM MgCl2, 5 mM DTT, 5 mM ATP, 25% (w/v)
polyethylene glycol-8000) (Gibco BRL Life Technologies) were used.
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2.2.10. Transformation of competent bacteria
JM 109 competent cells (Promega) were used for transformation of plasmid DNA by
heat-shock. All bacteria were grown in sterilised Luria-Bertani (LB) medium
(Sambrook et al., 1989) with addition of appropriate antibiotics. Agar plates were
made with 15 g/1 bacteriological agar (ICN Biochemicals) in LB medium.
To 4 pi of ligation mix, 50 pi of JM 109 cells (Promega) were added and placed on
ice for 30 min. The cells were then placed at 42°C for 45 s (heat shocked) and then
chilled on ice for a further 2 min. SOC medium (900 pi) was added to the cells and
the mixture was incubated at 37°C for 1.5 h with shaking (250 rpm). The cells were
then centrifuged in a micro-centrifuge at 3500 x g for 2 min, resuspended in 200 pi
of SOC medium and spread onto LB agar plates containing an appropriate antibiotic
(100 pg/ml ampicillin or 50 pg/ml kanamycin A [Sigma]). The plates were inspected
after 18hat37°C.
For transformations involving the pGEM-T Easy vector, IPTG (isopropylthio-p-D-
galactoside) and X-gal (5-bromo-4-chloro-3-indolyl-[3-D-galactoside) [Bio-Gene
Ltd], were spread onto agar plates containing ampicillin just prior to use. IPTG was
used at 100 pi per plate (0.1 M stock, fdter-sterilised) and X-gal [50 mg/ml stock
dissolved in dimethylformamide (AnalaR)] was used at 20 pi per plate. The pGEM-T
Easy vector contains the a-peptide coding region of the enzyme P-galactosidase,
which allows identification of recombinant clones by blue/ white selection. In the
presence of IPTG (a lactose analogue that induces expression of P- galactosidase)
and X-gal (a substrate for P-galactosidase), blue colonies are produced. Insertion of a
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PCR product into the vector disrupts the (3-galactosidase gene, resulting in white
colonies.
2.2.11. Small-scale preparation of plasmid DNA
After transformation, bacterial colonies were picked and grown overnight in 5 ml of
liquid LB medium with appropriate antibiotic selection. Preparation of plasmid DNA
was carried out using a QIAprep Spin Miniprep kit (QIAGEN). The bacterial cells
were harvested by centrifugation at 600 x g for 5 min. The bacterial pellet was
resuspended in Buffer PI (50 mM Tris-HCl pH 8.0, 10 mM Ethylenediaminetetra
acetic acid (EDTA), 100 pg/ml RNase A) and then incubated in Buffer P2 (200 mM
NaOH, 1% (w/v) Sodium dodecyl sulphate (SDS) to lyse the bacterial cells. Buffer
N3 (3 M potassium acetate pH 5.5) was added to precipitate the genomic DNA,
proteins, cell debris and SDS. The supernatant containing the plasmid DNA was
separated from the precipitate by centrifugation in a micro-centrifuge, and then
passed through a column containing an anion-exchange resin. Addition of Buffer PB
followed by ethanol-containing proprietary Buffer PE to the column removed RNA,
proteins and low molecular weight impurities. Plasmid DNA was then eluted in 50 pi
of low salt Buffer EB (10 mM Tris-HCl, pH 8.5).
2.2.12. Large scale preparation of plasmid DNA
Large preparations of plasmid DNA were made using QIAGEN Plasmid Midi and
Maxi kits (QIAGEN). The principle of these kits is the same as the QIAprep Spin
Miniprep kit described above, except that the column is first equilibrated with Buffer
QBT (750 mM NaCl, 50 mM 3-[N-Morpholino] propanesulfonic acid (MOPS), pH
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7.0, 15% (v/v) isopropanol, 0.15% (v/v) Triton X-100) before addition of the
supernatant containing the plasmid DNA. Impurities were then removed by three
washes with Buffer QC (1 M NaCl, 50 mM MOPS pH 7.0, 15% (v/v) isopropanol).
The plasmid DNA was eluted in Buffer QF (1.25 M NaCl, 50 mM Tris-HCl pH 8.5,
15% (v/v) isopropanol) and precipitated with isopropanol. The pellet was then
washed once with 70% (v/v) ethanol to remove excess isopropanol, air-dried and
resuspended in TE buffer.
2.2.13. Automated sequencing of DNA
tm
DNA sequencing reactions were performed using a SequiTherm EXCEL II DNA
Sequencing kit (cycle sequencing protocol) on a 4000L automated sequencing
machine (MWG-Biotech) by Ian Bennet (Dept. of Veterinary Pathology, University
of Edinburgh).
2.3. Extraction and analysis of RNA
2.3.1. Extraction of total RNA from mammalian cells
Total RNA was extracted from cells using the RNAzol B reagent (Biogenesis).
Medium was removed and cell monolayers washed with sterile PBS. To lyse the
cells, 0.2 ml of RNAzol B per 1 x 106 cells was added directly onto the monolayers
in the culture flask and the resulting cell lysate passed through a 5 ml pipette several
times before transferring to a micro-centrifuge tube. To 2 ml of cell homogenate, 0.2
ml of chloroform was added. The samples were then vigorously shaken and
incubated on ice for 5 min. The suspension was centrifuged at 12000 x g for 15 min.
The upper aqueous phase was transferred to a micro-centrifuge tube, mixed with an
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equal volume of isopropanol and incubated for 15 min at 4°C. Samples were again
centrifuged at 12000 x g for 15 min. The RNA precipitate was washed with 0.8 ml of
75% (v/v) ethanol, centrifuged at 7500 x g for 8 min and resuspended in 200 pi of 1
mM EDTA pH 7.0.
2.3.2 Extraction of RNA from AIHV-1 -infected cells
RNA representing the three temporal classes of gene expression in AIHV-1 was
prepared. In all cases, virus was added in 5 ml of medium and left for 1 h before the
volume was increased to 30 ml. In preparation for this experiment, 15 T175 flasks of
BT cells were infected with AIHV-1 and a further 15 T175 flasks of subconfluent BT
cells were prepared. To each flask of subconfluent BT cells, the cells from one virus-
infected flask exhibiting 50-70% CPE were added. RNA was harvested as described
in 2.3.1.
To obtain RNA from expression of IE genes, Iscove's medium containing 2% (v/v)
FCS with cycloheximide (100 pg/ml) was added to BT cell monolayers 30 min prior
to addition of virus and maintained throughout the infection. The cells were
harvested 8 h after addition of virus.
To obtain RNA from expression of E genes, Iscove's medium containing 2% (v/v)
FCS with phosphonoacetic acid (PAA) (0.1 mg/ml) was added at the time of virus
addition and maintained throughout infection. Cells were harvested 24 h later.
Addition of PAA (a herpesvirus DNA polymerase inhibitor) inhibits DNA synthesis.
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To obtain RNA from expression of L genes, virus was added with no supplement and
harvested 24 h later.
2.3.3. Extraction of RNA from transfected cells
BHK 21 cells were transfected with the appropriate plasmid construct and RNA was
extracted 24 h after transfection using the TRIzol reagent (Life technologies.
Medium was removed and cell monolayers washed with sterile PBS. To lyse the
cells, 1 ml of TRIzol was added directly onto the monolayers in the 3.5 mm culture
dish and the resulting cell lysate passed through a 5 ml pipette several times before
transferring to a micro-centrifuge tube. To 1 ml of TRIzol reagent used, 0.2 ml of
chloroform was added. The samples were then vigorously shaken and incubated at
room temperature for 2-3 min. The suspension was centrifuged at 12000 x g for 15
min at 4°C. The upper aqueous phase was transferred to a micro-centrifuge tube,
mixed with an equal volume of isopropanol and incubated for 10 min at room
temperature. Samples were again centrifuged at 12000 x g for 15 min at 4°C. The
RNA precipitate was washed with 1 ml of 75% (v/v) ethanol, centrifuged at 7500 x g
for 5min at 4°C and the supernatant was removed. The pellet was resuspended in 200
pi of 1 mM EDTA pH 7.0.
2.3.4. Electrophoresis of RNA
This was carried out by the method in Sambrook et al. 1989. RNA samples were
electrophoresed in a 1.2% (w/v) agarose gel containing 2.2 M formaldehyde and
ethidium bromide (1 pg/pl) made with lx RNA gel-running buffer. The RNA
samples were made up to 5.5 pi with dH20. To this, 1 pi lOx RNA gel-running
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buffer, 3.5 jal formaldehyde and 10 pi formamide was added. The 0.24-9.5 kb RNA
ladder (Gibco BRL Life Technologies) or the RNA Molecular Weight Marker I
(Roche) was prepared in the same manner. All samples were denatured at 65°C for
15 min, cooled on ice and mixed with 2 pi lOx RNA gel-loading buffer. The
horizontal gel was submerged in lx RNA gel-running buffer and electrophoresed
overnight at 35 V with re-circulation of the buffer.
2.3.5. Northern hybridisation
The gel was washed in 50 mM NaOH, 150 mM NaCl for 30 min and then in 0.1 M
Tris-HCl pH 7.5, 150 mM NaCl for a further 30 min. The gel was rinsed with Milli-
Q water and soaked in 20x SSC for 45 min. Two pieces of 3 MM paper were cut to
the size of the gel tank and placed over the platform so that both ends were
submerged in the wells of the tank, which were filled with 20x SSC. The gel was
placed on the paper. Hybond-N nylon transfer membrane (Amersham), cut to the size
of the gel, was soaked in 20x SSC and placed on top of the gel. Two sheets of 3MM
paper, cut to the size of the gel, were soaked in 20x SSC and placed on top of the
membrane followed by a stack of blotting paper and a 500 g weight. Transfer of
RNA from the gel to the membrane took place overnight.
The RNA was cross-linked to the membrane by placing it in a 'Stratalinker'
(Stratagene) for 45 seconds, which exposes the membrane to UV having a
wavelength of 254 nm.
The marker track was cut from the rest of the membrane after cross-linking and air-
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dried. It was then incubated in 1 M acetic acid for 10 min at room temperature and
then in RNA Marker staining solution (see section 2.6) for 10 min. Finally, it was
washed in sterile distilled water until the blue background disappeared.
2.3.6. Probe labelling
To label a double-stranded DNA probe, 25 ng of DNA in 11 pi dH20 was boiled for
10 min and quenched on ice. To this, 5 pi of [a- P] dCTP (10 mCi/ml) (Amersham)
followed by 4 pi of High Prime, containing random oligonucleotide primers, 0.125
mM each of dATP, dGTP and dTTP, Klenow enzyme (4 U) and reaction buffer
(Boehringer Mannheim/Roche) were added. This was incubated at 37°C for 30 min.
The reaction was stopped by boiling for 10 min. This was followed by the addition of
100 pi of TE buffer. Labelled DNA was separated from unincorporated radiolabelled
nucleotides by gel filtration on NICK columns (Amersham Pharmacia Biotech).
2.3.7. Probing the membrane
The membrane was incubated for 1 h at 45°C in 50 ml of pre-hybridisation buffer.
The pre-hybridisation buffer was 5x SSPE buffer, 5x Denhardt's solution, 50% (v/v)
formamide, 0.5% (w/v) SDS and 100 pg/rnl denatured salmon sperm DNA. The pre-
hybridisation buffer was replaced with hybridisation buffer (pre-hybridisation buffer
plus 10% (w/v) dextran sulphate and 200 pg/ml instead of 100 pg/ml denatured
salmon sperm DNA). The labelled probe was then added and incubated with the
membrane overnight at 45°C.
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Following hybridisation, the membrane was washed twice in 2x SSC, 1% (w/v) SDS
for 15 min at room temperature and twice in 0.5x SSC, 1% (w/v) SDS for 15 min at
65°C. The membrane was then washed with TE, excess liquid was removed using 3
MM paper, and the membrane was wrapped in clingfilm and placed in a
phosphorimager cassette. This was analysed using a phosphorimager (Molecular
Dynamics).
2.3.8. PolyA TractRmRNA isolation system
To isolate mRNA from total RNA, PolyA TractR mRNA Isolation System was used
(Amersham Pharmacia). The different steps in the isolation procedure is described
below.
Annealing of probe: In a sterile, RNase-free tube, 1 mg of total RNA was made up to
a final volume of 500 pi using RNase free water. The tubes were placed in a 65°C
heating block for 10 min, and then 3 pi of the Biotinylated-Oligo (dT) probe and
13 pi of 20X SSC was added. The tubes were mixed gently and incubated at room
temperature until completely cooled.
Washing of the Streptavidin-Paramagnetic Particles (SA-PMP): The SA-PMPs were
resuspended by gently flicking the bottom of the tube until they were completely
dispersed. The SA-PMPs were captured by placing the tube in a Magnetic Stand until
the SA-PMPs collected at the side of the tube. The supernatant was carefully
removed and the SA-PMPs were washed three times with 0.3 ml of 0.5 X SSC, each
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time capturing them using the Magnetic Stand and then carefully removing the
supernatant. The washed SA-PMPs were resuspended in 0.1 ml of 0.5 X SSC.
Capture and Washing of Annealed Oligo (dT)-mRNA Hybrids: The entire contents
of the annealing reaction was added to the tube containing the washed SA-PMPs, and
incubated at room temperature for 10 min. The tube was mixed gently by inversion
every 1-2 min. The SA-PMPs were captured using the Magnetic Stand and the
supernatant was carefully removed without disturbing the SA-PMP pellet. The
particles were washed four times with 0.3 ml of 0.1 X SSC by gently flicking the
bottom of the tube until all of the particles were resuspended. After the final wash, as
much of the aqueous phase as possible was removed without disturbing the SA-
PMPs.
Elution of mRNA: To elute the mRNA, the final SA-PMP pellet was resuspended in
0.1 ml of the RNase-free water by gently flicking the tube. The SA-PMPs were
magnetically captured and the eluted mRNA in the aqueous phase transferred to a
sterile, RNase-free tube.
2.3.9. Reverse transcriptase-polymerase chain reaction (RT-PCR)
DNase I (Gibco BRL Life Technologies) was used to remove DNA from the RNA
preparation. To 1 pg of RNA, 1 pi of lOx DNase I buffer (200 mM Tris-HCl pH 8.4,
20 mM MgCh, 500 mM KC1) and 1 pi of DNase I (1 U/pl) was added and the
mixture made up to 10 pi with RNase-free distilled water. This was incubated at
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room temperature for 15 min. The DNase I was inactivated by addition of 1 pi of 25
mM EDTA and incubation at 65°C for 10 min.
Superscript II RNase H" Reverse Transcriptase (Gibco BRL Life Technologies) was
used for the reverse transcription reaction. To 10 pi of RNA from above, 1 pi of
oligo d (T) primer (500 pg/ml) was added along with 1 pi of dH20 to make a final
volume of 12 pi. This sample was incubated at 70°C for 10 min. To the mixture, 4 pi
of 1st strand buffer (250 mM Tris-HCl (pH 8.3), 375 mM KC1, 15 mM MgC^), 2 pi
of 0.1 M DTT and 1 pi of 10 mM dNTP mix was added. The sample was then
incubated at 42°C for 2 min followed by addition of 1 pi (200 U) of Superscript II
reverse transcriptase and a further incubation at 50°C for 50 min. The enzyme was
inactivated by incubating at 70°C for 15 min. PCR was carried out as in section 2.2.2.
One tenth of the reverse transcribed sample was used in a PCR reaction.
2.3.10. 5'-rapid amplification of cDNA ends (5' RACE)
Attempts were made to identify the unknown 5'-end of the ORF 50 transcript using a
5'RACE kit (5'-Full RACE Core Set, Takara Shuzo) according to the manufacturer's
instructions. The target RNA was the total RNA harvested from BT cells infected
with A1HV-1 at 24h post-infection. Synthesis of cDNA was carried out with 5 pg of
total RNA using a 5'-end phosphorylated RT primer (lpl containing 200pmoles)
specific for ORF 50 mRNA, 5'-GAG GCA GTG GCA CAT AGA AG
(corresponding to Nt 73424-73405 in the A1HV-1 genome). The DNA-RNA hybrid
was treated with lpl of RNase H (60 units/pl) to remove the RNA, leaving the single
stranded cDNA. lpl of T4 RNA ligase (40units/pl) was used to enable the single
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stranded cDNA to form concatemers. PCR was carried out to amplify the DNA
straddling the upstream non-translated region.
2.4. Expression of cloned genes in mammalian cells
2.4.1. Protein localisation study
To examine the cellular and subcellular localisation of the ORE 57 protein, BHK-21
cells were transfected with ORF 57 expression constructs and harvested at 4h, 8h, 12
h and 24 h after transfection. The expression constructs used were pORF57EGFP and
pEGFPORF57. In pORF57EGFP the ORF 57 was fused to the N-terminus of the
GFP and in pEGFPORF57 the ORF 57 was fused to the C-terminus of the GFP. To
harvest the cells, the medium from each plate was removed and cells were rinsed
twice thoroughly with sterile PBS. One ml of PBS was added to the cells and they
were scraped out gently using a rubber policeman and were transferred into an
eppendorf tube. Cells were sedimented by centrifugation at 3000 rpm for 5 min. The
supernatant was removed and the cells were rinsed twice with PBS. Finally, the cells
were resuspended in 1 ml of fresh 4% (w/v) paraformaldehyde and left at room
temperature for 15-20 min for fixation. After fixation, the cells were rinsed twice
with PBS and resuspended in 100 pi of PBS. 20 pi of this cell suspension was loaded
onto each well of a 4 well slide and allowed to air dry quickly at room temperature.
At this stage, to identify the nuclei, the cells were stained with propidium iodide. The
cells were initially permeabilised by treating with 0.2% (v/v) Triton X 100 in PBS
for 2-10 min at room temperature. The cells were rinsed thoroughly with PBS four
times for more than 5 min to remove excess Triton X 100 and stained with propidium
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iodide (10 jul of lpg/ml propidium iodide, lOpl of Rnase A (lOOpg/ml) in 10 ml of
PBS) for 30 min at 37°C in the dark. The cells were twice rinsed thoroughly with
PBS and allowed to air dry quickly. The slides were mounted using DAKO
fluorescent mounting medium and examined by Confocal Laser Scanning
microscopy (CLSM).
2.4.2. Immunofluorescence
The subcellular localisation studies were performed using antibody staining. The
mouse monoclonal antibody C 23 (MS-3) was used to perform this study (obtained
as a kind gift from Dr. Adrian Whitehouse). C 23 is a major nucleolar
phosphoprotein and C 23 (MS-3) is a mouse monoclonal IgG antibody raised against
a recombinant protein corresponding to aminoacids 1-706 of the human C 23. The
cells were harvested as described previously and permeabilised with a block solution
containing 1% BSA and 0.1% Triton X 100 in PBS at room temperature for 10 min.
The primary antibody [C 23 (MS-3)] was diluted 1/50 in block solution and
incubated with the cells for 30 min at room temperature. The cells were washed
twice with PBS. The secondary antibody [anti mouse IgG conjugated with
Tetramethylrhodamine B Isothiocyanate (TRITC)] was diluted 1/100 in block
solution along with 1/1000 dilution of 4-[3-(3-methyl-2 (3H)-benzothiazolylidene)-l-
propenyl]-l-[3-trimethylammonio) propyl]-diiodide (TO-PRO-3 iodide, for nuclear
staining). Cells were incubated with secondary antibody for 30 min at room
temperature. The cells were rinsed three times with PBS and air dried quickly. The
slides were mounted with DAKO fluorescent mounting medium.
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2.4.3. Nuclear cytoplasmic shuttling experiment
BHK-21 cells were electroporated with the ORE 57 expression constructs.
Actinomycin D was added to media to a concentration of 10 pg/ml, 20 h after
transfection. Cells were incubated for a further 3 h. The cells were then fixed with
4% (w/v) paraformaldehyde and counterstained using propidium iodide as described
earlier. The slides were mounted with DAKO fluorescent medium and examined
with CLSM.
2.5. Detection and analysis of proteins from cloned genes
2.5.1. Protein sample preparation
Transfected cell monolayers were rinsed twice with PBS. The cells scraped off from
the plate in 1ml PBS and transferred to a micro-centrifuge tube. Cells were then
sedimented by centrifuging at 3000 x g for 3 min and lysis buffer (see section 2.6)
was added. The cells and lysis buffer were mixed by pipetting and boiled for 10 min
before loading onto a SDS-PAGE gel. The Low Molecular Weight Calibration
Markers from Pharmacia Biotech were used to estimate sizes of proteins.
2.5.2. SDS-polyacrylamide gels for protein separation
Electrophoresis was carried out using a 12% (w/v) resolving gel and a 5% (w/v)
stacking gel (see section 2.6). The resolving gel was poured first and a layer of n-
butanol was added to smoothen the surface and to prevent trapping of air bubbles,
therefore accelerating polymerisation. Once the resolving gel polymerised, n-butanol
was removed and the stacking gel was poured on. The gel was run vertically at 100 V
for 1-1/2 h in SDS-PAGE running buffer (see section 2.6) (Sambrook et al., 1989).
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2.5.3 Protein gel staining
The protein gels were fixed and stained with brilliant blue G-colloidal concentrate
(Sigma). The gels were fixed for 1 h in a solution containing 7% (v/v) glacial acetic
acid and 40% (v/v) methanol. The staining solution was prepared by adding 1 part of
methanol to 4 parts of lx Brilliant Blue G-Colloidal Concentrate working solution
and mixed by vortexing. The gel was placed in the staining suspension for 2 h and
then destained for 60 s in 10% (v/v) glacial acetic acid and 25% (v/v) methanol.
Finally the gel was rinsed and then soaked in 25% (v/v) methanol for up to 24 h.
2.5.4. Western blots
Proteins separated by SDS-PAGE were transferred onto nitrocellulose membranes
using a semi-dry electroblotter (Ancos, Denmark). The nitrocellulose membrane, gel
and 6 pieces of 3MM paper were soaked in transfer buffer (25 mM Tris-HCl /20%
(v/v) methanol). Three pieces of 3 MM paper were placed on the blotter, followed by
the nitrocellulose membrane, the gel and three more pieces of 3 MM paper. Transfer
was carried out at 120 mA for 2 h.
The protein marker tracks were removed from the rest of the membrane and stained
in amido black (working solution: 0.2% (w/v) amido black, 10% (v/v) glacial acetic
acid, 90% (v/v) methanol) for 5 min and then destained in 50% (v/v) methanol/5%
(v/v) acetic acid.
The remainder of the nitrocellulose membrane was blocked in 5% (w/v) non-fat milk
powder/0.2% (v/v) Tween 20/PBS for 1 h at room temperature. The membrane was
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incubated overnight at 4°C in the presence of primary anti GFP rabbit IgG antibody
(Molecular probes) diluted 1/1000 in 5% (w/v) non-fat milk powder in PBS. The
membrane was washed 5 times in 0.1% (v/v) Tween 20/PBS and then incubated at
room temperature for 1 h in the presence of an anti rabbit IgG Biotin conjugate
(Sigma) (secondary antibody) diluted 1/20,000 in 5% (w/v) non-fat milk powder in
PBS. Five washing steps were carried out as before. Streptavidin alkaline
phosphatase conjugate (Boehringer Mannheim) (1/1000 dilution in PBS) was added
to the blot and incubated for 1 h. Five washing steps were carried out as before. The
membrane was developed by incubating in an alkaline phosphatase substrate (Sigma
fast 5-bromo-4-chloro-3-indolyl phosphate/nitro blue tetrazolium) for 10-15 min.
2.6. Common chemicals and solutions
Common solutions
PBS 137 mM NaCl
(Phosphate buffered saline) 2.7 mM KC1
4.3 mM Na2HP04
1.4 mM KH2P04 [pH 7.4]
TE buffer 10 mM Tris-HCl [pH 8.0]
1 mM EDTA [pH 8.0]
Solutions for agarose-gel electrophoresis
TAE buffer lx 40 mM Tris-acetate
1 mM EDTA [pH 8.0]
6x Loading buffer 10% (w/v) Ficoll
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0.25% (w/v) bromophenol blue
0.25% (w/v) xylene cyanoleFF
0.4% (w/v) orange G








5 g/1 bacto yeast extract
10 g/1 NaCl [pH 7.0]
LB + 15 g/1 bacto-agar
20 g/1 bacto-tryptone
5 g/1 bacto-yeast extract
0.5g/l NaCl
10 ml of 250 mM KC1
5 ml of 2M MgCh, autoclave and add
20 mM glucose [pH 7.0].
Solutions for mammalian cell work
Versene (0.02%) lg EDTA + lg phenol red in 5L PBS
Solutions for small scale preparation of plasmid DNA
Resuspension solution 50 mM glucose
25 mM Tris-HCl [pH 8.0]
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10 mM EDTA
Denaturation solution 0.2 M NaOH
1% (w/v) SDS
Neutralisation solution 3 M potassium acetate
2 M acetic acid













50 mM Tris-Cl [pH 8.0]
10 mM EDTA
100 pg/ ml Rnase A
200 mM NaOH, 1% (w/v) SDS
3 M potassium acetate [pH 5.5]
750 mM NaCl
50 mM MOPS [pH 7.0]
15 % (v/v) isopropanol
0.15 % (v/v) Triton X-100
1.0 M NaCl,
50 mM MOPS [pH 7.0]
15 % (v/v) isopropanol
1.25 M NaCl
50 m M Tris-Cl [pH 8.5]
15 % (v/v) isopropanol
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(pH 7.0) 0.3 M sodium citrate
50x Denhardt's solution 1% (w/v) Ficoll
1 % (w/v) polyvinylpyrrolidone
1% (w/v) BSA
lOx RNA gel-running buffer 0.2 M 3-(N-Morpholino) propanesulfonic acid (MOPS)
(pH 7.0) 80 mM sodium acetate
10 mM EDTA
lOx RNA gel-loading buffer 50% (v/v) glycerol
1 mM EDTA pH 8.0
0.25% (w/v) bromophenol blue
0.2% (w/v) methylene blue
0.4 M acetic acid
RNA marker staining
solution
0.4 M sodium acetate
Solutions for protein work
12% 9w/v) SDS-PAGE 12% (v/v) Acrylamide
resolving gel 0.375 M Tris-HCl [pH 8.8]
0.1% (w/v) SDS
0.1% (w/v) Ammonium persulphate
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0.04% (v/v) TEMED (N, N, N\ N'-tetramethyl
ethylenediamine
[Molar ratio of acrylamide: N, N'- methylenebisacrylamide is 29:1 (BioRad),
ammonium persulphate and TEMED are added just prior to pouring gel.]
5% (w/v) SDS-PAGE 5% (w/v) Acrylamide
stacking gel 0.125 M Tris-HCl [pH 6.8]
0.1% (w/v) SDS
0.1% (w/v) Ammonium persulphate
0.1% (v/v) TEMED
SDS-PAGE running buffer 48 mM Tris-HCl
0.5% (w/v) SDS
39 mM glycine




0.2% (w/v) Bromophenol blue
Solutions for protein localisation study
4 % (w/v) Paraformaldehyde 0.8 g Paraformaldehyde
1 N NaOH
10 x PBS 2 ml
dH20 18 ml
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Propidium Iodide 1 pg/ ml Propidium iodide 10 pi
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3.1. Transcription pattern of AIHV-1 ORF 57
The aim of this project was to characterise the AIHV-1 ORF 57 and examine its role
in the biology of the virus. This was achieved, firstly, by establishing the
transcriptional pattern of the gene and the sub-cellular localisation of the protein. A
second approach was to investigate the potential transactivating ability of the ORF
57 protein. Finally, attempts were made to elucidate the regulatory role of this
protein at the post-transcriptional level.
3.1.1. Cloning of AIHV-1 ORF 57
It was essential to all these experimental strategies to amplify the ORF 57 DNA
sequence. This allowed insertion of the gene into plasmid vectors. The coding region
of the ORF 57 was amplified from AIHV-1 viral DNA using a standard PCR method
(see section 2.2.2). The primers used were 5'- AGC TAG CAT GGC TCA GCA
GGC AAT TGT (Nt 84462-84481) and 5' - AGC GGC CGC ATT GGG GTC CAT
TTA CAT GG (Nt 85857-85876) respectively. Nhel and Notl restriction sites
respectively (underlined) were incorporated in primers for convenient cloning of the
PCR product. The 1414 bp PCR product (Nt 84462-85876) was inserted into the
cloning vector, pGEM-T Easy TA cloning vector (see section 2.2.1), deriving
pGEM-T Easy-ORF 57 (Fig. 3.1). Primers were based on the sequence of the A1HV-
1 genome published by Ensser et al., (1997).
3.1.2. RT-PCR analysis of ORF 57 gene expression
To understand the role of ORF 57 in the virus life cycle, it was necessary to








Fig. 3.1. Subcloninq of AIHV-1 ORF 57
A. Nhe1/Not1 digest of pGEM-T Easy-ORF 57 showing
the excised ORF 57 fragment.
B. Diagrammatic representation of pGEM-T Easy-ORF 57.
Ampr- ampicillin resistance gene
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57 during lytic infection was investigated by RT-PCR. The main objective of this
experiment was to find out the time of expression of this transcript in the virus life
cycle.
Total RNA was extracted from BHK-21 cells infected with A1HV-1. Chemical
inhibitors were used to establish the kinetic class of gene expression: immediate
early (IE), early (E) or late (L). Early and late gene expression requires de novo
protein translation and thus can be suppressed using cycloheximide, a drug that
inactivates the host cell ribosomes. Therefore, to isolate the RNA specific for the
immediate early stage of infection, one flask of cells was treated with cycloheximide
(100 pg/ml) for 30 min prior to adsorption of the virus and harvested at 8 h post¬
infection (see section 2.3.1. and 2.3.2).
Late gene expression follows replication of the virus genome. Therefore drugs that
inhibit virus replication prevent expression of late genes. Phosphonoacetic acid
(PAA) inhibits DNA polymerase. Therefore, early RNA was harvested (see section
2.3.1. and 2.3.2) at 24 h post-infection from cells that had been incubated with PAA
(100 pg/ml) for 2 h prior to adsorption of the virus and throughout infection. Late
RNA was obtained from un-trcated infected cells at 24 h post-infection.
In RT-PCR analysis, RNA extracted from each class of temporal transcript of
virulent (V) and attenuated (A) A1HV-1 was used as templates (see section 2.3.2).
RNA was also harvested from mock-infected BT cells referred to as BT.
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RNA samples were treated with DNase to remove the DNA contamination. DNase
treated RNA samples were then reverse transcribed using an oligo d (T) primer (see
section 2.3.9). Reverse transcribed RNA (RT) samples were used as templates in the
PCR. Water was used as a negative control. Primers were used to amplify the ovine
glyceraldehyde 3-phosphate dehydrogenase gene (GAPDH) to confirm the presence
and quality of intact RNA in the samples. The GAPDH primers used were 5'- CTG
GTC ACC AGG GCT GCT TT and 5'-AGG CCA TGT GGA CCA TGA GG. The
PCR programme was 1 cycle of 94°C for 1 min, 35 cycles of 94 °C for lmin, 50 °C
for 1 min and 72 °C for 1 min followed by 1 cycle of 72 °C for 7 min and finally 1
cycle of 35 °C for 30 min.
Fig. 3.2 shows the result of RT-PCR analysis with GAPDH primers. All the RT
samples showed a 950 bp product specific to the ovine GAPDH sequence amplified.
Water was used as a negative control and it did not show any product. This indicated
that the RNA samples were intact and that the reverse transcriptase reactions had
worked.
The primers used to amplify ORF 57 were 5'- GGA ATT CCA TGG CTC AGC
AGG CAA TTG (Nt 84462-84481) and 5'- AAC CGC GGG TCT CTG GGC TTA
CAA TAG (Nt 85876-85858) (Fig. 3.3). The PCR programme was 1 cycle of 94°C
for 1 min, 35 cycles of 94 °C for lmin, 52 °C for 1 min and 72 °C for 1 min followed
by 1 cycle of 72 °C for 7 min and finally 1 cycle of 35 °C for 30 min.
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Fig. 3. 2. RT-PCR analysis with GAPDH primers
RT-PCR analysis was performed using primers to amplify GAPDH.
RNA samples were obtained from BT cells infected with virulent
(V) or attenuated virus (A) at IE, E or L stages of infection.
Reverse transcribed samples of mock-infected BT cells (BT)
and water were used as controls.
84462
85876
SD 84553 SA 84605
RT-PCR PRIMERS
84462 85876
Fig. 3. 3. ORF 57 RT-PCR primers.
Diagram showing ORF 57 and its nucleotide position in the AIHV-1
genome taken from Ensser et a!., (1997).The PCR primers used in
the RT-PCR analysis are indicated. Also clearly shown are the splice
donor (SD) and splice acceptor (SA)sites.
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Fig. 3.4 shows the results of RT-PCR analysis with ORF 57 gene specific primers. V
RT represents the cDNA obtained from cells infected with virulent virus and A RT
represents the cDNA obtained from cells infected with attenuated virus. A product of
1362 bp could be seen in IE V RT sample. This suggested that ORF 57 is expressed
very early in the life cycle of virulent virus. The mock infected BT cells and water
did not show any product. Transcription of ORF 57 was not blocked by
cyclohcximide, which indicates that the ORF 57 is an immediate early gene. Since
the ORF 57 transcripts were not detectable at later time points during lytic infection,
it is likely that the ORF 57 transcripts were expressed at a level beyond the
sensitivity limits of this assay. Although, IE V RT sample showed a product of 1362
bp, there was no product in the IE A RT sample.
The absence of any product in the IE A RT sample could be due to the low level of
RNA being produced by the attenuated virus. Another possibility could be the
absence of ORF 57 transcript in the cells infected with attenuated virus. It is believed
that when the virus becomes attenuated a deletion and/or rearrangement occurs in the
genome following prolonged passage through tissue culture (Handley et al., 1995).
ORF 50 has been implicated as one of the genes, and ORF 57 may also be implicated
in this deletion. Hence an absence of ORF 57 transcript in the IE A RT sample could
be due to the rearrangement and/or deletion occurring in the A1HV-1 genome during
attenuation. No product could be observed with early and late virulent and attenuated
RT samples. This suggests that ORF 57 is an immediate early gene.
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Fig. 3. 4. RT-PCR analysis with ORF 57 gene specific primers
RT-PCR analysis was performed using primers to amplify ORF 57.
RNA samples were obtained from BT cells infected with virulent (V)
or attenuated virus (A) at IE, E or L stages of infection. Reverse
transcribed samples of mock-infected BT cells (BT)and water were
used as controls.
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3.1.3. Northern blot analysis of ORF 57 gene expression in AIHV-1
infected cells
In order to confirm the results obtained with RT-PCR, Northern blot analysis was
carried out. Total RNA containing transcripts from each temporal class of expression
(IE, E and L) as described above was harvested from virus-infected BT cells (see
section 2.3.2) and examined by Northern blot analysis (see section 2.3.4 and 2.3.5).
10 pg of total RNA was used in Northern blot analysis. The quality of RNA had been
verified by agarose gel electrophoresis and ethidium bromide staining. The gel
picture revealed that the RNA was intact (Fig.3.5). The blot was hybridised (see
section 2.3.6 and 2.3.7) with a [a32P] dCTP-labelled DNA probe corresponding to
ORF 57 specific sequence. This was produced by excising the ORF 57 sequence
from the pGEM-T Easy-ORF 57 plasmid.
An ORF 57 transcript was not detected in any of the samples. The lack of detection
may be due to the level and stability of the expression of ORF 57 transcript. As a
control for even loading and integrity of the RNA, the blot was stripped and re-
hybridised with a DNA probe corresponding to the ubiquitous cellular gene, (3-actin.
This attempt was not successful, despite the fact that the RNA appeared to be intact
as revealed by agarose gel electrophoresis and ethidium bromide staining.
PolvA+ mRNA purification
Total RNA was enriched for polyadenylated RNA (Amersham Pharmacia) and
analysed by Northern blotting (see section 2.3.8). This approach was taken to
concentrate the mRNA from total cellular RNA and to use that in Northern blot
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Fig. 3.5. Northern Blot analysis of ORF57 gene expression
RNA gel picture showing the intact RNA.
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analysis. mRNA accounts for a small proportion of total RNA (1-2 %). However,
this attempt was unsuccessful and no ORF 57 transcripts were detected by this
method.
3.2. Analysis of the function of AIHV-1 ORF 57 protein
The gene expression studies described above have confirmed that AIHV-1 ORF 57 is
an immediate early gene. Many herpesvirus IE proteins function as transactivator
proteins. Hence, it is possible that the AIHV-1 ORF 57 protein might act as a
transactivator protein. Therefore, it was decided to investigate the transactivator
properties of AIHV-1 ORF 57 protein. Transient Iransfection reporter assays were
used to determine if AIHV-1 ORF 57 protein could act as a transactivator protein.
The principle of this technique is that the vectors containing promoter sequences
linked to a reporter gene are co-transfected with a plasmid expressing the predicted
transactivator. If the product of expression vector activates the specified promoter,
this can be detected by measuring the activity of the reporter gene, which gives an
indication of transactivator potential.
The promoters of several candidate AIHV-1 ORFs were chosen to test the
transactivation potential of AIHV-1. The promoters chosen were from the different
temporal classes of transcripts. Although no detailed transcript mapping of AIHV-1
had been carried out previously, by comparison with other yHVs, ORF 50 and ORF
57 were chosen as representative IE genes, thymidine kinase (TK), ORF A5 and
ORF A9 as E genes and ORF6 as a delayed early/late gene. In other yHVs, ORF 50
encodes for a transcriptional activator, ORF 57 encodes for a pleiotropic protein
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capable of acting both at transcriptional and post-transcriptional level, ORE 6 codes
for the single-stranded DNA-binding protein, TK codes for thymidine kinase, ORF
A5 codes for a potential viral homologue for the G protein-coupled receptors
(GPCRs) and ORF A9 codes for a potential viral homologue of the Bcl2 family of
regulators of apoptosis.
3.2.1. Construction of an ORF 57 expression construct - pCMVORF57
To generate a construct that allowed expression of ORF 57 in mammalian cells, the
1414 bp ORF 57 sequence was excised from pGEM-T Easy via the Nhel and Notl
sites and subcloned into these sites in the pEGFP-N 1 vector (Clontech) downstream
of a CMV IE promoter. The EGFP sequence of this vector was excised by Nhel and
Notl and replaced with the ORF 57 sequence deriving pCMVORF57 (Fig. 3.6).
3.2.2. Construction of reporter constructs with AIHV-1 promoter
sequences
To generate AIHV-1 promoter constructs, approximately 800-900 bp of sequence
upstream of the predicted start codon and ~50 bp downstream of this was amplified
from AIHV-1 virus DNA. (Fig. 3. 7). This was done to ensure the inclusion of
AIHV-1 promoter sequences and was estimated by assessing other HV promoters,
e.g. in HVS the ORF 6 and ORF 57 promoters required up to 259 bp and 764 bp,
respectively, upstream of the transcription initiaton site for activation by HVS ORF
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pCMV ORF 57(6114 bp)
CMV ORF 57 (1414bp) SV40polyA
Nhe\ Not\
Fig. 3. 6. Construction of pCMV ORF 57
(A). Diagram of construction of pCMV ORF 57. ORF 57 insert
was excised out from pGEM-T Easy vector by Nhe\ and Not\
and introduced into the same sites in pEGFPNI after replacing
the EGFP sequence to derive pCMVORF57.










Fig. 3. 6. Construction of pCMV ORF 57
(B). NheI and Not\ digest of pCMV ORF 57showing the
the ORF 57 fragment.
Promoter regions inserted into










Fig. 3. 7. Diagrammatic representation of AIHV-1 promoter constructs
AIHV-1 ORF 50, 57, TK, 6, A5 and A9 promoter sequences were
inserted upstream of the firefly luciferase gene in the pGL3basic
vector.The restriction enzymes used in the subcloning procedure,
the position of the sequences in the AIHV-1 genome, predicted by
Ensser et ai,(1997), and their positions relative to their predicted
translational start sites within the virus are shown.
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The A1HV-1 ORF 57, TK and ORF A6 promoter constructs were made in this
laboratory by Dr. Fiona Frame, the A1HV-1 ORF A5 and A9 constructs were made
by Karen Knudsen and the ORF 50 promoter construct was obtained from Dr. Rikki
Irrerri, Moredun Research Institute.
The A1HV-1 ORF 57 promoter was amplified by PCR using primers 5' - AAG AGC
TOT GGT AGA GGA AGG TC (Nt 83700-83714) and 5'- AAG CTA GOT CTT
ACC CTC CAT GG (Nt 84519-84505) with Sacl and Nhel sites incorporated,
respectively (underlined).
The A1HV-1 TK promoter was amplified by PCR using primers 5'- AAG GTA CCG
TGG TGA GAT AGT CG (Nt 37540-37559) and 5' - AAC TCG AGC TTT GGG
CAC ATC G (Nt 38408-38395) with Kpnl and Xhol sites incorporated, respectively
(underlined).
The A1HV-1 ORF A6 promoter was amplified by PCR using primers 5' - AAG GTA
CCG CCA GTA AAT GGA CC (Nt 10435-10449) and 5' - AAG CTA GCA GAT
GAA GCC GCA GG (Nt 11341-11327) with Kpnl and Nhel sites incorporated,
respectively (underlined).
The A1HV-1 ORF A5 promoter was amplified by PCR using primers 5'- AAG GTA
CCT TTG CTA GCC CCA TCA AGT T (Nt 21837-21856) and 5'-AAG CTA GCA




The A1HV-1 ORF A9 promoter was amplified using primers 5'-AAG GTA CCT
AGA GCT CAT GCCTGT TAT C (124774-124793) and 5'-AAG CTA GCT TCT
CCT TAA ACT CGG GTT C (125805-125786) with Kpnl and Nhel sites
incorporated respectively (underlined).
The PCR programme used for amplification of the ORF6 promoter sequence was: 1
cycle of 2 rnin at 96°C; 40 cycles of 1 min at 96°C, 1 min at 60°C and 1 min at 72°C
and finally one cycle of 7.5 min at 72°C. The same programme was used to amplify
the ORF57, A5, A9 and TK promoters, except that an annealing temperature of 50°C
was used. All PCR products were inserted into the pGEM-T Easy vector.
pGL3-Basic is a luciferase reporter vector encoding the firefly luciferase gene but
has no promoter or enhancer sequences, allowing testing of potential promoter
sequences. To make promoter reporter constructs, each of the amplified and
subcloned putative promoter sequences was inserted upstream of the firefly
luciferase coding region in the pGL3-Basic vector, thus deriving 57p, TKp, and A6p,
A5p, A9p (Fig. 3.8.A).
From the pGL2basic50p vector the ORT 50 promoter sequence was excised out
using Kpnl and Bglll and subcloned into Kpnl/Bglll sites of pGL3basic vector to
derive pGL3basic50p. Diagrammatic representation of pGL3b50p and pGL2b50p
constructs is shown in Fig. 3.7. B&C. pGL2basic encodes for a spliced firefly
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Fig. 3. 8 A. Construction of AIHV-1 promoter constructs
The pGL3baic vector is represented indicating the position
of the multiple cloning site relative to the luciferase gene.
AIHV-1 promoter sequences are inserted into the MCS of
pGL3basic vector deriving corresponding promoter construct.
Lane 2. Kpnl and Xhol digest of pGL3basicTKp showing the
TK promoter sequence (868 bp).
Lane 3. Sacl and Nhel digest of pGL3basic57p showing the
ORF 57 promoter sequence (819bp).
Lane 4. Kpnl and Nhel digest of pGL3basic6p showing the
ORF 6 promoter sequence (906 bp).
Lane 5. Kpnl and Nhel digest of pGL3basicA9p releasing the
ORF A9 promoter sequence (1031 bp).
B.
C.
Fig. 3. 8 (B&C) Diagrammatic representation of AIHV-1 ORF 50
promoter constructs
B. AIHV-1 ORF 50 promoter seguences were inserted
upstream of the unspliced firefly luciferase gene in the
pGL3basic vector to derive pGL3b50p.
C. AIHV-1 ORF 50 promoter seguences were inserted
upstream of the spliced firefly luciferase gene in the
pGL2basic vector to derive pGL2b50p.
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The functional activity of all the promoter constructs was determined by transfection
of BHK cells with the promoter constructs followed by super-infection with A1HV-1
(C-500 virulent isolate) 24h later. Luciferase activity was determined 24h after
superinfection. To assess whether activation of the promoter had occurred, the fold
induction of promoter activity was measured by dividing the luciferase values
obtained from super-infected samples with the luciferase values obtained from
uninfected samples. Both the TK promoter and the ORF 6 promoter were up-
regulated in the presence of virus 12-fold and 18-fold, respectively. The ORF 57
promoter showed no significant activity under the conditions used. These results are
from a single experiment (Frame, 2001). Although all promoters used in this study
were tested again using virus superinfection it was not successful, possibly owing to
slow growth of the virus.
3.2.3. Activation of AIHV-1 promoters by pCMVORF57
Transient transfection reporter assays were employed to assess whether AlHV-l
ORF 57 could activate any of the AIHV-1 promoters. BHK cells were transfected
with 2pg of the promoter reporter constructs and co-transfected with 2pg of
pCMVORF57. The promoter constructs were also transfected alone to allow the
calculation of fold induction values of reporter gene activity in the presence of
AIHV-1 ORF 57 expression construct. BHK cells were also transfected with the
pGL3-basic vector. The experiment was repeated three times. The fold induction of
activation of the promoters was calculated by dividing the activity obtained from
samples transfected with pCMVORF57 by the activity obtained in samples without
pCMVORF57. The pGL3-basic fold induction value was considered as the
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background value in each of these experiments. The fold induction values of other
promoter constructs were compared to this basic value in determining whether the
activation was significant or not.
The Dual luciferase Reporter system (Promega) was used to assess the potential
activity of putative promoter sequences. This system was used because it allowed the
measurement of both firefly and Renilla luciferase values. These two luciferase
enzymes use different substrates hence it is possible to discriminate between their
bioluminescence reactions. The luminescent signal from each of the two luciferase
reporter enzymes can be quantitated immediately following lysate preparation.
Initially the luminescence signal from the firefly reaction is measured. Quenching of
firefly luminescence, and concomitant activation of the Renilla luciferase is
accomplished further by adding Stop&Glo™ reagent. The measurement of Renilla
luciferase values in all transfections was used for the assessment of transfection
efficiency between different samples.
Fig 3.9. shows the results obtained in transient transfection assay and it represents the
mean value of fold induction of three individual experiments. It indicated that A1HV-
1 ORF 57 was capable of transactivating ORF 50 promoter about 45 fold. Raw
luciferase values and individual fold induction values are presented in Appendix 1 (1
A&B). The fold induction of other tested A1HV-1 promoters were in the range of 1-
3. The fold induction value of the pGL3basic vector also lies in the range of 2-3.
Since the fold induction value of other tested promoter constructs were in the same














































Fig. 3. 9. Activation of AIHV-1 promoters
BHK cells were transfected with promoter constructs with
or without co-transfection of pCMV ORF 57. Results show
the fold induction of activity of samples with pCMV ORF 57
over the activity of those without pCMV ORF 57.
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transfection mix was prepared independently and electroporated individually. This
might be the one possible explanation for the range of fold induction values.
However, the Renilla luciferase values obtained for each sample indicated that there
was little variation of transfection efficiency among different samples (see Appendix
1 for raw Renilla luciferase values). The transient transfection assay has proved that
ORE 57 strongly induces ORF 50 promoter driving expression of a reporter construct
to 45 fold. Although no other A1HV-1 promoter was responsive to the effect of ORF
57, the ORF 50 promoter was strongly transactivated by ORF 57. This experiment
demonstrates that the ORF 57 gene product is a transactivator protein capable of
transactivating another immediate early gene product encoded by ORF 50.
All other promoter constructs except ORF 50 promoter were constructed
incorporating around 50 bp downstream of start codon. The presence of a start
codon for promoter fragment upstream of the start codon of luciferase gene might
interfere with transcription. This might be one of the possible explanation for not
observing any significant activator effect with respect to all other promoter
constructs except ORF50.
3.2.4. Analysis of transactivator function of ORF 57 protein on reporter
constructs containing introns in the target gene coding region
The previous experiment has shown that the A1HV-1 ORF 57 protein transactivates
the ORF 50 promoter. In the above experiment the ORF 50 promoter was linked to
an unspliced firefly luciferase reporter gene. In order to determine whether the ORF
57 expression construct behaves differently depending on whether the ORF 50
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promoter is linked to a spliced or an unspliced reporter gene, it was decided to repeat
the transient transfection assay using two different reporter constructs driven by the
ORF 50 promoter. This hypothesis was based on the fact that in other yHVs, the ORF
57 protein is capable of upregulating non-intron containing genes and down-
regulating intron containing genes.
3.2.5. Effect of ORF 57 protein on ORF 50 promoter driving expression
of a spliced and an unspliced firefly luciferase gene
The two different promoter reporter constructs chosen were pGL2b50p and
pGL3b50p. In pGL2b50p, the ORF 50 promoter drives the expression of spliced
firefly luciferase gene and in pGL3b50p, the ORF 50 promoter drives the expression
of unspliced firefly luciferase gene. Details of these two different constructs are
described in section 3.2.2 and Fig. 3.8.B.
BHK cells were transfected with 2pg of promoter constructs and then co-transfected
with 2pg of pCMVORF57. BHK cells were also transfected with the promoter
constructs alone in order to calculate the fold induction values and with the
pGL3basic vector, which, serve as a control. Luciferase activity was measured 48 h
after transfection using the Dual luciferase reporter assay system and the fold
induction was calculated by dividing the luciferase values obtained in samples with
the expression construct pCMVORF57 by luciferase values obtained in samples
without the expression construct.
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The result of the transient transfection assay is shown in Fig. 3.10. This represents
the mean value of fold induction of three independent experiments using single
samples. All raw luciferase values and individual fold induction values for these
experiments can be found in Appendix 1(11 A&B). The result obtained indicated that
the A1HV-1 ORF 57 was capable of activating ORF 50 promoter driving expression
of a spliced firefly luciferase gene to 7 fold and capable of activating ORF 50
promoter driving expression of an unspliced firefly luciferase gene to 52 fold. The
fold induction value of luciferase activity of ORF 50 promoter driving an unspliced
firefly luciferase reporter gene in this experiment was slightly higher than the value
obtained in the previous experiment. Although the fold induction value was varied,
the trend was the same. This difference in the fold induction values could be due to
the variation in the individual samples.
In comparison to the fold induction value of ORF 50 promoter driving expression of
an unspliced firefly luciferase gene, the fold induction value of ORF 50 promoter
driving expression of a spliced firefly luciferase gene was 7 fold lower. The fold
induction of luciferase activity of pGL3basic was 2-3. Hence, a fold induction value
obtained above three could be regarded as significant. So, in total there is a 7 fold
difference between the fold induction value of ORF 50 promoter driving expression
of an unspliced firefly luciferase gene and ORF 50 promoter driving expression of a
spliced firefly luciferase reporter gene. Three conclusions can be drawn from this
result: (1) A1HV-1 ORF 57 protein is a transactivator protein capable of strongly
activating the A1HV-1 ORF 50 promoter (2) A1HV-1 ORF 57 was capable of up-











Fig. 3. 10. Effect of ORF 57 on ORF 50 promoter driving
expression of spliced and unspliced firefly luciferase
reporter gene constructs.
BHK cells were transfected with ORF 50 promoter constructs with
or without co-transfection of pCMV ORF 57. Results show the fold
induction of activity of samples with pCMV ORF 57 over the activity
of those without pCMV ORF 57.
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gene (3) A1HV-1 ORF 57 was able to up-regulate the ORE 50 promoter to 7 fold
when it is linked to a spliced reporter gene.
The notable feature of this result was the striking difference in the fold induction
value of the ORF 50 promoter reporter constructs in the presence of ORF 57 protein,
depending on whether it is linked to a spliced or an unspliced reporter gene. The
difference in the fold induction values of two different constructs was above the
basic value. Hence, the question to be addressed was whether the difference in the
fold induction could be regarded as a down-regulatory effect of ORF 57 protein
because of the presence of an intron within the target gene coding region. However,
at this point it was difficult to draw a definite conclusion and so it was decided to
repeat the experiment with the inclusion of more controls.
3.2.6. Effect of ORF 57 protein on spliced and unspliced reporter gene
constructs
The different plasmid constructs used in this experiment included pGL2b50p,
pGL3b50p, pCMV luc, pGL3basic, pGL2basic, pGL3control and pGL2 control.
pCMV luc was constructed by Dr. P. Harrison by inserting the CMV IE promoter,
excised from the pCDNA3.1 vector, upstream of the firefly luciferase coding region
in pGL3basic (Harrison et al., 1999). This construct was included as a positive
control. It contained the CMV immediate-early promoter/enhancer region, which
provides strong, constitutive expression of firefly luciferase in a variety of cells.
Similarly, pGL2 control and pGL3 control vectors both contained the SV40 promoter
and enhancer sequences so as to provide strong expression of luciferase activity. The
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pGL3 basic and the pGL2 basic vectors lack eukaryotic promoter and enhancer
elements.
BHK cells were transfected with 2 pg promoter reporter constructs and co-
transfected with ORF 57 expression construct. BHK cells were also transfectcd with
the promoter constructs alone to allow the calculation of fold induction of luciferase
activity. Dual luciferase reporter assay system was used to measure the luciferase
activity, which allowed the measurement of both firefly and Renilla luciferase. The
results of this experiment are shown in Fig.3. 11. This represents the mean value of
fold induction of luciferasc activity of triplicate experiment.
The results showed that A1HV-1 ORF 57 protein was capable of activating ORF 50
promoter driving expression of an unspliced firefly luciferase gene to 63 fold. The
fold induction value obtained with the ORF 50 promoter reporter construct linked to
an unspliced firefly reporter gene in the previous two experiments was in the range
of 39-55. Although there was a variation in the individual fold induction value of
luciferase activity between experiments, the range of fold induction value was
similar.
The fold induction of luciferase activity of ORF 50 promoter driving expression of
spliced firefly luciferase gene obtained here was in the range of 4-5. This fold
induction value was slightly lower than the result obtained in the previous transient
transfection assay. The fold induction of luciferase activity of pGL2basic was 0.3-1
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Fig. 3. 11. Effect of ORF 57 on ORF 50 promoter driving
expression of spliced and unspliced firefly luciferase
reporter gene constructs.
BHK cells were transfected with ORF 50 promoter constructs with
or without co-transfection of pCMV ORF 57. Results show the fold
induction of activity of samples with pCMV ORF 57 over the
activity of those without pCMV ORF 57.
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similar to the value obtained in the previous experiment. The fold induction of pGL2
control was 3 and fold induction of pGL3 control was 2-3 fold. The fold induction of
luciferase activity of pCMV luc was in the range of 3-4. Since the fold induction of
luciferase activity obtained with all other constructs used in the experiment except
the 50 promoter constructs falls within that range it was considered as the
background level of fold induction.
Detailed analysis of this data shows that the only two promoter reporter constructs
activated by ORE 57 were pGL2b50p and pGL3b50p. The ORF 57 protein did not
have any effect on the strong CMV promoter or the SV40 promoter reporter
constructs. This indicated that the A1HV-1 ORF 57 protein was capable of activating
transcription only from the A1HV-1 ORF 50 promoter. The fold induction value of
ORF50 promoter driving expression of a spliced and an unspliced firefly reporter
gene in the presence of ORF 57 was showing a similar trend. Although the fold
induction of pGL2b50p was slightly low (4-5), it was above the basic level and hence
considered to be significantly activated by ORF 57. However the important question
addressed here was whether the ORF 57 possesses down-regulatory effect on the
reporter gene due to the presence of an intron. At this point, although there was a
down-regulatory effect due to the presence of intron within the target gene coding
region, this effect could not be conclusively proved. The significant point to
remember here was that there was a consistent 6-12 fold difference in the activation
of the same 50 promoter linked to an unspliced and a spliced reporter gene.
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3.2.7. Analysis of down-regulatory effect of ORF 57 protein on ORF 50
promoter
The aim of this experiment was to find out whether ORF 57 protein showed any
difference in the transactivator property because of the presence of introns at the 5'
end of the target gene coding region. From the earlier experiments it was clear that
there was significant difference in the transactivation of ORF 50 promoter when it is
linked to a spliced reporter gene and an unspliced reporter gene. This difference can
be due to its regulatory effect on splicing. In order to elucidate the regulatory role of
ORF 57, it was decided to carry out transient transfection assay using reporter
constructs driven by the ORF 50 promoter and which encodes for spliced Renilla
luciferase. This reporter gene has a splice site at 5' end rather than the 3' splice site
of the firefly luciferase gene in pGL2basic vector. The different plasmid constructs
included in this experiment were pRLnull, pRL50p, pRL50punspliced, pRLSV40
and pRLSV40unspliced.
The pRLnull vector lacks cukaryotic promoter and/or enhancer elements upstream of
spliced Renilla luciferase reporter gene (Rluc). The construct pRL50p was made by
amplifying the ORF 50 promoter sequence from pGL2b50p using primers 5'- AAC
TCG AGA ACA TAC TCT CAA TGT TTT C and 5'- AAGAATTCT TTT GGG
TAG TCA AAT TTG incorporating Xho\ and EcoRl sites respectively. The 471 bp
product obtained was inserted into pGEM-T Easy TA cloning vector. It was then
excised using Xhol and EcoRl and subcloned into the same sites in the pRLnuli
vector to derive pRL50p. The construct pRL50punspliced was made by excising the
intron spanning within the Xmal and Nhel sites and then blunt end ligating the
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vector. The pRLSV40 vector encodes for the spliced Renilla luciferase reporter gene
driven by the strong SV40 promoter. The construct pRLSV40unspliced was made by
excising the intron spanning within the Nhe 1 and Hind III sites and then blunt end
ligating the vector. Diagrammatic representation of the constructs made and the gel
picture revealing the insert can be seen in Fig. 3. 12. A&B. The objective of making
these constructs was to identify the regulatory effect of ORF 57 protein in the
presence and absence of an intron by transient transfection assay. Two constructs
were driven by ORF 50 promoter: one with an intron at 5' position and the other
without an intron. Since my earlier data suggests that the ORF 57 protein activates
ORF 50 promoter, it was thought that in transient transfection assay using the above
two constructs driven by ORF 50 promoter would clearly indicate a difference in the
transactivator effect of ORF 57 protein on ORF 50 promoter reporter constructs with
or without introns and thus be able to draw some conclusions on the down-regulatory
effect. Moreover, the constructs pRLSV40 and pRLSV40unspliced would be
considered as positive control constructs since the strong SV40 promoter drives
expression of a spliced Renilla luciferase gene and an unspliced Renilla luciferase
gene respectively. pRLnull construct lacks any promoter enhancer elements and
would be considered as a negative control.
BHK cells were transfected with the reporter constructs and co-transfected with the
ORF 57 expression construct. Cells were harvested 48 h after transfection and
assayed for luciferase activity using the Dual luciferase reporter assay system. The
results of this experiment are shown in Fig. 3. 13. The fold induction of luciferase





















































Fig. 3. 13. Effect of ORF 57 on ORF 50 promoter driving
expression of spliced and unspliced Renilla luciferase
reporter constructs.
BHK cells were transfected with reporter constructs with or
without co-transfection of pCMV ORF 57. Results show the
fold induction of Renilla luciferase.
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presence of ORE 57 expression construct with the luciferase activity obtained
without the presence of ORF 57 expression construct. The fold induction of
luciferase activity of control plasmid pRLnull ranged from 2-3. The fold induction of
luciferase activity of positive control plasmid pRLSV40 also ranged from 2-3. The
fold induction of ORF 50 promoter driving expression of the spliced Renilla
luciferase reporter construct was also in the range of 2-3. From these observations it
was clear that the ORF 57 protein does not have any transactivator effect on ORF 50
promoter when it is linked to a spliced Renilla luciferase gene. The fold induction
values of positive control plasmid, negative control plasmid and the ORF 50
promoter reporter construct were in the same range as obtained with previous
experiments. However, the fold induction value of the pRL50punspliced construct
was less than one or nearly one. Hence, once again it was impossible to draw any
specific conclusion regarding the down-regulatory effect of ORF 57 when an intron
was present in the target gene coding region. The fold induction of luciferase activity
of the positive control plasmid from which intron was removed also fell down to less
than one fold.
The raw luciferase values obtained in this transfection assay can be seen in the
Appendix 1 (IV A&B). The raw luciferase values for the positive control plasmid
pRLSV40 in the absence of ORF 57 protein was in the range of 50-60 and was in the
range of 140-160 in the presence of ORF 57 protein. However, the raw luciferase
value of the positive control plasmid from which the intron has been removed
dropped to 2 in the absence and presence of ORF 57 protein. This indicated that the
construct became functionless when the intron was removed. Similarly, the raw
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luciferase value of pRL50p was 3 in the absence of ORF 57 protein and was in the
range of 7-8 in the presence of ORF 57 protein. The raw luciferase value of
pRL50punspliced was 2-3 in the absence of ORF 57 protein and 2-3 in the presence
of ORF 57 protein. These results suggested the non-functioning of the constructs
when the introns are removed since the raw luciferase value of the positive control
plasmid dropped from a value of 50-60 to 2-3.
Detailed analysis of the results obtained in this transfection assay has clearly
demonstrated that the ORF 57 protein is not activating transcription from ORF 50
promoter when it is linked to a spliced Renilla luciferase gene. However, it can
activate the ORF 50 promoter when it is linked to a spliced firefly luciferase reporter
gene. The analysis of these two different reporter constructs revealed that in the
spliced firefly reporter gene construct the intron is at the 3' end and in the spliced
Renilla luciferase reporter construct the intron is at the 5' end of the reporter gene.
The transient transfection assays described above were not able to definitely prove
whether the difference in the transactivation effect exerted by ORF 57 protein on
ORF 50 promoter driving expression of spliced firefly and Renilla luciferase
constructs was influenced by the position of introns. The major problem of this
experiment was the non-functioning of the constructs from which the intron has been
excised as revealed clearly by the raw luciferase values. As a result of this the fold
induction obtained with other constructs cannot be compared and hence it was
difficult to draw any specific conclusions. Another possible explanation for this




3.2.8. Analysis of transactivator effect of ORF 57 protein on
heterologous promoters
Earlier transfection experiments have indicated that the ORF 57 protein activates
transcription only from the A1HV-1 ORF 50 promoter. The strong CMV and the
SV40 promoters were unaffected in the presence of ORF 57 protein when it was
linked to a spliced and an unspliced firefly luciferase reporter gene (see section
3.2.6). However, the effect of ORF 57 protein on heterologous promoters linked to
spliced Renilla luciferase reporter gene was not tested in the earlier experiment. In
order to determine whether A1HV-1 ORF 57 protein could act as promiscuous
transactivator and exerted any effect on heterologous promoters, it was decided to
carry out a transient transfection assay using two different promoter reporter
constructs and then co-transfect with the expression construct of ORF 57. The
different promoter reporter constructs chosen were pGL3promoter, pRLSV40,
pGL3bTK and pRLTK. pGL3 promoter and pGL3bTK encode for an unspliced
firefly luciferase gene driven by the SV40 and HSV TK promoters respectively.
pRLSV40 and pRLTK encode for a spliced Renilla luciferase gene driven by the
SV40 and HSV TK promoters respectively.
BHK cells were transfected with 2 pg of promoter reporter constructs and co-
transfected with the expression construct of ORF 57. Cells were harvested 48 h after
transfection and luciferase activity was measured using Dual Luciferase reporter
assay system. The fold induction was calculated as described previously. The fold
induction of unspliced firefly reporter gene was measured with respect to the
































Fig. 3.14. Effect of ORF 57 on heterologous promoters
The results show the average fold induction of activity of each
promoter in the presence of pCMV ORF57.
BHK cells were transfected with SV 40 and HSV TK promoter
constructs with or without co-transfection of pCMV ORF 57.
Results show the fold induction of activity of samples with
pCMV ORF 57 over the activity of those without pCMV ORF 57.
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luciferase activity was measured with respect to the constructs of pRLSV40 and
pRLTK.
The result of the transient transfection assay is shown in Fig.3.14. This represented
the mean fold induction of firefly or Renilla luciferasc activity. The raw luciferase
data can be seen in Appendix. 1 (V A&B). The fold induction of firefly luciferase
activity of pGL3 promoter vector was 2-3. The fold induction of Renilla luciferase
activity of pRLSV40 was also 2. Both these constructs were driven by SV40
promoter. Although pGL3 promoter encodes for an unspliccd firefly reporter gene
and pRLSV40 encodes for a spliced Renilla luciferase reporter gene, there was no
difference in the fold induction of luciferase activity. This indicated that ORF 57
protein does not have any activity on SV40 promoter. The fold induction of firefly
luciferase activity of pGL3bTK was 2 and the fold induction of Renilla luciferase
activity of pRLTK was also 2. Both these reporter constructs were driven by HSV
TK promoter. There was no difference in the fold induction of firefly or Renilla
luciferase activity between these two constructs. This suggested that ORF 57 protein
does not exert any effect on HSV TK promoter. The fold induction of firefly or
Renilla luciferase activity obtained in this transient transfection assay was below or
almost the same level of fold induction obtained with the control plasmids
pGL3basic, pGL2basic and pRLnull vectors in the previous experiments (see Fig. 3.
10, 3. 11 and 3. 13). Hence the fold induction obtained with these constructs cannot
be regarded as significant. This observation clearly establishes that A1HV-1 ORF 57
protein does not have any effect on heterologous promoters SV 40 and HSV TK in-
spitc of the fact that whether they are linked to an unspliced firefly luciferase reporter
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gene or a spliced Renilla luciferase reporter gene. Hence the result of this experiment
has shown that the ORF 57 protein is not a broad-spectrum transactivator.
3.2.9. Comparison of ORF 57 sequences in different gamma
herpesviruses
Since A1HV-1 ORF 57 was shown to be a transactivator, studies were initiated to
investigate different functional domains of the protein. Sequence analysis has shown
that in other members of the gammaherpesviruses ORF 57 is highly conserved at the
C-terminal region of the gene (Fig.3. 15). This region contains a cysteine-histidine
rich region, which resembles a "Zinc finger-like" motif and is conserved among all
ORF 57 homologues except for ORF 57 of MHV-68 (Vaughan et al., 1992; Virgin et
al., 1997). A hydrophobic "GLFF" motif has also found to be conserved among ORF
57 homologues. These two motifs were regarded as the highly conserved motifs
amongst its homologues (Fig.3.16). Studies on HVS have shown that the residues
contained within the highly conserved hydrophobic domain are required for the
transactivation properties of ORF 57 protein (Goodwin et al., 2000). These authors
have also demonstrated that the Zinc finger-like residues are involved in the
transactivator and repressor properties of ORF 57 protein. There were some arginine-
rich and leucine-rich areas at the amino-terminal region of A1HV-1 ORF 57 protein
which could potentially function as NLS and NES.
3.2.10. Analysis of the functional domains of ORF 57 protein
The transient transfection assays carried out have demonstrated that the A1HV-1
















































































Fig.3.15. Sequence alignment of six gammaherpesvirus ORF 57 homologues.
The sequences were aligned using the Blosum scoring matrix with the "ClustalW"
programme, which can be found at http:www.ch.embnet.org/software/ClustalW.html.
Residues that are identical in two or more sequences are highlighted in black, while
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Fiq. 3.16. Conserved structural motifs at the C-terminus of
ORF 57 homoloques
Diagrammatic representation of the sliuuluial motifs predicted
to be present in AIHV-1 ORF57 protein.
A. Shows the Zinc finger-like element (shaded blue) and
hydrophobic GLFF domain (shaded green).
B. Comparison of sequence of these structural motifs with
other gammaherpesviruses.
The sequences were aligned using the "Clustal W" programme.
Residues that are identical in two or more sequences are shown
in Red.
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identify the functional domain(s) responsible for this activation. In order to
determine the activation domain of ORF 57 protein, transient transfection assays
were carried out using constructs expressing truncated forms of the ORF 57 protein.
Two different ORF 50 promoter driven reporter constructs were chosen as they were
shown to be activated by ORF 57 protein. The promoter constructs used included
pGL2b50p and pGF3b50p. Both pGF2basic and pGL3basic vectors were included as
controls.
ORF 57 constructs used in this study were pEGFPORF57, pEGFPORF57 (l-296aa),
pEGFPORF57 (250-453aa), pEGFPORF57-GLFF (l-426aa) and pEGFPORF57-
Zinc (l-397aa). The diagrammatic representation of truncations of ORF 57
expression constructs is shown in Fig.3.17. pEGFPORF57 was able to transactivate
ORF 50 promoter to a similar fold as obtained with pCMVORF57 (see section
3.2.11.) and therefore it is chosen here as the construct of ORF 57 expressing full
length protein. pEGFPORF57 and all the truncated forms of ORF 57 constructs were
found to produce a protein (see section 3.4.1).
pEGFPORF57 was constructed by inserting the coding sequence of ORF 57 (Nt
84462-85824) in frame with the EGFP sequence in the vector pEGFPCl by PCR. To
make this construct the coding sequence of ORF 57 was amplified from the construct
pCMVORF57 by PCR using the primers 5'- GGA ATT CCA TGG CTC AGC AGG
CAA TTG (Nt 84462-84481) and 5'- AAC CGC GGG TCT CTG GGC TTA CAA
TAG (Nt 85824-85806) incorporating EcoRl and SVzcII restriction sites respectively.






















57 (890 bp) pEGFPORF57 (1-296aa)
84462 85352
pEGFPORF57 (250-453aa) 57 (611 bp)
85212 85824
Fig. 3.17. Diagrammatic representation of ORF57 truncations
A. The size of each ORF 57 construct and their position in the






1278 bp 1191 bp
C.
831 bp
890 bp 611 bp
B. Gel picture showing the digest of pEGFPORF57-GLFF (1-426aa)
and pEGFPORF57-Zinc (1-397aa) with EcoR\ and Sac II revealing
the1278 bp and 1191 bp fragments.
C. Gel picture showing the digest of pEGFPORF57(1-296aa) and
pEGFPORF57(250-453aa) with EcoR\ and Sac II revealing the
890 bp and 611 bp products.
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94°C lmin, 52 °C lmin and 72 °C 1 min. An extension time of 7 min at 72 °C and 30
min at 35 °C was also given. A 1362 bp PCR product was gel purified and inserted
into PCR cloning vector pGEM-T Easy. The 1362 bp fragment was then excised
using EcoR\ and SacII enzymes and inserted into the same sites in pEGFPCl vector
to derive pEGFPORF57.
pEGFPORF57 (l-296aa) comprises a fragment (Nt 84462-85352) amplified using
the antisense primer, 5'-AAC CGC GGG CAG CAA AGG CAC ACA AGT T (Nt
85352-85334) containing a Sacll site and the same sense primer and PCR
programme used to generate pEGFPORF57. A 890bp product was gel purified,
inserted into the PCR cloning vector pGEM-T Easy and then excised out using
EcoRl and SVzcII enzymes and subcloncd into the same restriction sites in pEGFPCl
vector to derive pEGFPORF57 (1 -296aa).
The construct pEGFPORF57 (250-453aa) comprises a fragment (Nt 85212-85824)
amplified using the sense primer, 5'-GGA ATT CCC ATT TCA ACC AAG TAT
CTA G (Nt 85213- 85232) containing an EcoRl site and the same antisense primer
and PCR programme used to generate pEGFPORF57. A 611 bp product was gel
purified and inserted into the PCR cloning vector pGEM-T Easy. This fragment was
then excised out using EcoRl and Sacll enzymes and subcloned into the same
restriction sites in pEGFPCl to derive pEGFPORF57 (250-453aa).
The construct pEGFPORF57-GLFF (l-426aa) comprises a fragment (Nt 84462-
85740) amplified using the antisense primer, 5'-AAC CGC GGA ACA GAC CAG
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TCA CAG (Nt 85740-85725) containing a SaclI site and the same sense primer and
PCR programme used to generate pEGFPORF57. A 1278 bp product was then gel
purified and inserted into the PCR cloning vector pGEM-T Easy. This fragment was
then excised out using EcoRl and SacII enzymes and subcloned into the same
restriction sites in pEGFPCl to derive pEGFPORF57-GLFF (l-426aa). This
construct was derived by deleting the conserved hydrophobic "GLFF" domain from
ORF 57.
The construct pEGFPORF57-Zinc (l-397aa) comprises a fragment (Nt 84462-
85653) amplified using the antisense primer, 5'-AAC' CGC GGT ACA GAA ATG
CAT AAG (Nt 85653-85638) containing a Sr/cll site and the same sense primer and
PCR programme used to generate pEGFP ORF 57. An 1191 bp product was then gel
purified and inserted into the PCR cloning vector pGEM-T Easy. This fragment was
then excised using EcoRl and ShrcII enzymes and subcloned into the same restriction
sites in pEGFPCl to derive pEGFPORF57-Zinc (l-397aa). This construct was
derived by deleting the conserved "Zinc finger domain" from ORF 57.
BHK cells were transfected with 2 pg of ORF 50 promoter reporter construct and co-
transfected with different truncations of ORF 57 expression construct separately.
BHK cells were also transfected with promoter constructs alone to allow the
calculation of fold induction of luciferase activity. The experiment was performed in




The effect of full length and truncated ORF 57 constructs on the control plasmids
pGL3basic and pGL2basic vectors are shown in Fig. 3.18 A&B. The corresponding
raw luciferase values can be seen in Appendix. 1 (VI A,B & VII A,B). The Renilla
luciferasc values were also measured to ensure the transfcction efficiency with
respect to different samples. The fold induction of firefly luciferase activity of the
pGL3basic vector was 3 in the presence of full-length ORF 57 construct
(pEGFPORF57). However, the fold induction of luciferase activity of the same
vector co-transfected with different truncations of ORF 57 expression construct was
in the range of 1-2. The fold induction of firefly luciferase activity of pGL2basic
vector was 1 in the presence of the full-length ORF 57 construct (pEGFPORF57).
However, the fold induction of luciferase activity of the same vector co-transfected
with different truncations of ORF 57 expression construct was in the range of 0.5-1.
The fold induction of firefly luciferase activity of both the control plasmids in the
presence of pEGFPORF57was in the same range as with the previous transient
transfection assays. The raw Renilla luciferase values measured in this transient
transfection assay with or without different ORF 57 expression constructs ranged
between 1-2. This suggested that the transfection efficiency was same in all
transfections although there was a slight variation between individual values.
The fold induction values of luciferase activity of ORF 50 promoter driving
expression of unspliced reporter construct co-transfected with pEGFPORF57 and
truncations of ORF 57 is shown in Fig. 3.19. The fold induction of luciferase activity
of ORF 50 promoter driving expression of an unspliced reporter construct in the










































Fiq.3.18. Effect of full length and truncated ORF 57 constructs
on control plasmids.
A. pGL3basic
BHK cells were transfected with control plasmid constructs
with or without co-transfection of pEGFPORF57,
pEGFPORF57-GLLF (1-426aa),pEGFPORF57-Zinc (1-397aa),
pEGFPORF57(1-296aa) and pEGFPORF57(250-453aa).
Results show the fold induction of activity of samples with











Fiq.3.18. Effect of full length and truncated ORF 57 constructs
on control plasmids.
B. pGL2basic
BHK cells were transfected with control plasmid constructs
with or without co-transfection of pEGFPORF57,
PEGFPORF57-GLLF (1-426aa),pEGFPORF57-Zinc (1-397aa),
pEGFPORF57(1-296aa) and pEGFPORF57(250-453aa).
Results show the fold induction of activity of samples with
































































Fig. 3. 19. Effect of full length and truncated ORF 57constructs
on ORF 50 promoter driving expression of unspliced firefly luciferase
reporter construct.
BFIK cells were transfected with ORF 50 promoter constructs
with or without co-transfection of pEGFPORF57,
pEGFPORF57-GLLF (1-426aa),pEGFPORF57-Zinc (1-397aa),
pEGFPORF57(1-296aa) and pEGFPORF57(250-453aa).
Results show the fold induction of activity of samples with
ORF 57 over the activity of those without ORF 57.
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activity of ORF 50 promoter driving expression of an unspliced reporter construct in
the presence of pCMVORF57 in the earlier transient transfection assays also ranged
between 39-65. Although the individual fold induction values varied between
experiments and between individual samples all of them were showing the same
trend. The value obtained here was well above the level of fold induction of
luciferase activity of pGL3 basic and hence considered as a significant activation by
pEGFPORF57.
The fold induction of luciferase activity of the ORF 50 promoter driving expression
of an unspliced reporter construct was 4-5 fold in the presence of pEGFPORF57 (1-
296aa), 2-3 fold in the presence of pEGFPORF57 (250-453aa), 5-6 fold in the
presence of pEGFPORF57-GLFF (l-426aa) and 4-5 fold in the presence of
pEGFPORF57-Zinc (l-397aa). As mentioned earlier the fold induction value of
pGL3basic vector ranged between 2-3 and was considered to be the background level
of luciferase activity. In comparison to the fold induction value of 48-50 of the ORF
50 promoter linked to an unspliced firefly reporter gene in the presence of
pEGFPORF57, the fold induction value of ORF 50 promoter linked to an unspliced
firefly reporter gene in the presence of truncated versions of ORF 57 protein varied
between 2-6. This observation suggested that none of the truncated ORF 57 protein
were able to strongly activate the ORF 50 promoter.
The fold induction of luciferase activity of an ORF 50 promoter driving expression
of a spliced reporter construct co-transfected with pEGFPORF57 and truncations of
























































































Fig. 3. 20. Effect of full length and truncated ORF 57 constructs on
QRF 50 promoter driving expression of spliced firefly luciferase
reporter construct.
BFIK cells were transfected with ORF 50 promoter constructs with
or without co-transfection of pEGFPORF57,
pEGFPORF57-GLFF (1-426aa), pEGFPORF57-Zinc (1-397aa),
pEGFPORF57(1-296aa) and pEGFPORF57(250-453aa).
Results show the fold induction of activity of samples with
ORF 57 over the activity of those without ORF 57.
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promoter driving expression of a spliced reporter construct in the presence of
pEGFPORF57 was between 6 and 7 fold. The fold induction of luciferase activity of
ORF 50 promoter driving expression of a spliced reporter construct in the presence
of pEGFPORF57 in the earlier transient transfection assays also ranged between 5
and 7 fold. Although the individual fold induction values varied between
experiments and between individual samples all of them were showing the same
trend.
The fold induction of luciferase activity of ORF 50 promoter driving expression of a
spliced reporter construct was 2-4 fold in the presence of pEGFPORF57 (l-296aa), 2
fold in the presence of pEGFPORF57 (250-453aa), 3 fold in the presence of
pEGFPORF57-GLFF (l-426aa) and 2-3 fold in the presence of pEGFPORF57-Zinc
(l-397aa). The fold induction value of pGL3basic vector also ranged between 2-3
and was considered to be the background level of luciferase activity. In comparison
to the fold induction value of 6-7 of ORF 50 promoter linked to a spliced firefly
reporter gene in the presence of pEGFPORF57, the fold induction value of ORF 50
promoter linked to a spliced firefly reporter gene in the presence of truncated
versions of the ORF 57 protein varied between 2-4. Hence, this observation
suggested that none of the truncated ORF 57 protein were able to activate the ORF
50 promoter driving expression of spliced reporter gene to the extend of value as
observed in the presence on pEGFPORF57.
Analysis of data obtained in the transient transfection assay have indicated that the
truncations of ORF 57 protein were incapable of activating the ORF 50 promoter
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driving expression either of a spliced reporter gene or an unspliced reporter gene to a
similar fold as observed in the presence of pEGFPORF57. Although pEGFPORF57
(l-296aa), pEGFPORF57-GLFF (l-426aa) and pEGFPORF57-Zinc (l-397aa)
activated the ORF 50 promoter driving expression of a spliced and an unspliced
reporter constructs to 4-5 fold, this fold induction value can not be considered as
significant, as the fold induction values of the control plasmids also were in the same
range. In addition to this, the fold induction of ORF 50 promoter driving expression
of an unspliced reporter construct had been increased to 40-50 fold in the presence of
pEGFPORF57. This suggested that none of the C-terminal deleted proteins were able
to transactivale the ORF 50 promoter to a similar fold as the full-length protein.
These observations establish that the activation domain of ORF 57 lies at the C-
terminal region of the protein. This also suggests that the C-terminal GLFF domain
is specifically involved in the transactivation property.
3.2.11. Assessment of the function of different expression constructs of
ORF 57
In addition to the expression construct pCMVORF57, two other constructs were also
made. This was performed specifically to study the cellular localisation of ORF 57
gene product (see section 3.4.2). Since there was a difference in the pattern of
expression of ORF 57 protein in the cells transfected with two different EGFPORF57
expression constructs, an attempt was made to study the functional capability of




The different expression constructs of ORF 57 included in this study were pCMV
ORF57, pEGFPORF57 and pORF57EGFP. The details of pCMVORF57 and
pEGFPORF57 constructs were described earlier in the section 3.2.1 and 3.2.10
respectively. pORF57EGFP was constructed by inserting the coding sequence of
ORF 57 (Nt 84462-85822) in frame with the EGFP sequence in the vector pEGFPNl
by PCR. To make this construct the coding sequence of ORF 57 was amplified from
the construct pCMVORF 57 by PCR using the primers 5'- CGG AAT TCC GAT
GGC TCA GCA GGC AAT T (Nt 84462-84481) and 5'- CCCCGCGGG TCT CTG
GGC TTA CAA TAG (Nt 85824-85806) incorporating EcoRl and .Shell restriction
sites respectively. The PCR programme was one cycle of 94°C for 3 min, followed
by 30 cycles of 94°C lmin, 50 °C lmin and 72 °C 1 min. An extension time of 7 min
at 72 °C and 30 min at 35 °C was also given. A 1362 bp PCR product was gel
purified and inserted into PCR cloning vector pGEM-T Easy. The 1362bp fragment
was then excised using EcoRl and 6acII enzymes and inserted into the same sites in
pEGFPNl vector to derive pEGFPORF57. In pEGFPORF57 the coding sequence of
57 was inserted at the C-terminus of EGFP whereas, in pORF57EGFP the coding
sequence of ORF 57 was inserted at the N-terminus. Fig.3.21 shows the gel picture
of pEGFPORF57 and pORF57EGFP digested with EcoRl and Sacll revealing the
inserted 1362 bp ORF57 fragment.
BHK cells were transfected with 2 pg of ORF 50 promoter driven reporter constructs
(pGL2b50p and pGL3b50p) and co-transfected with 2 pg of pCMVORF57,
pEGFPORF57 and pORF57EGFP. BHK cells were also transfected with promoter
constructs alone to allow calculation of fold induction of luciferase activity.
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pEGFPORF57 cut with EcoRI and Sacll
pORF57EGFP cut with EcoRI and Sacll
Fig. 3.21. Gel picture revealing the digest of pEGFP ORF57
and pORF57EGFP with EcoR\ and Sacli showing the
1362bp ORF 57 seguence.
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PGL3basic vector was included as a control. Cells were harvested 48h after
transfection and luciferase activity was measured using Dual Luciferase assay
reporter system.
The fold induction of luciferase activity is shown in Fig. 3.22. The fold induction of
luciferase activity for pGL2b50p ranged from 6-8 when pCMVORF57 and
pEGFPORF57 was used. When pORF57EGFP was used the fold induction for
pGL2b50p was in the range of 1-3. The fold induction of luciferase activity for
pGL3b50p varied from 54 to 64 in the presence of pCMVORF57 and pEGFPORF57.
The fold induction of luciferase activity for pGL3b50p also again changed to 1-2 fold
in the presence of pORF57EGFP. The fold induction of luciferase activity for control
plasmid in the presence of pCMVORF57 and pEGFPORF57 was also showing a
similar range of value in contrast to the fold induction obtained with pORF57EGFP.
This data indicated that both pCMVORF57 and pEGFPORF57 were capable of
transactivating the ORF 50 promoter reporter constructs to a similar fold. However,
pORF57EGFP failed to elicit any significant effect on both the ORF 50 promoter
reporter constructs tested. Hence it was concluded that the expression construct made
by inserting the ORF 57 protein to the C-terminal region of GFP (pEGFPORF57)
and the pCMVORF57 were functional and the expression construct of ORF 57 made
by inserting the ORF 57 protein at the N-terminal region of GFP (pORF57EGFP)
was not functional.
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Fig. 3. 22. Effect of different expression constructs of ORF 57 on
ORF 50 promoter reporter constructs.
BHK cells were transfected with ORF 50 promoter constructs with
or without co-transfection of pCMV ORF 57 or pEGFP ORF 57 or
pORF 57 EGFP. Results show the fold induction of activity of
samples with ORF 57 over the activity of those without
ORF 57.
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3.2.12. Identification of the ORF 50 transcriptional start site
To analyse the transcription from the ORF 50 promoter, 5'RACE was chosen. Total
cellular RNA extracted from virus infected BT cells treated with cycloheximide
(section 2.3.1 & 2.3.2) was used for 5'-RACE. A diagrammatic representation of 5'-
RACE method is shown in Fig.3. 23. The diagram shows the mRNA transcript of
ORF 50 and position of the complimentary phosphorylated RT primer relative to it.
The reverse transcription reaction results in cDNAs with a phosphate group at one
end allowing concatemerisation. The concatemerised cDNAs were used as the
template for a PCR reaction with primers SI (5'-CCA GGA GAA CAA ATT TAG
AA (Nt 73287-73306) and A1 (5'-GAC ATC ATA TAC TTC CCT GG (Nt 73272-
73253) to generate the primary PCR product. This product was used in turn as a
template for the second round of PCR using primers S2 (5'-AGA GTT AGG ACC
CAC TTT GG (Nt 73378-73397) and A2 (5'-CAC CAA GAT CAG CAG TGA TG
(Nt 73180-73161). The secondary PCR product obtained was seen as a smear rather
than a defined product (Fig.3. 24). Attempts were taken to avoid non-specific
priming by designing new sets of primers and using more stringent conditions for
amplification of the product. However, successful defined amplification of the
product was not achieved. The PCR product obtained (800-1500 bp) was cloned into
pGEM-T Easy vector and was sequenced. The sequence was not homologous to any
A1HV-1 sequence. This indicated that the secondary PCR product obtained was non¬
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Fiq.3.23. Diagrammatic representation of the 5' RACE method.
The diagram shows the mRNA transcript of ORF 50 and the
position of complimentary phosphorylated RT primer relative
to it. The reverse transcription reaction results in cDNAs with a
phosphate group at one end allowing concatemerisation. The
concatemerised cDNAS are used as a template for a PCR
reaction with primers SI and A1 to generate the primary PCR
product. This product was used in turn as a template for the
second round of PCR using primers S2 and A2.




Fig. 3.24. Gel picture showing the secondary PCR product
obtained by 5'- RACE .
Secondary PCR product obtained appeared as a smear
rather than a clearly detined product.
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3.3.Analysis of post-transcriptional regulation by ORF 57 protein
The transient transfection assays carried out on ORF 50 promoter have shown that
the ORF 57 protein exerted a significantly different transactivator effect on protein
expression from a gene driven by ORF 50 promoter depending on whether it was
linked to a spliced or an unspliced reporter gene. This difference in the amount of
protein produced might be due to a regulatory effect of ORF 57 protein at the post-
transcriptional level. In order to elucidate the regulatory role of ORF 57 protein at the
post-transcriptional level, it was decided to carry out a RT-PCR analysis for the
luciferase gene using two different ORF 50 promoter reporter constructs (ORF 50
promoter driving expression of a spliced and an unspliced luciferase reporter gene)
for determining the level of mRNA.
BHK cells were transfected with 2pg of pGL2b50p and pGL3b50p constructs and
co-transfected with the ORF 57 expression construct. BHK cells were also
transfected with pGL2b50p and pGL3b50p constructs. Total RNA was extracted
from transfected cells 24 h after transfection using Trizol as described in section
2.3.3. 5pg of total RNA was used in subseqent reverse transcription reaction.
RNA samples were treated with DNAse I enzyme to prevent possible DNA
contamination and then reverse transcribed using the Stratagene reverse transcriptase
enzyme and an oligo d (T) primer as described in section 2.3.5. The cDNA obtained
was used as the template for PCR. To ensure the quality of cDNA obtained a PCR
was performed for the ubiquitous cellular gene GAPDH. The primers used were 5'
CCT TCA TTG ACC TCA ACT ACA T and 5' CCA AAG TTG TCA TGG ATG
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ACC. The PCR programme for GAPDH was 1 cycle of 94 °C for 3 min; 30 cycles
of 94 °C for 1 min, 50 °C for 1 min 72 °C for 1 min; 1 cycle of 72 °C for 7 min and
finally 1 cycle of 35 °C for 30 min. The RT PCR result for GAPDH is shown in
Fig.3.25. All the four samples showed a band for a 400bp product. Water was
included as a negative control and it did not show any product. This indicated that
the RNA was intact and the cDNA synthesis had been successful.
Two different sets of primers were used to amplify the luciferase gene from the
different constructs pGL2b50p and pGL3b50p. The diagrammatic representation of
the constructs and the primers used are shown in Fig. 3.26. To amplify the spliced
firefly luciferase gene the primers used were 5' TTA CCG GAA AAC TCG ACG
(Nt 1652-1669) and 5' CCA CCA CTG CTC CCA TTC (Nt 2069-2055). To amplify
the unspliced firefly luciferase gene the primers used were 5' TTG ACC GCC TGA
AGT CTC (Nt 1391-1408) and 5' CAC GGC GAT CTT TCC GC (Nt 1787-1771).
The PCR programme for both was the same. It was one cycle of 94°C for 3 min,
followed by 30 cycles of 94°C I min, 52 °C lmin and 72 °C 1 min. An extension time
of 7 min at 72 °C and 30 min at 35 °C was also given. The PCR products obtained
were run on 1% agarose gel.
The result of RT-PCR for luciferase gene is shown in Fig.3. 27. A. Water was
included as a negative control and it did not show any product (Lane 5&9). The lane
one represents the RNA extracted from the cells transfected with pGL2b50p alone,
lane two represent the RNA extracted from the cells co-transfected with pGL2b50p




















































Fig. 3. 25. RT-PCR analysis with GAPDH primers
RT-PCR analysis was performed using primers to amplify
GAPDH. RNA samples were obtained from BHK cells
transfected with pGL2b50p, pGL2b50p+57, pGL3b50p
and pGL3b50p+57.
50p Firefly luciferase SV40polyA
1391 bp 1787 bp
50p Firefly luciferase
1652 bp
Sv4 D p oly A
V*=
2069 bp
Fig. 3. 26. Diagrammatic representation of RT PCR primers
for luciferase gene in pGL2b50p and pGL3b50p reporter
constructs.
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Fig. 3. 27. RT-PCR analysis with pGL2basic and pGL3basic
luciferase gene specific primers.
A. RT-PCR analysis was performed using primers to amplify
Luciferase gene. RNA samples were obtained from BHK
cells transfected with pGL2b50p, pGL2b50p+57, pGL3b50p
and pGL3b50p+57. (30 cycles of reaction). pGL2basic +ve
DNA and pGL3basic +ve DNA PCR was also done to serve
as positive controls.
Lane 2, 3, 4 represents the 417 bp product obtained with
pGI2b50p, pGL2b50p+57 and pGL2basic +ve DNA control.
Lane 6,7,8 represents the 396 bp product obtained with
pGI3b50p, pGL3b50p+57 and pGL3basic +ve DNA control.
Lane 5 & 9 shows the negative control using water.
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control. A 417 bp product was obtained in all the three samples. The lane 6
represented the RNA extracted from cells transfected with pGL3b50p alone, lane 7
represented the RNA extracted from the cells transfected with pGL3b50p and co-
transfected with ORF 57 expression construct and the lane 8 represented the positive
DNA control. A 396 bp product was obtained in all these samples. As indicated in
the Fig. 3.27. there was no significant difference in the RNA levels before and after
the addition of ORF 57 expression construct to ORF 50 promoter reporter constructs
driving expression of both spliced and unspliced firefly reporter genes. However,
from the previous transient transfection assays it was very clear that there was a
significant difference in the amount of protein produced by addition of ORF 57
expression construct as measured by the fold induction of luciferase activity. Since
there was no significant difference in the Luc RNA level obtained by transfection
with the spliced pGL2b50p and the unspliced pGL3b50p constructs alone and co-
transfected with ORF 57 it was thought that the difference in the amount of protein
produced may be due to the action of ORF 57 at the post-transcriptional level.
To elucidate the post-transcriptional regulatory role of ORF 57 the same experiment
was repeated with different number of cycles of PCR ranging from 25 to 40. The
result of this experiment is shown in Fig.3. 27.B. Although the number of cycles of
reaction varied there was no significant difference in the level of spliced and
unspliced firefly luciferase mRNA with or without addition of ORF 57 expression
construct. This experiment was carried out in an attempt to conclusively prove the
role of ORF 57 protein at the post-transcriptional level. Earlier transient transfection







































































































































35 cycles 25 cycles
Fig. 3. 27. RT-PCR analysis with pGL2basic and pGL3basic
luciferase gene specific primers.
B. RT-PCR analysis was performed using primers to amplify
luciferase gene. RNA samples were obtained from BHK cells
transfected with pGL2b50p, pGL2b50p+57, pGL3b50p and
pGL3b50p+57. (40, 35 and 25 cycles of reaction). pGL2basic
+ve DNA and pGL3basic +ve DNA PCR was also done at all three
different cycles of reaction to serve as positive controls. 2bRT- and
3bRT- represents the negative controls respectively.
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activity depending on whether the ORF 50 promoter is linked to an unspliced or a
spliced firefly luciferase reporter gene. The result obtained in the above two RT-PCR
experiments have demonstrated that there was no 6-12 fold difference in the level of
mRNA expression from the unspliced and spliced firefly luciferase gene. The level
of mRNA expression from both the spliced and the unspliced firefly reporter gene
constructs was similar with or without addition of ORF 57 protein. This indicated
that the 6-12 fold difference in the amount of protein produced by these two reporter
gene constructs in the presence of ORF 57 protein might be due to the action of ORF
57 at the post-transcriptional level. This suggests that the ORF 57 protein acts both at
transcriptional and post-transcriptional level in regulating gene expression.
An alternative method is to serially dilute the cDNA obtained and the PCR can be
performed with different cycles of reaction. This method would be a much better
quantitative PCR rather than the PCR performed above for comparison of RNA
levels.
3.4. Studies on ORF 57 protein expression
It is striking that ORF 57 is the only A1HV-1 IE protein with homologs not only
among other y herpesviruses, but also throughout the herpesviridae. The ORF 57
homologues in other herpesviruses act as transactivator proteins with trans-regulatory
functions (Whitehouse et al., 1998a,b; Krishner et al., 2000; Sekulovich et al., 1988;
Semmes et al., 1998). They are required for the switch from IE to early and late gene
expression. Cellular localisation studies have revealed that the ORF 57 protein of
HVS, KSHV, HSV-1 and EBV was located predominantly to the nucleus and was
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also able to shuttle from nucleus to the cytoplasm. The experiments described above
have established that A1HV-1 ORF 57 encodes for a transactivator protein. It has
been shown to strongly activate another immediate early gene product encoded by
ORF 50. The results of RT-PCR analysis demonstrated that the increase in luciferase
activity was not correlated with a similar increase in Luc RNA levels in the presence
of ORF 57 protein. This suggests that the ORF 57 protein also acts post-
transcriptionally to modulate gene expression. In order to elucidate the role of ORF
57 protein in regulating gene expression especially at the post-transcriptional level, it
was decided to investigate the cellular localisation of the ORF 57 protein. The mode
of action of the A1HV-1 ORF 57 transactivator is not understood. It might act at the
level of transcription, RNA processing, transport, or translation of mRNA.
Determining the cellular localisation of the protein in the cell may help to narrow
down these options.
3.4.1. Cellular localisation of ORF 57 protein
To determine the cellular localisation of the ORF 57 protein two different expression
constructs of ORF 57 were used. They were pEGFPORF57 and pORF57EGFP
(described in section 3.2.11). In pEGFPORF57 the ORF 57 coding sequence was
inserted at the C-terminal region of EGFP. In pORF57EGFP, the coding sequence of
ORF 57 was inserted at the N-terminal region of EGFP. pEGFPCl and pEGFPNl
were used as controls.
BHK cells were transfected individually with 20 pg of these two ORF 57 expression
constructs and control plasmids. Cells were harvested at different time points after
transfection e.g. 4, 8, 12, 24 and 48 h. Slides were prepared with the transfected cells
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as described in section 2.4.1. The fluorescence pattern was subsequently evaluated
using CLSM.
EGFP-C1 and EGFPN1 protein displayed a fluorescence signal in both nucleus and
cytoplasm at all time points. The cellular localisation of EGFP CI at 8 h, 12 h and 24
h are shown in Fig. 3. 28 (unstained cells). Fig 3. 29 shows the cellular localisation
of EGFPC1 in BHK cells at 4h. The cells were stained with propidium iodide to
identify the cell nuclei. A software associated with the Leica TCSNT system can
measure the intensity of the fluorescence and a graph can be plotted accordingly.
This will indicate the distribution of GFP expression in the cells. Fig. 3.30 shows the
distribution of GFP in the cells transfected with pEGFPCl and harvested at 8 h, 12 h
and 24 h (propidium iodide stained). Fig 3. 31 shows the distribution of GFP in cells
transfected with pEGFPCl and harvested at 48 h after transfection. In contrast, the
GFPORF57 fusion protein exhibited a fluorescence pattern that was confined to the
nucleus and resembled the punctate pattern displayed by the HSV-1 IE 63 (Phelan et
al, 1993). Fig 3. 32, 3. 33 and 3. 34 shows the localisation of ORF 57 protein in the
nucleus of BHK cells at different time points studied. Fig 3. 32 show the distribution
of GFPORF57 fusion protein in the nucleus of the transfected cells at 4h. Using the
TCSNT software the distribution and the intensity of GFPORF57 fusion protein in
the cells was measured. Fig 3. 33 represents the distribution of GFPORF57 in the
cells at 8 h, 12 h, 24 h and 48 h. Fig. 3. 34 shows the localisation of GFPORF57
protein in the nucleus at 48 h and the confirmation of the localisation by plotting the
graph using Leica TCSNT software. Fig 3. 35 shows the bright green punctate
pattern of expression of GFPORF57 protein in the nucleus of unstained cell at 4 h
and 8 h.
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Fig. 3. 28. Cellular localisation of EGFPC1
BFIK cells were transfected with 20f.ig of plasmid DNA.
Cells were harvested at A. 8 h, B. 12 h and C. 24 h.
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Length [pm]: Sum: Mean: Std. dev.: Minimum: Maximum:
27.98 24425 67.47 77.31 0.00 255.00
27.98 5679 15.69 22.89 0.00 115.00
Fig. 3. 29. Cellular localisation of EGFPC1 at 4h
(propidium iodide stained cell)
BHK cells were transfected with pEGFPCI and cells were
harvested at 4 h after transfection. It shows the localisation
of EGFP in both nucleus and cytoplasm.
An imaginary line was drawn through the cell across the area
where GFP is expressed. Software associated with the Leica
TCSNT system measures the intensity of the fluorescence
and plots this graphically to indicate the distribution of EGFP
in the cell nucleus and cytoplasm.
Channel 1- (green line)- represents both the localisation and
the intensity of EGFP.
Channel 2- (red line) indicates the boundary of nucleus
This picture shows that the distribution of EGFP is in both the
nucleus and cytoplasm as the EGFP can also be seen out side
the nuclear border.
Fig. 3.30. Cellular localisation of EGFPC1 at different time points.
BHK cells were transfected with 20 jug of pEGFPCI and harvested at
8 h, 12 h and 24 h. Cells were stained with propidium iodide and shows
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Fig. 3. 31. Cellular localisation of EGFPC1 at 48 h
(propidium iodide stained cell)
BHK cells were transfected with 20 j.ig of pEGFPCI and cells
were harvested at 48 h after transfection. It shows the
localisation of EGFP in both nucleus and cytoplasm.
An imaginary line was drawn through the cell across the
area where GFP is expressed. Software associated with the
Leica TCSNT system measures the intensity of the fluorescence
and plots this graphicaly to indicate the distribution of EGFP in
the cell nucleus and cytoplasm.
Channel 1- (green line)-represents both the localisation and the
intensity of GFP.
Channel 2- (red line) indicates the boundary of nucleus.
This picture shows that the distribution of GFP is in both the
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Length [pm]: Sum: Mean: Std. dev.: Minimum: Maximum:
18.51 12039 59.60 90.17 0.00 255.00
18.51 14650 72.52 56.09 0.00 162.00
Fig. 3. 32. Cellular localisation of GFPORF57 at 4 h
(propidium iodide stained cell)
BHK cells were transfected with pEGFPORF57 and cells were
harvested at 4 h after transfection. It shows the localisation of
GFPORF57 fusion protein in the nucleus with a clear punctate
pattern of expression.
An imaginary line was drawn through the cell across the area
where GFP is expressed. Software associated with the Leica
TCSNT system measures the intensity of the fluorescence and
plots this graphically to indicate the distribution of GFP in the cell
nucleus and cytoplasm.
Channel 1- (green line) represents both the localisation and the
intensity of GFP.
Channel 2- (red line) indicates the boundary of nucleus.
This picture shows that the distribution of GFPORF57 fusion
protein is in the nucleus as the green line is confined only within
the nuclear boundary.
Fig. 3.33. Cellular localisation of GFPORF57 at different time points.
BFIK cells were transfected with 20 |ag of pEGFPORF57 and harvested
at 8 h, 12 h, 24 h and 48 h. Cells were stained with propidium iodide
and show the distribution of GFPORF57 fusion protein in the cell nucleus
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Mean: Std. dev.: Minimum: Maximum:
46.50 78.24 0.00 212.00
37.47 36.82 0.00 125.00
Fig. 3. 34. Cellular localisation of GFPORF57 at 48 h
(propidium iodide stained cell)
BHK cells were transfected with 20 pg of pEGFPORF57 and cells
were harvested at 48 h after transfection. It shows the localisation
of GFPORF57 fusion protein in the nucleus.
An imaginary line was drawn through the cell across the area
where GFP is expressed. Software associated with the Leica
TCSNT system measures the intensity of the fluorescence and
plots this graphically to indicate the distribution of GFP in the cell
nucleus and cytoplasm.
Channel 1- (green line) represents both the localisation and the
intensity of GFP.
Channel 2- (red line) indicates the boundary of nucleus.
This picture shows that the distribution of GFPORF57 fusion protein




Fig. 3.35. Cellular localisation of GFPORF57 in BHK cells.
Cells were transfected with 20 jLig of pEGFPORF57 and
harvested at 4 h and 8h after transfection.This shows the
distribution of GFPORF57 fusion protein in the cell nucleus
at two time points in an unstained cell.
CHAPTER 3 RESULTS
pORF57EGFP exhibited a fluorescence signal in both cytoplasm and nucleus like
that of control plasmids at all time points examined (Fig.3. 36, 3. 37 and 3. 38).
The confocal microscopic images have shown that the GFP was exhibiting a strong
fluorescence signal in both nucleus and cytoplasm. This indicates that the control
plasmid is functional and the GFP is expressed. Cells transfected with pEGFP
ORF57 was displaying a fluorescence signal that was confined to the nucleus. This
expression pattern of GFPORF 57 fusion protein was quite different from the control
plasmid. Detailed analysis of the confocal images of cells transfected with this ORF
57 expression construct taken at different time points established that the pattern of
expression is well defined and definitely not diffuse. At earlier time points (4,8 and
12 h) the GFPORF57 fusion protein was exhibiting a clear well defined punctate
pattern of expression. At later time points, the pattern of expression tends to be little
widespread within the nucleus. This is possibly due to the increased amounts of the
protein produced. However, the protein was localised to definite areas of the nucleus
rather than completely spreading over the nucleus. This demonstrates that the
GFPORF57 fusion protein was exhibiting clear punctate pattern of expression and
was localised to specified areas within the nucleus.
The fusion protein generated by inserting the coding sequence of 57 to the N-
terminus of the GFP was exhibiting a fluorescence signal in both the nucleus and the
cytoplasm. pEGFPNl was included as a control and the expression of GFP was
similar to the other control plasmid pEGFPCl. The possible explanation for the







Format 1,024 x 1,024 x 1













Sea labar 100 pm
ZrfOS 0.020 M
Method FITC/TRITC
















Length [pmj: Sum: Mean: Std. dev.: Minimum: Maximum:
27.06 6288 23.46 34.61 0.00 191.00
27.06 4787 17.86 20.79 0.00 106.00
Fig. 3. 36. Cellular localisation of ORF57GFP at 4 h
(propidium iodide stained cell)
BHK cells were transfected with 20 ug of pORF57EGFP and cells
were harvested at 4 h after transfection. It shows the localisation
of ORF57GFP fusion protein both in the nucleus and the cytoplasm.
An imaginary line was drawn through the cell across the area
where GFP is expressed. Software associated with the Leica
TCSNT system measures the intensity of the fluorescence and
plots this graphically to indicate the distribution of GFP in the cell
nucleus and cytoplasm.
Channel 1- (green line) represents both the localisation and the
intensity of GFP.
Channel 2- (red line) indicates the boundary of nucleus.
This picture shows that the distribution of ORF57GFP fusion protein
is in the nucleus and cytoplasm as the green line is seen within the
nucleus and outside the nucleus.
Fig. 3.37. Cellular localisation of ORF57GFP at different
time points.
BHK cells were transfected with 20 pg of pORF57EGFP
and harvested at 4 h, 8 h, 12 h, 24 h and 48 h. Cells were
stained with propidium iodide and the images show the
diffuse distribution of ORF57GFP fusion protein in the cell
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Fig. 3. 38. Cellular localisation of ORF57GFP at 48 h
(propidium iodide stained cell)
BHK cells were transfected with 20 pg of pORF57EGFP and cells
were harvested at 48 h after transfection. It shows the localisation
of ORF57GFPfusion protein both in the nucleus and the cytoplasm.
An imaginary line was drawn through the cell across the area
where GFP is expressed. Software associated with the Leica
TCSNT systemmeasure the intensity of the fluorescence and plots
this graphically to indicate the distribution of GFP in the cell nucleus
and cytoplasm.
Channel 1- (green line) represents both the localisation and the
intensity of GFP.
Channel 2- (red line) indicates the boundary of nucleus.
This picture shows that the distribution of ORF57GFP fusion protein
is in the nucleus and cytoplasm as the green line is seen within the
nucleus and outside the nucleus.
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terminus of the GFP, is that when it was fused to the N-terminus of the GFP, proper
folding of protein might not be occurring and might affect the stability of the protein.
In order to confirm that the pORF57EGFP construct is non-functional a transient
transfection assay was performed using these two constructs with ORF 50 promoter
reporter construct. The results of that experiment (see 3.2.11) clearly indicated that
the construct pORF57EGFP was unable to transactivate the ORF 50 promoter
reporter construct as the other two expression constructs of ORF 57 thus proving it as
a non-functional construct.
From these experiments, it was concluded that the ORF 57 protein localises in the
nucleus with a clear punctate pattern of expression. The cells were harvested at
different time points to analyse the expression pattern in detail. It was observed that
the ORF 57 protein was expressed as early as 4h after transfection with a well-
defined clear punctate pattern of expression. As the time progresses, although there
was a gradual increase in the amount of protein the punctate pattern was still
maintained until 24 h. By 48 h after transfection, it appeared as a diffuse area of
fluorescence loosing the original well defined and clear punctate pattern. This may
be because the amount of protein produced was in large amounts. However, the
protein still appeared to occupy a defined area of nucleus. It was not a wide spread or
a diffuse area of fluorescence occupying the whole of the nucleus but rather
confining to certain localised areas within the nucleus. Hence, the results of this




3.4.2. Analysis of ORF 57 protein expression
Western blots were carried out using crude extract from BFIK cells transfected with
pEGFPORF57 and pORF57EGFP (see section 2.5). Initial results showed a very
faint band indicating the presence of A1HV-1 ORF 57, however the background was
high. The resolving gel used was 12% and the size of the protein was expected to be
80 kDa. The size of GFP was 28kDa for the N-terminal plasmid and 32kDa for the
C-terminal plasmid. This is because of the multiple cloning sites at the C-terminus in
pEGFPCl before the stop codons. In order to better visualise the bands of fusion
protein and the control GFP it was decided to run a 7.5% gel. However within the
available period, it was not possible to detect the protein.
3.4.3. Sub cellular localisation of ORF57 protein
The ORF 57 protein was localised in the nucleus with a clear punctate pattern of
expression. A similar pattern of distribution was observed in the case of HSV-1 IE 63
(Phelan et al., 1993) and with HVS ORF 57 (Cooper et al., 1999). The punctate
pattern of distribution clearly indicated that the protein was confined to some distinct
nuclear domains. Moreover this well-defined punctate pattern was maintained up to
12-24 h after transfection. This also indicates that the protein formed is stable. In
order to further investigate the site of localisation of the ORF 57 protein in the
nucleus of transfected cells an immunofluorescence study was performed. The
antibody used in this study was a mouse monoclonal antibody raised against the
nucleolar phosphoprotein C23. The monoclonal antibody was designated as MS 23.
143
CHAPTER 3 RESULTS
BHK cells were transfecled with 20 fig of pEGFPORF57 and the cells were
harvested 12h after transfection. This time point was chosen because from the
previous cellular localisation studies the ORF 57 protein was observed to maintain
the well-defined punctate pattern up to 24 h. Hence 12 h is considered as the suitable
time point to observe the expression pattern. The cells were harvested and slides
were prepared as described earlier in the section 2.4.1. Both primary and secondary
antibodies were allowed to act for 30 min. The secondary antibody was an anti
mouse antibody conjugated to TR1TC. To the secondary antibody mix, 1/1000
dilution of TOPRO was added in order to stain the nucleus. These cells were not
previously stained with propidium iodide and hence TOPRO was used. This was
performed because the TRITC conjugate will fluoresce red and it will be difficult to
visualise the co-localisation, if it was stained with the red propidium iodide stain.
TOPRO will fluoresce blue and it would be easy to visualise the co-localiscd protein.
CLSM was performed on the stained cells.
The results of this experiment are shown in Fig.3. 39 A, B, C. Fig.3. 39.A represents
the confocal image of the transfected cells viewed through TOPRO/TR1TC channel.
Here the cell nucleus appeared blue and the GFPORF 57 fusion protein was observed
as bright green punctate spots within the nucleus. The same cell when viewed
through the TRITC channel appeared as red. Within the red stained nucleus, the
TRITC conjugated antibody - C23 complex was observed as bright punctate red
spots (Fig.3. 39.B). Fig.3. 39.C. represents the superimposed image of the above two.
Fig. 3.40 shows the confirmatory data of co-localisation of GFPORF57 fusion
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Fig. 3. 39. Subcellular localisation ofGFPORF57.
BHK cells were transfected with 20 pg of pEGFPORF57 and cells
were harvested at 12 h after transfection. The immunofluorescence
study was performed on transfected cells using a mouse monoclonal
antibody raised against the major nucleolar phosphoprotein C 23.
A. Cells viewed through TOPRO/TRITC channel showing the
distribution of GFPORF57 fusion protein at specific areas within
the nucleus.
B. Cells viewed through TRITC channel showing the distribution of
TRITC conjugated antibody-antigen complex within the nucleolus.
C. Superimposed image of the above two images indicating the
co-localisation of GFPORF57 with TRITC conjugated antibody-
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Fig. 3. 40. Subcellular localisation of GFPORF57
Immunofluorescence study
BHK cells were transfected with pEGFPORF57and cells were
harvested at 12 h after transfection. It shows the co-localisation
of GFPORF57 fusion protein with the nucleolar
phosphoprotein C 23 in the nucleolus.
An imaginary line was drawn through the cell across the
area where GFP is expressed. Software associated with the
Leica TCSNT system measures the intensity of the fluorescence
and plots this graphically to indicate the distribution of GFP in the
cell nucleus and cytoplasm.
Channel 1- (green line) represents both the localisation and the
intensity of GFP.
Channel 2- (red line) indicates the distribution of TRITC conjugated
antibody-antigen complex within the nucleus.
Channel 3- (blue line) indicates the boundary of nucleus.
This picture shows that the GFPORF57 fusion protein co-localises
with the TRITC conjugated antibody-antigen complex in the
nucleolus as the green areas and red areas are seen merged
together within the nucleus.
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protein with the C 23 nucleolar phosphoprotein by plotting a graph using the TCSNT
software.
The Immunofluorescence studies carried out using the mouse monoclonal antibody
to C 23 have demonstrated that the GFPORF57 fusion protein localises to specific
regions within the nucleus. In the Fig. 3.39.A. the GFPORF57 fusion protein
appeared as bright, punctate green fluorescent spots. This cell was viewed through a
channel having the emission spectra similar to that of GFP at a wavelength of
530nm. This was the reason why the GFPORF57 fusion protein appeared as bright
green spots. In order to demonstrate the localisation of TRITC conjugated
monoclonal antibody with C 23 nucleolar phosphoprotein, the cells were examined
through TRITC channel (emission wavelength 600-630nm). Here the antigen
antibody complex was observed as bright red spots within the nucleus. Apart from
the antigen antibody complex, the nucleus also appeared diffuse red. This diffuse
staining of nucleus is a commonly observed phenomenon when TRITC is used. It
was reasoned that some amount of "bleach through" could always occur when the
TRITC conjugate is fresh and strong. When the above two images were
superimposed (Fig. 3. 39 C) it was clear that the GFPORF57 and the TRITC
conjugated antigen antibody complex localises in the same areas within the nucleus.
This suggested that the GFPORF 57 fusion protein co-localised with the nucleolar
phosphoprotein C23. The superimposed image was taken to demonstrate the co-
localisation in a clearer pattern.
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The earlier experiments have demonstrated that ORF 57 encodes for a nuclear
protein and it specifically localises to certain well-defined areas within the nucleus.
The specific localisation site was identified as the nucleolus by immunofluorescence
studies carried out using a monoclonal antibody raised against the major nucleolar
phosphoprotein C 23. As shown in the Fig. 3. 39 C, the GFPORF57 protein co-
localised with the TR1TC conjugated antigen antibody complex. Hence it was
concluded that the ORF 57 encoded protein co-localises with C23 in the nucleolus.
Therefore the specific localisation site of ORF 57 protein in the nucleus was
identified as the nucleolus. In addition, ORF 57 protein was also supposed to localise
with splicing components in the nucleus as shown in Fig. 3.35. This observation has
to be proved by performing an immunofluorescence study using monoclonal
antibody raised against the splicing components.
3.4.4. Identification of nuclear localisation signal
The above experiments have shown that A1HV-1 ORF 57 protein localises in the
nucleus. This observation would suggest that it should possess a nuclear localisation
signal (NLS). To locate a potential NLS within the ORF 57 protein, cells were
transfected with expression constructs that would produce truncated forms of ORF
57 protein.
BHK cells were transfected with plasmid construct encoding full-length 57
(pEGFPORF57), pEGFPORF57 (l-296aa), pEGFPORF57 (250-453aa),
pEGFPORF57-GLFF (l-426aa) and pEGFPORF57-Zinc (l-397aa). The details of
how these constructs were made and the diagrammatic representation of these
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constructs are given in section 3.2.10. and Fig. 3. 17 The constructs pEGFPORF57
(l-296aa), pEGFPORF57-GLFF (l-426aa) and pEGFPORF57-Zinc (l-397aa)
represent different C-terminal deletion constructs of ORF 57. pEGFPORF57 (250-
453aa) was a N-terminal deletion construct and it lacks the N-terminus 250aa. Cells
were harvested 12 h after transfection. Slides were prepared as described above in
section 2.5.and confocal images were obtained by CLSM.
The confocal image of cells transfected with the full length ORF 57 protein is shown
in Fig. 3.41. As observed earlier, ORF 57 was localised to the nucleus exhibiting a
distinct punctate pattern of expression.
The constructs pEGFPORF57-GLFF (l-426aa) and pEGFPORF57-Zinc (l-397aa)
represents the fragments of ORF 57 from which the hydrophobic "GLFF" domain
and the "Zinc-finger like" elements have been removed. As shown in Fig. 3.16, these
domains in other gamma herpesviruses are also located at the C-terminal region of
the protein. The cells transfected with these C-terminal deleted constructs also
displayed a fluorescent signal in the nucleus. Fig.3.42 shows the distribution of the
fusion protein produced in the cells transfected with pEGFPORF57-GLFF (l-426aa).
Similar to the full-length protein construct, this fusion protein from which the C-
terminal GLFF domain has been removed was also confined to the nucleus. The
pattern of expression was also punctate and although not well defined similar to the
full-length protein. Fig. 3.43. shows the localisation of protein in cells transfected
with the expression construct pEGFPORF 57-Zinc (l-397aa). As can be seen in the
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Length [pm]: Sum: Mean: Std. dev.: Minimum: Maximum:
18.43 14892 65.89 81.01 0.00 255.00
18.43 11830 52.35 51.86 0.00 159.00
Fig. 3. 41. Cellular localisation of GFPORF57 at 12 h
(propidium iodide stained cell)
BHK cells were transfected with20 |.ig of pEGFPORF57 and
cells were harvested at 12 h after transfection. It shows the
localisation of GFPORF57 fusion protein in the nucleus with
a clear punctate pattern of expression.
An imaginary line was drawn through the cell across the
area where GFP is expressed. Software associated with the
Leica TCSNT system measures the intensity of the fluorescence
and plots this graphically to indicate the distribution of GFP in the
cell nucleus and cytoplasm
Channel 1- (green line) represents both the localisation and the
intensity of GFP.
Channel 2- (red line) indicates the boundary of nucleus.
This picture shows that the distribution of GFPORF57 fusion
protein is in the nucleus as the green line is seen localised only
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Fig. 3. 42. Cellular localisation of GFPORF57-GLFF (1-426aa)
at 12 h (propidium iodide stained cell)
BHK cells were transfected with 20 pg of pEGFPORF57-GLFF and
cells were harvested at 12 h after transfection. It shows the localisation
of GFPORF57-GLFF (1-426aa) fusion protein in the nucleus with a clear
punctate pattern of expression.
An imaginary line was drawn through the cell across the area where
GFP is expressed. Software associated with the Leica TCSNT system
measures the intensity of the fluorescence and plots this graphically to
indicate the distribution of GFP in the cell nucleus and cytoplasm.
Channel 1- (green line) represents both the localisation and the intensity
of GFP.
Channel 2- (red line) indicates the boundary of nucleus.
This picture shows that the distribution of GFPORF57-GLFF (1-426aa)
fusion protein is in the nucleus as the green line is seen localised only
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Fig. 3. 43. Cellular localisation of GFPORF57-Zinc(1-397a)
at 12h (propidium iodide stained cell)
BHK cells were transfected with 20 pg of pEGFPORF57-Zinc(1-391aa)
and cells were harvested at 12 h after transfection. It shows the
localisation of GFPORF57-Zinc (1-397aa) fusion protein in the nucleus
with punctate pattern of expression.
An imaginary line was drawn through the cell across the area where
GFP is expressed. Software associated with the Leica TCSNT system
measures the intensity of the fluorescence and plots this graphically to
indicate the distribution of GFP in the cell nucleus and cytoplasm.
Channel 1- (green line) represents both the localisation and the intensity
of GFP.
Channel 2- (red line) indicates the boundary of nucleus.
This picture shows that the distribution of GFPORF57-Zinc (1-397aa)
fusion protein is in the nucleus as the green line is seen localised only
within the nuclear boundary.
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The construct pEGFPORF57 (l-296aa) represents the fragment of ORF 57 from
which a major part of the sequence at the C-terminal region of the protein has been
removed. Similar to the full-length protein, this 296aa fusion protein was also
localised in the nucleus with a punctate pattern of expression (Fig.3.44).
The construct pEGFPORF57 (250-453aa) represents the fragment of ORF 57 from
which the N-terminal 249aa has been deleted, but which retains an intact C-terminal
region. An image of the cells transfected with this construct is shown in Fig. 3.45. In
contrast to the above constructs, this was displaying a fluorescent signal in both the
nucleus and the cytoplasm.
The transient transfection assays carried out with different deletion constructs of
ORF 57 protein have established that the constructs which have their N-terminal
region intact, produced a protein, which was localised to the nucleus. The constructs
used in this experiment had 33aa, 62aa and 157aa deleted from the C-terminus. All
of these constructs were able to produce a protein that was localised in the nucleus
exhibiting a distinct punctate pattern although not well defined. The cells were
harvested at the same time point to observe the pattern of expression. Interestingly,
when cells were transfected with the N-terminal deleted construct [pEGFPORF57
(250-453aa)] the fusion protein showed a diffuse fluorescence signal in both nucleus
and nucleus. This pattern of expression was similar to that obtained with the control
plasmid. This indicated that the N-terminal deleted construct produced a protein,
which was distributed diffusely in both nucleus and cytoplasm
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Length [pm]: Sum: Mean: Std. dev.: Minimum: Maximum:
21.38 23272 87.16 103.67 0.00 255.00
21.38 24741 92.66 44 44 0.00 163.00
XY-PosNlon [pm]
Fig, 3. 44. Cellular localisation of GFPORF57 (1-296aa)
at 12 h (propidium iodide stained cell)
BHK cells were transfected with pEGFPORF57(1-296aa) and
cells were harvested at 12 h after transfection. It shows the
localisation of GFPORF57 (1-296aa) fusion protein in the
nucleus with punctate pattern of expression.
An imaginary line was drawn through the cell across the
area where GFP is expressed. Software associated with the
Leica TCSNT system measures the intensity of the fluorescence
and plots this graphically to indicate the distribution of GFP in the
cell nucleus and cytoplasm.
Channel 1- (green line) represents both the localisation and the
intensity of GFP.
Channel 2- (red line) indicates the boundary of nucleus.
This picture shows that the distribution of GFPORF57 (1-296aa)
fusion protein is in the nucleus as the green line is seen localised
only within the nuclear boundary.
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This experiment has conclusively proved that all the different constructs of ORF 57
used in this experiment were functional and was able to produce a protein. However,
only those constructs, which had their N-terminus intact, were able to produce a
protein, which localised to the cell nucleus. The pattern of expression of different
fusion proteins was also similar to the pattern observed with the full-length protein.
This suggested that the C-terminal region is not responsible for the nuclear
localisation of the protein produced. However, when 249 aa were deleted from the N-
terminus, the protein was unable to localise in the nucleus. This indicated that the
nuclear localisation signal of A1HV-1 ORF 57 encoded protein resides at the N-
terminus.
3.5. Nuclear cytoplasmic shuttling property of ORF 57 protein
It is known that some nuclear proteins are not con Fined to the nucleus and they
continuously traffic between nucleus and cytoplasm of the cell. Moreover these
shuttling proteins have been shown to have significant roles in mRNA transport.
A1HV-1 ORF 57's nuclear localisation and post-transcriptional effects on gene
expression suggested the possibility that it might shuttle between the nucleus and the
cytoplasm of cells, similar to what has been observed for some other post-
transcriptional regulatory proteins including several heteronuclear ribonuclear
proteins (hnRNP) proteins and H1V-1 Rev (Pinol Roma and Dreyfuss, 1992; Flach et
al., 1994).
In order to find out whether, A1HV-1 ORF 57 is a shuttling protein, BHK cells were
transfected with the ORF 57 expression construct and treated with Actinomycin D 4h
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and 20 h after transfection as described in section 2.4.3. Actinomycin D inhibits
transcription and prevents nuclear protein import. This will lead to the hindrance of
import of proteins to the nucleus while the export continues. Hence whatever protein
formed before treating with Actinomycin D will get accumulated in the cytoplasm.
The different constructs used in this experiment included the full-length ORF 57,
pEGFPORF57 (l-296aa), pEGFPORF57 (250-453aa), pEGFPORF57-GLFF (1-
426aa) and pEGFPORF57-Zinc (l-397aa).
BHK cells were transfected with different expression constructs of ORF 57 and were
treated with Actinomycin D at two different time points (4 h & 20 h) after
transfection. Actinomycin D was allowed to act for 3h and the cells were harvested.
CLSM was performed on the stained cells and the results are shown in Fig. 3.46,
3.47, 3.48, 3.49, 3.50 and 3.51.
In cells transfected with pEGFPORF57, pEGFPORF57 (l-296aa), pEGFPORF57-
GLFF (l-426aa) and pEGFPORF57-Zinc (l-397aa), the protein was found to
accumulate in the cytoplasm at both time points (Figs. 3.46, 3.47, 3.48, 3.49 and
3.50). In contrast to this, the cells transfected with the expression construct
pEGFPORF57 (250-453aa), there was fluorescent signal in both the nucleus and the
cytoplasm (Fig. 3.51). This suggested that this fusion protein was unable to shuttle
from the nucleus to the cytoplasm when treated with Actinomycin D.
The cellular localisation studies performed earlier have shown that the ORF 57
encodes for a nuclear protein. The fusion protein was formed as early as 4h after
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Fig. 3. 46. Nuclear shuttling property of different ORF 57 constructs.
BHK cells were transfected with 20 pg of pEGFPORF 57,
pEGFPORF 57-GLFF (1-426aa), pEGFPORF 57-Zinc (1-397aa),
pEGFPORF 57 (1-296aa) and pEGFP ORF 57 (250-453aa) and
were treated with Actinomycin D 4h after transfection. Full length
protein and the different C-terminal truncations of the ORF 57 protein
shuttled from the nucleus to the cytoplasm. The N-terminal deleted
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24.25 12069 48.67 45.32 0.00 193.00
Fig. 3.47. Nuclear shuttling property of GFPORF57
BFIK cells were transfected with 20 pg of pEGFPORF57 and 20 h
after transfection cells were treated with Actinomycin D.
An imaginary line was drawn through the cell across the area
where GFP is expressed. Software associated with the Leica
TCSNT system measures the intensity of the fluorescence and
plots this graphically to indicate the distribution of GFP in the cell
nucleus and cytoplasm.
Channel 1- (green line) represents both the localisation and the
intensity of GFP.
Channel 2- (red line) indicates the boundary of nucleus.
This picture shows that the distribution of GFPORF57 fusion protein
is outside the nucleus as the green line is seen outside the red nuclear
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Fig. 3.49. Nuclear shuttling property of GFPORF57-Zinc (1-397aa)
BHK cells were transfected with 20 pg of pEGFPORF57-Zinc (1-397aa)
and 20 h after transfection cells were treated with Actinomycin D.
An imaginary line was drawn through the cell across the area
where GFP is expressed. Software associated with the Leica
TCSNT system measures the intensity of the fluorescence and plots
this graphically to indicate the distribution of GFP in the cell nucleus
and cytoplasm.
Channel 1- (green line) represents both the localisation and the intensity
of GFP.
Channel 2- (red line) indicates the boundary of nucleus.
This picture shows that the distribution of GFPORF57-Zinc (1-397aa)
fusion protein is outside the nucleus as the green line is seen outside
the red nuclear margin and confirms the localisation of
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Fig. 3.50. Nuclear shuttling property of GFPORF57(1-296aa)
BFIK cells were transfected with 20 pg of pEGFPORF57 (1-296aa)
and 20 h after transfection cells were treated with Actinomycin D.
An imaginary line was drawn through the cell across the area
where GFP is expressed. Software associated with the Leica
TCSNT system measures the intensity of the fluorescence and
plots this graphically to indicate the distribution of GFP in the cell
nucleus and cytoplasm.
Channel 1- (green line) represents both the localisation and the
intensity of GFP.
Channel 2- (red line) indicates the boundary of nucleus.
This picture shows that the distribution of GFPORF57 (1-296aa)
fusion protein is outside the nucleus as the green line is seen outside
the red nuclear margin and confirms the localisation of





GFP ORF 57 (250-453aa)
Fig. 3.51. Nuclear shuttling property of ORF 57 constructs (20 h)
BHK cells were transfected with pEGFP ORF 57,
pEGFP ORF 57-GLFF(1-426aa), pEGFP ORF 57-Zinc (1-397aa),
pEGFP ORF 57 (1-296aa) and pEGFP ORF 57 (250-453aa)
and 20h after transfection treated with Actinomycin D. Full length
protein and the different C-terminal truncations of the ORF 57
protein shuttled from the nucleus to the cytoplasm. The N-terminal
deleted protein [pEGFPORF57 (250-453aa)] wasrefractory to
Actinomycin D treatment.
CHAPTER 3 RESULTS
transfection displaying a clear punctate pattern of expression. This definite pattern of
expression was maintained until 24 h. By 48 h, the expression pattern could not be
well maintained. This is possibly due to the large amounts of protein formed. Hence
in this shuttling experiment 4 h and 20 h were taken as the appropriate time points.
When the cells were transfected with the construct pEGFPORF57 (250-453aa), the
fusion protein was not localised to the nucleus (see section 3.4.1). This construct
lacks the N-terminal region of the protein and since the nuclear localisation signal
resides at the N-terminus, it was unable to localise in the nucleus. The cells
transfected with this construct was displaying a diffuse fluorescence signal in both
the nucleus and the cytoplasm. When cells were transfected with this expression
construct and treated with Actinomycin D, the same pattern of expression was
obtained. Whereas, in the cells transfected with full-length ORF 57 protein and C-
terminal deletions of the protein, the fusion protein shuttled from the nucleus to the
cytoplasm after treating with Actinomycin D. The shuttling was observed at both
time points. This effect is characteristic of several shuttling proteins and appears to
reflect a linkage between their nuclear import and ongoing RNA polymerase II
transcription.
As shown in Fig. 3.46 and 3.47, the full-length protein was maintaining the punctate
pattern of expression even when it is shuttled from the nucleus to the cytoplasm. The




The results of this experiment have demonstrated that ORF 57 is a shuttling protein,
as it can efficiently traffic between nucleus and cytoplasm. Shuttling of ORF 57
protein could be observed at an earlier time point as 4 h. This indicates the active
shuttling property of the A1HV-1 ORF 57 protein.
The ORF 57 protein was able to efficiently shuttle from the nucleus to the cytoplasm
even when transiently expressed in un-infected cells. This indicates that shuttling
does not require any viral infection or any other viral proteins. The capacity of a
nuclear protein to shuttle demonstrates that its nuclear import is counter-balanced
with its nuclear export. Therefore the observations of this shuttling experiment and
the earlier studies to identify a potential nuclear localisation signal within the ORF
57 protein described in section 3.4.4 clearly indicated that the nuclear localisation
signal and the domain involved in shuttling resides at the N-terminus of the protein.
3.6. Summary of results
RT-PCR experiments (section 3.1.3) carried out on RNA extracted from virus-
infected BT cells suggest that ORF 57 protein is expressed very early in the life cycle
of the virulent virus. This indicates that A1HV-1 ORF 57 is expressed as an
immediate early gene. However, the absence of ORF 57 expression in the attenuated
virus life cycle could not be conclusively proved.
This study has demonstrated that the A1HV-1 ORF 57 encodes for a regulatory
protein. In transient transfection assays it strongly activated the A1HV-1 ORF 50
promoter. Although a variety of A1HV-1 promoters were tested A1HV-1 ORF 57
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protein does not seem to have any effect on them. This data suggest that A1HV-1
ORF 57 protein is not a broad-spectrum transactivator and it only specifically
activates ORF50 promoter.
The transactivator function of ORF 57 protein on reporter gene constructs having
introns within the target gene coding region was analysed by carrying out transient
transfection assay using ORF 50 promoter driving expression of a spliced and an
unspliced reporter gene constructs. The results demonstrated that there was
approximately a 7-8 fold difference in the activation of ORF50 promoter depending
on whether it is linked to a spliced firefly luciferase reporter gene or an unspliced
firefly luciferase reporter gene.
To examine whether A1HV-1 ORF 57 protein could act as a promiscuous
transactivator, transient transfection assay was carried out using the SV40 and HSV
TK promoter driving expression of a spliced Renilla luciferase reporter gene and an
unspliced firefly luciferase reporter gene. The results of this transfection assay
revealed that A1HV-1 ORF 57 protein does not exert any transactivator effect on
SV40 and HSV TK promoters whether it is linked to a spliced or an unspliced
reporter gene. This also suggested that A1HV-1 ORF57 protein requires the ORF 50
promoter elements to induce transactivation.
To identify the activation domain of A1HV-1 ORF 57 protein, four truncated versions
of A1HV-1 ORF 57 protein were constructed, consisting of N-terminal and C-
terminal regions of A1HV-1 ORF 57. These constructs were used to determine
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whether they were capable of activating ORF 50 promoter in comparison to full-
length ORF 57 protein construct in transient transfection assays. Except the full-
length ORF 57 construct none of the other truncated forms of the ORF 57 protein
have transactivated ORF 50 promoter. This indicated that the activation domain of
ORF 57 protein lies at the C-terminal region of the protein.
To determine the regulatory role of ORF 57 protein at the post-transcriptional level
RT-PCR experiment was carried out using RNA extracted from BHK cells
transfected with pGL2b50p and pGL3b50p with or without the presence of ORF 57
expression construct. As shown in the Fig. 3.27. no significant difference in the level
of mRNA could be seen with or without the addition of ORF 57 protein. The
measurement of fold induction of luciferase activity of these two constructs has
revealed an approximately 7-8 fold difference in the amount of protein produced.
Comparative analysis of the RT-PCR and luciferase data demonstrated that this 7-8
fold difference in the level of protein produced could be due to the post-
transcriptional regulatory effect of ORF 57 protein. This suggested that A1HV-1 ORF
57 protein acts at the transcriptional and post-transcriptional level in regulating gene
expression.
To determine the cellular localisation of the protein BHK cells were transfected with
pEGFPORF57 and pORF57EGFP and cells were harvested at different time points.
The C-terminal fusion protein was localised to the nucleus exhibiting a clear punctate
pattern of expression. This suggested that A1HV-1 ORF 57 encodes for a nuclear
protein. The N-terminal fusion protein was displaying a fluorescent signal in both the
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nucleus and cytoplasm similar to control plasmids. This could be due to the
difference in the protein folding making it unstable and quickly disintegrating.
Transient transfection assay has also shown that the N-terminal fusion protein was
unable to transactivate the ORF 50 promoter indicating it is non-functional.
Immunofluorescence studies performed using the monoclonal antibody raised against
the nucleolar phosphoprotein C 23 have shown that the A1HV-1 ORF 57 encoded
protein co-localise with the nucleolar phosphoprotein in the nucleolus.
To identify the nuclear localisation signal within the ORF 57 protein, cells were
transfected with different C-terminal truncated forms of ORF 57 protein and a N-
terminal truncated form of the ORF 57 protein. CLSM images of the cells have
revealed that the C-terminal deleted proteins were localised in the nucleus similar to
the full-length protein. However, when the N-terminal region of the protein was
deleted, the fusion protein was exhibiting a fluorescent signal in both the nucleus and
the cytoplasm like that of control GFP constructs. This indicated that the nuclear
localisation signal of ORF 57 protein resides at the N-terminus.
To determine whether ORF 57 protein encodes for a nuclear cytoplasmic shuttling
protein, the cells transfected with ORF 57 expression construct were treated with
Actinomycin D. The different truncations of ORF 57 protein constructs were used to
analyse this property. The results of this experiment have established that ORF 57 is
a active shuttling protein and it traffic efficiently between nucleus and the cytoplasm
where it accumulates during treatment with Actinomycin D. This also indicated that
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ORF 57 of A1HV-1 is homologous to genes identified in all three classes of
herpesviruses (Nicholas et al., 1988; Kenney et al., 1989b; Bello et al., 1999). In
those viruses, ORF 57 encodes for one of the two major transcription regulating
genes (Whitehouse et al., 1998a; Kirshner et al., 2000). This thesis describes several
approaches taken to investigate the function of A1HV-1 ORF 57 including
transcriptional analysis, expression of the protein and an examination of its potential
transactivator property. In order to evaluate the individual contribution of this gene
to viral pathogenesis, attempts were made to analyse its role at the transcriptional and
post-transcriptional level.
4.1. Transcription pattern of ORF 57
The transcriptional expression pattern of the ORF 57 gene product was examined by
RT-PCR. The kinetic class of the ORF 57 transcript was established by treating the
cells with metabolic inhibitors. ORF 57 transcription was resistant to treatment with
cycloheximide, which inhibits protein synthesis. This revealed the presence of an
ORF 57-specific transcript during the very early stage of the virus life cycle showing
that the gene is expressed as an immediate early gene. This is in agreement with the
observations in other gamma herpesvirus homologues.
A HVS ORF 57 transcript was observed in cells infected at a MOI of 25 PFU/cell
and incubated in the continuous presence of cycloheximide (Whitehouse et al.,
1998b). A KSHV ORF 57 was found to express between 2 and 4 h after TPA
induction of BCBL-1 cells, immediately following the appearance of ORF 50
transcripts (Lukac et al., 1999).
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4.2. Analysis of the function of ORF 57 protein
Investigations of the functions of ORF 57 homologues in other gamma herpesviruses
led to the assumption that ORF 57 may encode a transactivator protein. Transient
transfection assays have shown that ORF 57 protein modulates gene expression
driven by the A1HV-1 ORF 50 promoter. Although a range of other A1HV-1
promoters were tested, the ORF 57 protein did not exert any effect on them.
Similarly ORF 57 protein had no effect on heterologous strong promoters such as the
SV40 and the CMV promoters.
This observation is similar to the results obtained with the KSHV ORF 57 protein. In
transient reporter gene assays, KSHV ORF 57 protein had little effect on a wide
variety of promoters, suggesting that it is not a broad-spectrum activator. The CMV
IE and SV 40 E promoters were unaffected by the presence of KSHV ORF 57
protein (Kirshner et al., 2000). However, expression from some promoters,
especially nut-1, that were up-regulated by ORF 50 can be synergistically enhanced
by co-expression with ORF 57 protein (Kirshner et al., 2000).
In contrast to this, HVS ORF 57 can significantly activate transcription from the
HVS promoters for the genes encoding DNA polymerase, thymidine kinase, major
capsid protein and glycoprotein B in transient transfection assay (Whitehouse et al.,
1998a). Similarly, EBV Mta was also found to significantly increase the activity of
both latent and productive EBV promoters linked to CAT (Kenney et al., 1989b).
However, the activity of the same promoters linked to the human growth hormone
gene was not transactivated. This indicated that the transactivator effect of Mta is
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reporter gene dependent. Mta transactivator is not specific and it activated a variety
of promoters of EBV and unrelated viruses including adenovirus, SV 40, HSV and
HIV (Wong and Levine, 1989).
The regulatory effect of ORF 57 protein on the ORE 50 promoter driven genes was
subsequently investigated by transient transfection assays. The reporter gene
constructs used were pGL2b50p, which encodes a spliced firefly luciferase gene,
pGL3b50p, which encodes an unspliced firefly luciferase gene, and pRL50p, which
encodes a spliced Renilla luciferase gene. The fold induction of luciferase activity of
these reporter gene constructs in the presence of ORF 57 protein indicated that there
was a 7-fold upregulation of the spliced firefly gene, 50-fold upregulation of the
unspliced firefly luciferase gene and 2-3 fold upregulation of the spliced Renilla
luciferase gene. The 2-3 fold upregulation of pRL50p construct can not be regarded
as significant since the control plasmids also showed the similar fold induction. This
denotes a significant difference in the activation of ORF 50 promoter depending on
whether it is linked to a spliced firefly or an unspliced firefly luciferase gene.
Although the spliced firefly luciferase reporter construct was activated to 7-fold, the
spliced Renilla luciferase reporter construct was not induced. This may be due to a
reporter gene dependent action of ORF 57 protein similar to that of Mta. Another
possibility is that the spliced site is located at a different position in the above two
constructs tested. In the spliced firefly reporter gene the splice site is in the 3' UTR
and in the Renilla luciferase gene the splice site is in the 5' UTR. However, this
hypothesis could not be conclusively proved in this study. To elucidate the regulatory
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role of ORE 57 protein with regard to the position of the splice site, the experiment
has to be repeated with the same reporter gene construct having splice sites at
different positions.
The significant difference in the luciferase activity of spliced and unspliced firefly
luciferase reporter gene constructs driven by the ORF 50 promoter in the presence of
ORF 57 protein could be due to its effects at the transcriptional level, post-
transcriptional level or translational level. This was analysed further by a RT-PCR.
When luciferase RNA levels were compared there was no significant difference
between the two constructs in the presence or absence of ORF 57 protein. This
indicated that although the protein produced from genes driven by the ORF 50
promoter was up-regulated differently in both contexts (as seen from the luciferase
activity), there was no noticeable difference in the RNA levels. This suggested that
the increase in the level of protein was not correlated to a similar increase in the
luciferase RNA level. Since the ORF 57 protein does not significantly enhance the
luciferase RNA levels, the increase in the luciferase activity could be due to the
action of ORF 57 protein at the post-transcriptional level. This observation indicates
that the A1HV-1 ORF 57 protein acts at a post-transcriptional level in effectively
processing the RNA to modulate gene expression. Although the pGL2b50p vector
was predicted to encode for a spliced transcript, an unspliced transcript was obtained.
A possible explanation for this result could not be achieved. A RT-PCR experiment
was not performed to determine the Renilla luciferase RNA level in the presence or
absence of ORF 57 protein.
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Detailed analysis of the backbone of the pGL2 and pGL3 vectors showed that a
higher level of expression can be expected when using pGL3 vector compared to
pGL2 vector. This point should also be taken into account while interpreting the
significant difference in the fold induction value of luciferase activity obtained when
the spliced and unspliced luciferase reporter genes were driven by the ORF 50
promoter in the presence of ORF 57 protein.
Kenney et al., (1989b) have performed SI nuclease analysis on EBV promoter
driven CAT mRNAs and found that the Mta transactivator increased the level of
CAT activity produced by EBV promoter CAT constructs; but it was not
accompanied by a similar increase in steady-state level of CAT mRNA. Similar
results were obtained when they used the primer extension method to examine the
effect of the Mta transactivator on the level of CAT mRNA. The Mta transactivator
does not significantly increase the level of CAT mRNA, which suggests a post-
transcriptional mechanism. In addition, as mentioned earlier, the reporter gene
dependence of the Mta transactivator also argues for a post-transcriptional
mechanism, since any transcriptional effect would be expected to be independent of
the reporter gene used.
KSHV ORF 57 protein has also been shown to preferentially up-regulate the activity
of ORF 50 on the nut-1 promoter depending on whether it is linked to a spliced
version or an unspliced version of the gene. The expression of the intronless version
of the gene is up-regulated 10-fold more efficiently than its intron-bearing derivative.
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This observation also clearly indicated that the KSHV ORF 57 protein is principally
acting by a post-transcriptional mechanism (Kirshner et al., 2000).
Similar regulatory effects have also been observed with HVS ORF 57 protein. The
HVS ORF 57 gene product transactivates promoter p-Gal constructs to a greater
extent than the promoter CAT constructs despite the fact the promoter sequences in
the CAT and P-Gal constructs were identical. This was found to be due to the
presence of an intron in the CAT construct. They have also observed that the ORF 57
gene product transactivates a wide range of HVS promoters but does not
significantly up-regulate the level of mRNA identical to the level of CAT or P-Gal
activity. This observation indicates a post-transcriptional mechanism of gene
regulation by the ORF 57 protein (Whitehouse et al., 1998a).
This evidence for a post-transcriptional regulation by A1HV-1 ORF 57 protein
suggests that the protein interacts with RNA in infected cells. To investigate this
further a cellular localisation study was performed.
4.3. Cellular localisation of ORF 57 protein
Cells were transfected individually with a C-terminal and a N-terminal tagged
version of the ORF 57 protein. The C-terminal tagged version of the ORF 57 protein
was localised in the nucleus with a clear punctate pattern of expression. The punctate
pattern of expression suggests that the ORF 57 protein may be distributed at sites
close to the splicing machinery and it is also possible that it might play an important
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role in viral transcription/RNA processing. Similar results have been observed with
other gamma herpes virus homologues.
IE 63 of HSV-1 was shown to be localised in the nucleus with concomitant
reorganisation of the cellular splicing small nuclear ribonucleoprotein particles
(snRNPs) from a diffuse speckled pattern to a highly punctate organisation (Phelan et
al., 1993). Similarly, transfection of COS 7 cells with an expression plasmid of Mta
also resulted in clear nuclear fluorescence. Recently, a C-terminally tagged version
of the KSHV ORF 57 protein was also found to localise in the nucleus and to exhibit
a punctate nuclear distribution that co-localised with the cellular splicing factor SC-
35 (Bello et al., 1999; Kirshner et al., 2000). HVS ORF 57 protein redistributes both
U2 and SC-35 splicing factors during HVS infection into intense nuclear
aggregations and causes more intense nuclear spotting with less diffuse SC-35
background staining (Cooper et al., 1999).
The N-terminal tagged version of A1HV-1 ORF 57 protein displayed a diffuse
fluorescent signal in both nucleus and cytoplasm similar to the control plasmid. This
was assumed to be due to the inappropriate folding of the protein making it less
stable when it was fused to the N-terminus of the GFP. This hypothesis was further
substantiated by a transient transfection assay carried out using the ORF 50 promoter
reporter gene constructs in the presence or absence of different expression constructs
of ORF 57 protein. The C-terminal tagged version (pEGFPORF57) and untagged
pCMVORF57 were able to upregulate the ORF 50 promoter reporter constructs to a
similar level, whereas the N-terminal tagged version of ORF 57 (pORF57EGFP)
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could not exert any activator effect on ORF 50 promoter reporter constructs. This
suggests that the N-terminal tagged version of ORF 57 protein is non-functional
which may be due to improper protein folding.
The punctate pattern of expression of A1HV-1 ORF 57 protein also suggests that it is
confined to certain specific areas in the nucleus rather than completely occupying the
nucleus. In order to investigate the localisation site of ORF 57 protein an
immunofluorescence study was performed using a monoclonal antibody raised
against the major nucleolar phosphoprotein C 23. This study demonstrated that the
ORF 57 protein co-localises with the nucleolar phosphoprotein C 23 in the nucleolus.
HSV IE 63 was found to co-localise with spliceosome components and has also been
shown to redistribute the snRNP components of the spliceosome (Phelan et al., 1993;
Sandri-Goldin et al., 1995). In an indirect immunofluorescence assay, Mta showed
strongly staining speckles, which co-localised with the nuclear speckles
characteristic of the splicing factor SC 35 (Semmes et al., 1998). KSHV ORF 57
protein exhibited a punctate nuclear distribution that co-localised with a component
of the cellular splicing machinery (Bello et al., 1999). In HVS infected cells and in
cells transfected with the HVS ORF 57 expression construct, there was a
redistribution of the SC-35 and snRNP U2 components of the spliceosome.
Moreover the redistributed spliceosome components co-localised to the regions of
the nucleus where the ORF 57 gene product was concentrated (Cooper et al., 1999).
The co-localisation studies on ORF 57 homologues suggested that the ORF 57
protein is present at sites adjacent to nascent mRNA synthesis. The redistribution of
the spliceosome complex has found to have a profound effect on the splicing ability
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of a cell and subsequently on the processing of viral intron containing mRNAs. The
redistribution of the snRNPs that are components of the splicing complex and the co-
localisation of ORE 57 gene product with these components are believed to
contribute to the repression of host cell splicing that occurs in HSV-infected cells.
However detailed investigations have revealed that the repression of host cell
splicing is more complex and the redistribution of these spliceosome components
alone is insufficient to bring about this effect (Sandri-Goldin et al., 1995).
The punctate pattern of expression and the co-localisation of ORF 57 protein with the
C 23 nucleolar protein also indicate a possible association of this protein with the
splicing machinery of the cell. However, further experiments need to be performed to
completely elucidate its mechanism of action.
4.4. Nuclear cytoplasmic shuttling property of ORF 57 protein
Many nuclear proteins studied have been found to continuously traffic between
nucleus and cytoplasm and play a major role in export of viral transcripts. Hence the
ability of A1HV-1 ORF 57 nuclear protein to shuttle between the nucleus and
cytoplasm was analysed. The ORF 57 protein was found to shuttle from the nucleus
to the cytoplasm. In the cytoplasm the "shuttled" protein was found to localise to
certain specific domains rather than displaying a diffuse fluorescent signal. However,




The shuttling property of A1HV-1 ORF 57 protein is in agreement with HSV IE 63,
where it has been demonstrated that IE 63 can shuttle from the snRNP and RNA rich
nucleus to the cytoplasm, where it accumulates during treatment with Actinomycin D
(Phelan and Clements, 1997).
In contrast to this, the KSHV ORF 57 protein does not shuttle from the nucleus to the
cytoplasm during Actinomycin D treatment. However in a sensitive interspecies
heterokaryon assay, the fusion protein was capable of shuttling from the donor
transfected nucleus to the recipient nucleus (Bello et al., 1999). Similarly, in EBV
Mta was also capable of shuttling from the originally transfected cells into the nuclei
of the recipient cells (Semmes et al., 1998). HVS ORF57 protein was also capable
of shuttling in an interspecies heterokaryon assay (Goodwin et al., 1999)
The very apparent shuttling of A1HV-1 ORF 57 following Actinomycin D treatment
suggests that ORF 57 protein plays a role in mediating the nuclear export of viral
transcripts. The ability of ORF 57 protein to shuttle from the nucleus to the
cytoplasm in transfected cells even in the absence of viral infection suggests that it is
a active shuttling protein and does not require other viral proteins. Moreover this
effect is characteristic of several shuttling proteins and appears to reflect a link
between their nuclear import and the ongoing RNA polymerase II transcription. The




Recent studies with HVS ORF 57 protein have shown that the ORF 57 protein
interacts with importin a isoforms 1 and 5 and this interaction is mediated via the
hydrophobic, internal, importin a armadillo repeats. The arginine rich amino-
terminal NLS is also involved in this interaction (Goodwin and Whitehouse, 2001).
4.5. Identification of the functional domains of ORF 57 protein
An activation domain was found to reside at the C-terminal region of the A1HV-1
ORF 57 protein. Transient transfection assays in HVS permissive OMK cells and the
highly transfectable 293T cells using glycoprotein B promoter reporter constructs in
the presence or absence of ORF 57 C-terminal deletion constructs have shown that
CAT activity was severely reduced when each deletion construct was utilised as
against the full-length protein. This suggested that the C-terminal region is required
for the transactivation of the ORF 57 protein (Goodwin et al., 2000).
The C-terminus of gamma herpesvirus ORF 57 homologues possesses two important
functional domains: a hydrophobic "GLFF" domain and the "Zinc finger-like"
element. In HVS, both the hydrophobic "GLFF" and the "Zinc finger-like" domains
are involved in the transactivator property of ORF 57. The transactivator domain of
IE 63 has also been mapped to the C-terminal portion of the protein (McMahan and
Schaffer, 1990). Furthermore, it has been demonstrated that these conserved motifs
were required for transactivation by IE 63 (Rice and Lam, 1994). The conserved
hydrophobic residues with activation domains were found in a variety of viral, yeast,
and mammalian transcriptional activators, including HSV-1 VP 16, EBV Rta, HVS
ORF 50 and Spl. The essential role of these residues for transcriptional activation
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have also been established by mutational analysis (Hardwicke et al., 1992; Hall et
al., 1999).
Although the exact role of these conserved motifs in A1HV-1 is not known, transient
transfection assays using the C-terminal deleted constructs lacking these conserved
motifs, suggested a significant role played by these conserved motifs in exerting the
activator effect. To further analyse the pivotal role of these conserved motifs,
transient transfection assays should be performed with site-directed mutations within
the conserved motifs.
The nuclear localisation signal of A1HV-1 ORF 57 protein was found to reside at the
N-terminal region of the protein. Similar observations were seen with the KSHV
ORF 57 protein. The cellular distribution studies involving the N-terminal truncated
version of the KSHV ORF 57 protein have revealed that the fusion protein was
confined mainly to the cytoplasm (Bello et al., 1999). This result indicates that the
nuclear localisation signal of ORF 57 protein resides at the N-terminal region of the
protein.
Immunofluorescence analysis of cells transfected with C-terminal deleted constructs
of HVS ORF 57 protein resulted in a strong fluorescence in the nuclei of transfected
cells. This suggested that each deletion construct produced a protein, which localised
to the cell nucleus (Goodwin et al., 2000). Further, they have also observed that the
cells transfected with the C-terminal deleted constructs showed no SC-35
redistribution suggesting that the C-terminal region of the protein is also required for
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the intense nuclear spotting of the SC-35 spliceosome component.
Immunofluorescence studies performed with mutations in the hydrophobic "GLFF"
domain and the "Zinc-finger like" element to determine the role of these domains in
the subcellular localisation have revealed that the Zinc finger-like domain is required
for the intense nuclear spotting which correlates with the spliceosome component
redistribution. In contrast to this, there was no observable difference in the
distribution, intensity, or pattern of expression of A1HV-1 ORF 57 protein with either
the GLFF or Zinc finger domain deleted version of ORF 57 protein.
The sequence analysis of the A1HV-1 ORF 57 protein has shown that there are some
arginine-rich areas, which could potentially function as a NLS. In addition to this, it
also possesses leucine-rich areas at the amino terminus of the protein. This may
function as a nuclear export signal (NES) in facilitating the protein to shuttle between
the nucleus and the cytoplasm.
4.6. Aggresomes
A1HV-1 ORF 57 protein was found to shuttle from the nucleus to the cytoplasm
when treated with Actinomycin D. In the cytoplasm the shuttled protein was
confined to some specified areas. The reason for this reproducible specific site of
localisation is unclear. However, the recent research on aggresomes suggest that the
ORF 57 protein may be localised in an aggresome.
The formation of aggresomes is thought to be part of a general cytoplasmic response
to aggregated protein (Johnston et al., 1998). Such aggregates could form when the
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synthesis of aggregation-prone proteins exceeds the capacity of cytoplasmic
chaperone and proteolytic systems, either as a result of overexpression, or by the
acquisition of mutations that alter the balance between folding and misfolding. Thus,
cytoplasmic indigestion can result from acquired or inherited deficiencies in the
digestive machinery itself, from toxic food or in response to dislocated variants of
transmembrane proteins such as cystic fibrosis transmembrane conductance regulator
(CFTR) (Garcia-Mata et al., 1999).
Formation of aggresomes exploits transport on microtubules and is formed around
the microtubule organising centre (MTOC). They cause disruption of either the
microtubule cytoskeleton or the retrograde motor leads to the deposition of dispersed
inclusions throughout the cytoplasm. A second distinguishing feature of aggresomes
is the presence of dispersed type III intermediate filament like vimentin, which
relocates from its normal extended cytoplasmic distribution, collapsing to form a
dense cage-like structure around the pericentriolar mass of aggregated protein
(Garcia-Marta et al., 1999; Wigley et al., 1999). Although it is not clear whether the
vimentin collapse contributes to the formation or the stabilization of aggresomes, it is
a consistent feature that distinguishes aggresomes from other types of inclusion
bodies (Kopito and Sitia, 2000).
Future experiments are necessary to determine whether the shuttled ORF 57 protein
is localised in aggresomes. This would be done by immunofluorescence studies using




The transient transfection assays have shown that the A1HV-1 ORF 57 protein acts as
a regulator of gene expression. The regulatory effect of ORF 57 protein was
observed only when the expression of reporter gene was driven by A1HV-1 ORF 50
promoter. RT-PCR analysis has shown that the A1HV-1 ORF 57 regulates gene
expression post-transcriptionally. The cellular localisation study and the co-
localisation of A1HV-1 ORF 57 protein with the C 23 nucleolar phosphoprotein in
the nucleolus possibly reflects an in vivo RNA-binding activity. These observations
suggest that the ORF 57 protein may be binding directly to RNA in inducing the
effect. Another possibility could be that ORF 57 protein binds to specific ORF 50
promoter elements initially and then moves on to bind to mRNA to exert its effect. It
is also possible that in the presence of ORF 57 protein the ORF 50 promoter driven
RNAs may be transported quickly to the cytoplasm. However, further work needs to
be carried out to clarify the above hypotheses.
In conclusion, the A1HV-1 ORF 57 protein has a regulatory role at the post-
transcriptional level. It encodes for a shuttling nuclear protein which may be
involved in mediating the nucleocytoplasmic transport of viral transcripts. The
results of this study have led to the initial functional characterisation of A1HV-1 ORF
57 gene product. Several potential avenues of investigation have been proposed to
analyse the function and mechanism of action of A1HV-1 ORF 57 protein.
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The raw luciferase values for all the luciferase assay results given in Chapter 3 are shown below. The
fold induction values are also shown beneath the table showing raw values.
I.A Effect of ORF 57 on different A1HV-1 promoters driving expression of unspliced Firefly
luciferase gene (Individual raw values for Fig,3.9)











































I.B Effect of ORF 57 on different A1HV-1 promoters driving expression of unspliced Firefly
luciferase gene (Individual fold induction for Fig. 3.91























II.A Effect of ORF 57 on ORF 50 driving expression of spliced and unspliced Firefly luciferase gene
("Individual raw values for Fig, 3,101




















II.B Effect of ORF 57 on ORF 50 driving expression of spliced and unspliced Firefly Luciferase gene
("Individual fold induction values for Fig.3.101










III.A Effect of ORF 57 on ORF 50 promoter driving expression of spliced and unspliced Firefly
Luciferase gene (Individual raw values for Fig.3.11)











































III.B Effect of ORF 57 on ORF 50 promoter driving expression of spliced and unspliced Firefly
luciferase gene (Individual fold induction values for Fig.3.111























IV.A Effect of ORF 57 on ORF 50 promoter and SV40 promoter driving expression of spliced Renilla

































IV.B. Effect of ORF 57 on ORF 50 promoter and SV40 promoter driving expression of spliced
Renilla Luciferase gene (Individual fold induction values for Fig.3.13)


















V.A Effect of ORF 57 on heterologous promoters (SV40 & HSV TK) driving expression of both
spliced Renilla Luciferase and unspliced Firefly luciferase gene (Individual raw values for Fig.3.14')


























V.B Effect of ORF 57 on heterologous promoters fSV 40 & HSV TK) driving expression of both
spliced Renilla Luciferase and unspliced firefly luciferase gene (Individual fold induction values for
Fig.3.14)














VI.A Effect of Full length and truncated ORF 57 constructs on control plasmid fpGL3basic')
[Individual raw Fireflv/Renilla values for Fig.3.18 A]









pGL3basic+pEGFPORF57( 1 -296aa) 1.823 1.198
pGL3basic+pEGFPORF57( 1 -296aa) 2.478 1.243




pGL3basic+pEGFPORF57-GLFF( 1 -426aa) 2.678 1.434
pGL3basic+pEGFPORF57-GLFF( 1 -426aa) 2.469 1.223
pGL3basic+pEGFPORF57-GLFF( 1 -426aa) 2.534 1.342
pGL3basic+pEGFPORF57-Zinc(l-397aa) 2.398 1.498
pGL3basic+pEGFPORF57-Zinc(l-397aa) 2.321 1.46
pGL3basic+pEGFPORF57-Zinc( 1 -397aa) 2.312 1.345
VI.B Effect of Full length and truncated QRF 57 constructs on control plasmid tpGL3basicl
[Individual fold induction of Firefly values for Fig.3.18 A]





pGL3basic+pEGFPORF57( 1 -296aa) 1.768
pGL3basic+pEGFPORF57( 1 -296aa) 2.284




pGL3basic+pEGFPORF57-GLFF( 1 -426aa) 2.597
pGL3basic+pEGFPORF57-GLFF( 1 -426aa) 2.275
pGL3basic+pEGFPORF57-GLFF( 1 -426aa) 2.355
pGL3basic+pEGFPORF57-Zinc( 1 -397aa) 2.325
pGL3basic+pEGFPORF57-Zinc( 1 -397aa) 2.139
pGL3basic+pEGFPORF57-Zinc( 1 -397aa) 2.148
h
VILA Effect of Full length and truncated ORF 57 constructs on control plasmid (pGL2basic/spliced1
[Individual FF and Renilla Luciferase values for Fig.3.18 B]








pGL2basic+pEGFPORF57( 1 -296aa) 0.208 1.541
pGL2basic+pEGFPORF57( 1 -296aa) 0.192 1.535




pGL2basic+pEGFPORF57-GLFF( 1 -426aa) 0.178 1.554
pGL2basic+pEGFPORF57-GLFF( 1 -426aa) 0.180 1.542
pGL2basic+pEGFPORF57-GLFF( 1 -426aa) 0.167 1.567
pGL2basic+pEGFPORF57-Zinc( 1 -397aa) 0.084 1.256
pGL2basic+pEGFPORF57-Zinc(l-397aa) 0.086 1.423
pGL2basic+pEGFPORF57-Zinc(l-397aa) 0.091 1.564
VII.B Effect of Full length and truncated ORF 57 constructs on control plasmid (pGL2basic/splicedl
[Individual fold induction of Firefly luciferase values for Fig.3.18 B]





pGL2basic+pEGFPORF57( 1 -296aa) 1.26





pGL2basic+pEGFPORF57-GLFF( 1 -426aa) 1.079
pGL2basic+pEGFPORF57-GLFF( 1 -426aa) 1.11
pGL2basic+pEGFPORF57-GLFF( 1 -426aa) 1.044




VIII.A Effect of Full length and truncated ORF 57 constructs on ORF 50 promoter driving expression











PGL3b50p+pEGFPORF57( 1 -296aa) 46.82 1.456





PGL3b50p+pEGFPORF57-GLFF( 1 -426aa) 51.13 1.421
PGL3b50p+pEGFPORF57-GLFF( 1 -426aa) 60.02 1.419
PGL3b50p+pEGFPORF57-GLFF( 1 -426aa) 48.15 1.432
PGL3b50p+pEGFPORF57-Zinc( 1 -397aa) 47.92 1.398
PGL3b50p+pEGFPORF57-Zinc( 1 -397aa) 44.34 1.621
PGL3b50p+pEGFPORF57-Zinc( 1 -397aa) 51.16 1.576
VIII.B Effect of Full length and truncated ORF 57 constructs on ORF 50 promoter driving expression
of unspliced Firefly luciferase gene(pGL3basic/unspliced') [Fold induction of firefly luciferase values
for Fig.3.19]




PGL3b50p+pEGFPORF57( 1 -296aa) 4.57
PGL3b50p+pEGFPORF57( 1 -296aa) 5.37





PGL3b50p+pEGFPORF57-GLFF( 1 -426aa) 6.2
PGL3b50p+pEGFPORF57-GLFF( 1 -426aa) 4.57
PGL3b50p+pEGFPORF57-Zinc( 1 -397aa) 4.67
PGL3b50p+pEGFPORF57-Zinc(l-397aa) 4.58
PGL3b50p+pEGFPORF57-Zinc( 1 -397aa) 4.86
j
IX.A Effect of Full length and truncated ORF 57 constructs on ORF 50 promoter driving expression
of spliced Firefly luciferase gene (pGL2basic/splicecD [Individual raw FireFlv luciferase values for
Fig.3.201








pGL2b50p+pEGFPORF57( 1 -296aa) 17.96 1.398





pGL2b50p+pEGFPORF57-GLFF( 1 -426aa) 12.89 1.128
pGL2b50p+pEGFPORF57-GLFF( 1 -426aa) 11.36 1.125
pGI .2b50p+pRGFPORF57-GLFF( 1 -426aa) 16.12 1.321
pGL2b50p+pEGFPORF57-Zinc( 1 -397aa) 15.12 1.508
pGL2b50p+pEGFPORF57-Zinc( 1 -397aa) 12.98 1.453
pGL2b50p+pEGFPORF57-Zinc(l-397aa) 13.23 1.432
IX.B Effect of Full length and truncated ORF 57 constructs on ORF 50 promoter driving expression
of spliced Firefly luciferase gene("pGL2basic/spliced) [Fold induction of Firefly luciferase values for
Fig.3.20]






pGL2b50p+pEGFPORF57( 1 -296aa) 4.11
pGL2b50p+pEGFPORF57( 1 -296aa) 3.04




pGL2b50p+pEGFPORF57-GLFF( 1 -426aa) 2.956
pGL2b50p+pEGFPORF57-GLFF( 1 -426aa) 2.654
pGL2b50p+pEGFPORF57-GLFF( 1 -426aa) 3.217
pGL2b50p+pEGFPORF57-Zinc( 1 -397aa) 3.467
pGL2b50p+pEGFPORF57-Zinc(l-397aa) 3.03
pGL2b50p+pEGFPORF57-Zinc( 1 -397aa) 2.64
k
X. A Effect of different expression constructs of ORF 57 on 50 promoter driving expression of
spliced and unspliced Firefly luciferase gene (Raw values for Fig.3.221























pGL2b5 Op+pEGFPORF 5 7 6.066 0.912














X. B Effect of different expression constructs of ORF 57 on 50 promoter driving expression of spliced
and unspliced Firefly luciferase gene.C Individual Fold induction for Fig.3.221
Constructs Fold induction of Firefly
Luciferase activity
pGL3basic+pCMVORF57 2.956
pGL3basic+pCMVORF57 2.765
pGL3basic+pCMVORF57 3.196
pGL3basic+pORF57EGFP 0.752
pGL3basic+pORF57EGFP 0.655
pGL3basic+pORF57EGFP 0.804
pGL3basic+pEGFPORF57 2.750
pGL3basic+pEGFPORF57 2.686
pGL3basic+pEGFPORF57 2.906
pGL2b50p+pCMVORF57 6.328
pGL2b50p+pCMVORF57 7.727
pGL2b50p+pCMVORF57 7.224
pGL2b50p+pORF57EGFP 1.428
pGL2b50p+pORF57EGFP 2.456
pGL2b50p+pORF57EGFP 2.279
pGL2b5Op+pEGFPORF5 7 6.600
pGL2b50p+pEGFPORF57 7.023
pGL2b50p+pEGFPORF57 7.532
pGL3b50p+pCMVORF57 57.627
pGL3b50p+pCMVORF57 63.763
pGL3b50p+pCMVORF57 53.943
pGL3b50p+pORF57EGFP 1.085
pGL3b50p+pORF57EGFP 1.528
pGL3b50p+pORF57EGFP 0.624
pGL3b50p+pEGFPORF57 58.932
pGL3b50p+pEGFPORF57 56.00
pGL3b50p+pEGFPORF57 53.805
